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ABSTRACT 
Acute lower respiratory tract infections are a leading cause of morbidity and 
mortality world-wide. Streptococcus pneumoniae (pneumococcus) is the most 
common bacterial cause of community-acquired pneumonia. Recovery from 
pneumococcal pneumonia results in the formation of resident memory CD4+ T 
cells, which act on lung epithelial cells to accelerate immune responses. Alveolar 
macrophages (AMs) are tissue-resident macrophages localized in the air spaces, 
where they orchestrate the lung anti-microbial responses. We hypothesized that 
recovery from pneumococcal pneumonia results in remodeling of the pool of 
alveolar macrophages, which act in concordance with other immune cells to 
protect the lungs from future infections. Although AM numbers were unchanged in 
experienced lungs, their surface phenotype showed significant changes, most 
prominently an increased MHC-II and a decreased SiglecF. This experienced AM 
phenotype was regionally-localized and long-lasting. Experienced AMs also 
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exhibited extensive remodeling on the metabolomics and transcriptional level. 
Experienced AMs demonstrated significant increases in phosphocreatine and its 
metabolite precursors. The transcriptional analyses also revealed extensive 
changes. At baseline, experienced AMs exhibited a significant reduction in cell 
cycle activity and mRNA processing compared to naïve mice. During acute 
pneumonia, experienced AMs exhibited significant increases in immune signaling 
and energy metabolism. Moreover, transcriptional data also revealed strong but 
imperfect enrichment of a signature previously associated with IFN signaling and 
marrow-derived AMs. IFN gain and loss of functions experiments corroborated 
transcriptional data and revealed an essential role for IFN in directly driving the 
AM MHC-II remodeling. Several immune cells produced IFN, with neutrophils 
being the most prominent source after the 1st pneumococcal challenge but other 
cells predominating after the 2nd pneumococcal challenge. CD4+ T cell depletion 
studies demonstrated that AMs' experienced phenotype was independent of CD4+ 
T cells. In contrast to naïve mice, lineage-tracing studies demonstrated that 
marrow-derived AMs predominately constitute the experienced AM pool. Upon 
experience, both embryonic AMs and marrow-derived AMs demonstrated similar 
remodeling for both SiglecF and MHC-II on their surfaces. While all AM similarly 
remodeled independent of their origin, marrow-derived AMs in experienced lungs 
displayed some differences from their embryonic counterparts, being less 
phagocytic.  
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In conclusion, recovery from pneumococcal pneumonia remodels the pool 
of alveolar macrophages to acquire adaptive characteristics. This remodeling 
involves a combination of recruitment of new cells and trained immunity via IFN 
signaling. 
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Chapter I INTRODUCTION 
 
Pneumonia 
History and Epidemiology 
The National Institute of Health defines pneumonia as "a bacterial, viral, or fungal 
infection of one or both sides of the lungs that causes the air sacs, or alveoli, of 
the lungs to fill up with fluid or pus." As an acute lower respiratory 
infection/inflammation, pneumonia obstructs the lungs' primary physiological 
respiratory function, making it difficult for pneumonia patients to breathe and 
requiring their admission to the hospital.  Pneumonia was first recognized as a 
disease during the 1800s, and since its recognition, pneumonia has been a leading 
cause of morbidity and mortality world-wide.  
 
In the 1900s, with the advent of disability-adjusted life years lost metric (DALY), 
pneumonia has continuously lead the charts of the greatest disease burden world-
wide (Mizgerd, 2012, Murray et al., 2012). Pneumonia disproportionally affects 
young children and older adults, where pneumonia is among the utmost prevalent 
reasons of death in children world-wide and the most common cause for childhood 
hospitalizations in the United States (Scott et al., 2012, Mizgerd, 2012, Vos et al., 
2012, Yu et al., 2011, Armstrong et al., 1999). Similarly, older individuals' statistics 
show that pneumonia is responsible for nearly half of all infectious disease 
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hospitalizations and deaths in the United States (Quinton and Mizgerd, 2015). In 
the early 20th century, pneumonia's overall fatality rate was estimated to be around 
30-40% (Ratner and Weiser, 2006). These estimates even increased further during 
the 1918 Spanish flu pandemic as secondary bacterial pneumonia has been 
regarded as a chief cause of death ( Morens et al., 2008; Fedson, 2009). With the 
discovery of antibiotics, pneumonia-associated deaths witnessed a significant 
decline. However, unfortunately, the rates of death due to pneumonia have not 
considerably changed since then, and pneumonia continues to be a prominent 
cause of morbidity and mortality here in the United States and worldwide 
(Armstrong et al., 1999). Pneumonia kills more children internationally than does 
any other disease, pushing it to the top of the DALY metrics (Rudan et al., 2008; 
Wardlaw et al., 2006). While children more commonly survive pneumonia in 
wealthier countries like the United States, pneumonia still leads the morbidity 
charts as the most common reason for children to be hospitalized (Yu et al., 2011). 
20% of pediatric pneumonia patients end up needing to be in intensive care units, 
and a third require mechanical ventilation (Jain et al., 2015). Even after pediatric 
patients are released from the hospital, they are subject to an increased risk of 
developing chronic respiratory diseases, including chronic obstructive pulmonary 
disease and asthma (Hayden et al., 2015; Edmond et al., 2012). Pneumonia 
mortality rates are even much worse in the more senior patients (Hansen et al., 
2016). While still a good percentage of pneumonia elder patients survive (Ewig et 
al., 2009), pneumonia patients are subject to long term consequences, including 
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increased incidence of depression, cognitive deterioration, physical limitation, 
worsened cardiovascular and cerebrovascular health, and decreased life-spans 
(Pandhartpande et al., 2010; Sandvall et al., 2013; Quinton et al., 2018; Shah et 
al., 2012; Herridge et al., 2011; Corrales-Medina et al., 2015; Bienvenu et al., 
2012). Additionally, pneumonia-linked economic costs are enormous and are 
estimated to range around 20-80 billion dollars per year in the states (Hayes et al., 
2018; File et al., 2010; Whitsett et al., 2015). Altogether, pneumonia is a serious 
burden of disease that requires a careful search for better solutions. 
Microbial causes of Pneumonia 
Pneumonia can be caused by a diverse range of microbial agents, including 
bacteria, viruses, and fungi (Quinton et al., 2018). Within these broad categories 
of microbial agents exists a wide range of characteristics. For example, Gram-
positive bacteria, Gram-negative bacteria, extracellular bacteria, intracellular 
bacteria, and cell wall-free bacteria can lead to bacterial pneumonia, and DNA 
viruses, RNA viruses, enveloped viruses, and non-enveloped viruses can lead to 
viral pneumonia (Quinton et al., 2018). Each of these microbes has a different 
prevalence and distribution among patients within different age-groups and other 
environmental settings (Cilloniz et al., 2016; Anand et al., 2009) and encompass 
different mechanisms and virulence factors to initiate the pathology and immune 
responses characteristic of pneumonia (Feldman et al., 2016; McCullers et al., 
2014; Moore et al., 2013; Palavecino et al., 2015; Parker et al., 2016; Schrauwen 
et al., 2014; Van der poll et al., 2009). While a wide variety of microbial agents 
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have been recognized to cause pneumonia, during hospitalizations, the microbial 
agent causing pneumonia is often not identified. In a nationwide study designed 
specifically to illuminate etiology, the microbial agent causing pediatric pneumonia 
could not be detected in about 20% of childhood cases and more than 50% of adult 
cases (Quniton et al., 2018; Jain et al., 2015). Even the most prevalent microbes 
causing pneumonia, like rhinoviruses (9%), influenza viruses (6%), and 
pneumococci (5%), represent a small minority of all pneumonia cases (Jain et al., 
2015; Quinton et al., 2018). Often enough, individuals who encounter these 
microbes only develop subclinical disease suggesting that host response 
contributes to the outcome and severity of pneumonia. While pneumonia incidence 
and prevalence remain high, the discovery of antibiotics and the development of 
vaccines against pneumococcus and influenza have modestly mitigated the 
morbidity and mortality rates of pneumonia, suggesting that targeting the microbes 
can help prevent or minimize pneumonia associated injury (Mizgerd., 2006; 
Quinton et al., 2018; Gessner et al., 2008; Griffin et al., 2013; Grijalva et al., 2015). 
However, with the rise of antibiotic-resistant bacteria and viruses like influenza 
undergoing continuous antigenic drifts and shifts, it becomes crucial to understand 
better how our immune systems function during health and pneumonia (Kyaw et 
al., 2006; Lipsitch et al., 2005). Thus, a key to both preventing and treating this 
disease is to understand what goes right in young adults that makes them less 
likely to acquire pneumonia, and what happens later in life that renders older adults 
more vulnerable to developing pneumonia. 
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Streptococcus pneumoniae 
History and Identification 
Streptococcus pneumoniae or pneumococci are Gram-positive, catalase-negative, 
facultatively anaerobic bacteria of the phylum Firmicutes (Abdulllahi et al., 2012; 
Yahiaoui et al., 2016; Weiser et al., 2018). They are customarily visualized under 
a microscope as lancet-shaped cocci (elongated spheres) measuring less than 2 
micrometers in diameter, forming pairs of cocci (diplococci) or short chains of 
single spheres. Pneumococcal cells do not form spores and are not motile 
(Firshein, 2013). 
Pneumococcus is a highly invasive bacterial pathogen (Henriques-Normark and 
Tuomanen, 2004) and a leading cause of bacterial disease among the very young 
and very old (Weiser et al., 1994). S. pneumoniae was first isolated and identified 
by Louis Pasteur in France and George Miller Sternberg in the United States in 
1881 (Watson, 1993, Austrian, 1999). In 1920, S. pneumoniae was recognized to 
cause lung infections and thereby started to be referred to as pneumococcus. In 
1974, pneumococcus was observed to grow as cocci chains in liquid media and 
thereby acquired its present name of Streptococcus pneumoniae based on its 
characteristic growth (Watson, 1993). 
Pneumococcus has more than 95 recognized serotypes (Weiser et al., 2018). This 
serotype-based classification is based on its polysaccharide capsule, which covers 
the cell wall and is made of peptidoglycans and unique teichoic acid structures 
(van der Poll and Opal, 2009). Each serotype has a structurally distinct capsular 
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polysaccharide, which is antigenic and is a critical determinant of the serotype 
virulence and invasiveness (Morona et al.,1999). 
Colonization and Disease 
Pneumococcus lacks environmental reservoirs and commonly establishes 
asymptomatic residence in healthy individuals' nasopharynxes (Weiser, 2010). 
Pneumococcus can have a wide range of interactions with humans, multifaceted, 
and differing in disease outcomes (Weiser et al., 2018). Depending on the entry 
route, pneumococcus can lead to otitis media, meningitis, pneumonia, and other 
manifestations (Weiser et al., 2018). Once pneumococcus is spread from one 
person to another via droplets/aerosols, pneumococcus colonizes the 
nasopharynx, where it adheres to the respiratory tract's epithelial lining (van der 
Poll and Opal, 2009; Bogaert et al., 2004). Colonization involves pneumococcal 
binding to cell-surface carbohydrates such as N-acetyl glucosamine on the non-
inflamed epithelium (Bogaert et al., 2004; Henriques-Normark and Tuomanen, 
2013). Within the nasal cavity, pneumococcus uses its negatively charged capsule 
to protect itself from being trapped in mucous, thereby allowing an effective 
attachment to the nasopharyngeal epithelium to launch colonization (Henriques-
Normark and Tuomanen, 2013). Colonization can last for long periods (weeks) in 
adults and even more extended periods (months) in children without any severe 
consequence of disease (Bogaert et al., 2004; Kadioglu et al., 2008). However, 
once pneumococcus translocates into the distant lung or other organs, 
asymptomatic colonization transitions to disease (Bogaert et al., 2004). 
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Early in life, children are commonly subject to pneumococcal infections, where 
more than 80% of children have had at least one occurrence of acute otitis media 
before their third birthday (WHO., 2006; Cordeiro et al., 2016; Bergenfelz et al., 
2017). Additionally, pneumococcus is commonly found in middle ear aspirates of 
acute otitis media patients (Korona-Glowniak et al., 2018). Pneumococcus is a 
severe cause of meningitis. with an incidence of 17 cases per 100000 in children 
below 5 years old (O'Brien et al.,2009). Pneumococcal meningitis has a high 
fatality rate in children below five (Central for Disease Control). Pneumococcus is 
the most prevalent bacterial cause of community-acquired pneumonia, with an 
annual incidence of 34 to 40 cases per 1,000 children in the western world (Juven 
et al., 2000; Ostapchuk et al., 2004). 
Despite the advent of antibiotic use and the development of pneumococcal 
vaccines, pneumococcus remains a serious cause of morbidity and mortality. 
Pneumococcus has evolved various mechanisms to evade immune responses 
and therapies (Brooks and Mias., 2018). Like other bacteria, there is an increase 
in antibiotic resistance with pneumococcus (Weiser et al., 2018). Additionally, 
pneumococcus can shed its polysaccharide capsule and acquire a different 
capsule from other pneumococcal serotypes (Weiser et al., 2018; Kietzman et al., 
2016) 
Pneumococcus prevalence and asymptomatic colonization of upper respiratory 
tracts and its ability to translocate into the distal lung, blood, and other organs and 
cause severe invasive disease, as well as the rise of antibiotic resistance and its 
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ability to escape the immune response, affords it to be considered as one of the 
most important causes of morbidity and mortality world-wide and highlights the 
need for a better understanding of our immune responses (Ortqvist et al., 2005; 
Kadioglu et al., 2008; Van der Poll and Opal, 2009). 
Innate immune responses to pneumococcus 
The lung immune system includes complex and coordinated responses that 
protect the lungs, allowing them to effectively carry out their physiological 
respiration functions (Quinton et al., 2018). These complex and coordinated 
immune responses need well-established, balanced reactions; on one side of this 
balance, the immune system needs to resist the microbial pathology and clear the 
microbe, but on the other side of this balance, the immune system needs to limit 
the damages that it itself creates and be able to restore the lung tissue's 
homeostasis (Quinton and Mizgerd., 2015). An imbalance on either side of the 
balance can disturb homeostasis and lead to uncontrolled pneumonia (Quinton 
and Mizgerd., 2015). 
When microbes translocate into the distal lungs, they rapidly face several defenses 
of the innate immune response, beginning with the anatomical barriers like the 
mucociliary response, which acts to restrain and remove the microbe out of the 
lung. Additionally, the microbe is faced with the epithelial barrier itself, which 
prevents the microbe from entering the internal lung microenvironment (Sahin-
Yilmaz., 2011). Epithelial cells act beyond just a physical barrier, as they secrete 
along with other immune cells several antimicrobial chemicals like lysozymes, 
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lactoferrins, defensins, immunoglobulins, opsonins, and others (Whitsett et al., 
2015).  These antimicrobial chemicals act via several different mechanisms to 
control and remove the invading microbe, including creating holes in the microbe's 
membranes, sequestering nutrients from the microbes, and engulfing the microbe, 
enhancing their recognition and engulfment by resident phagocytic cells (Whitsett 
et al., 2015). Phagocytic cells utilize built-in receptors called pathogen recognition 
receptors (PRR) to recognize conserved patterns on the microbe's outer surfaces 
(Taylor et al., 2005; Hajjar et al., 2005; Dudek et al., 2016; Mijares et al., 2011; 
Noulin et al., 2005; Perros et al., 2011; Raoust et al., 2009). Once a PPR 
recognizes a microbe, the phagocytic cells engulf, entrap, and sequester the 
microbe in internal acidic vesicles, which are referred to as phagolysosomes, and 
act to dismantle the microbe and process it into small peptides, which are referred 
to as antigens (Jubrail et al., 2016; Riazanski., 2015; Di et al., 2006; Di et al., 2017). 
When phagocytic cells recognize and engulf an invading microbe, the phagocytic 
cells instigate changes in their transcriptional responses and thereby begin several 
downstream immune responses to better handle the invading microbe (Cai et al., 
2010; Greenberger et al., 1996; Gregory et al., 2007; Jones et al., 2005; Herbold 
et al., 2010; Jones et al., 2006; Pittet et al., 2007l Quinton and Mizgerd, 2011). 
These transcriptional responses come in several forms and shapes, including the 
production of cytokines and chemokines, which act as an alarming system that 
there is something wrong, produce a pro-inflammatory response and recruit 
additional help from innate recruited cells like neutrophils, and recruited 
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monocytes/macrophages which also act as phagocytic cells and utilize more 
sophisticated arsenals to destroy the microbes (Cai et al., 2010; Greenberger et 
al., 1996; Gregory et al., 2007; Jones et al., 2005; Herbold et al., 2010; Jones et 
al., 2006; Pittet et al., 2007l Quinton and Mizgerd, 2011). Phagocytic cells can help 
recruit other cells including lymphocytes (O'Garra et al., 1998; Sinigaglia et al., 
1999; Murphy et al., 2000; Sallusto et al., 2000). Lymphocytes require additional 
help from innate cells called antigen-presenting cells (APC) like macrophages and 
dendritic cells to get activated (O'Garra et al., 1998; Sinigaglia et al., 1999; Murphy 
et al., 2000; Sallusto et al., 2000). APCs present the microbial processed peptides 
(antigens) to lymphocytes through molecules present on their surfaces called 
major histocompatibility complex proteins (MHC-I and MHC-II) (Neefjes et al., 
2011; Bonilla and Oettegen., 2010). Once activated, lymphocytes undergo rapid 
proliferation and build a massive army that, unlike phagocytic cells, specifically 
target the presented antigens with a specific arsenal (Bonilla and Oettegen., 2010). 
Lymphocytes produce such a robust, specific response that it needs additional 
restraints to prevent unnecessary activation of lymphocytes by harmless non-
immunogenic peptides and self-antigens; these restraints come in the form of 
secondary signals from APC that are critical to lymphocyte activation (Bonilla and 
Oettegen., 2010). In the case this tremendous immune response and cell 
recruitment goes uncontrolled, the lungs undergo excessive injuries leading to 
disruption of the lung's anatomy and accumulation of recruited cells and edema 
fluid in the airspaces; thereby, pneumonia ensues (Mizgerd., 2006; Quinton et al., 
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2018). The combined disruption of alveolar structures and accumulation of 
inflammatory cells leads to interference with the lung's physiological functions, 
making it difficult to provide oxygen to the body and release the body's built-up 
carbon dioxide. 
Lung Macrophages 
Central to instigating and orchestrating the above immune responses, to resolving 
the lung injury, and to restoring homeostasis are lung resident immune cells called 
macrophages (Wynn et al., 2013; Watanabe et al., 2019; Mould et al., 2019; Xu-
Vanpala et al., 2020; Gibbings et al., 2017; Hussel and Bell., 2014; Evern et al., 
2019). Macrophages were first discovered in 1884 by a Russian Zoologist Elie 
Metchnikoff (Cooper and Alder., 2006; Epelman et al., 2014). They were named 
due to their prominent appearance under the microscope (Macro) and their 
tendency to phagocytose (Phage: to eat). Macrophages are present in every tissue 
and play critical roles in development, homeostasis, and during injury and repair 
(Watanabe et al., 2019; Mould et al., 2019; Xu-Vanpala et al., 2020; Gibbings et 
al., 2017; Hussel and Bell., 2014; Evern et al., 2019). Macrophages have been 
recognized to have broad plasticity where they have been divided for simplification 
reasons into two categories an M1 (classically activated) and M2 phenotype 
(alternatively activated), where M1 holds a pro-inflammatory transcriptional profile 
that can be induced in vitro by IFN and M2 phenotype maintains an anti-
inflammatory transcriptional profile that can be generated in vitro by IL-4 and IL-13 
(Mills et al., 2000; Mills et al., 2012; Xue et al., 2014; Watanabe et al.,2019). 
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However, this simplification of macrophages phenotypes has since been less 
valued as both phenotypes have been found to exist simultaneously from in vivo 
studies (Janssen et al., 2011; Reyfman et al., 2018; Guilliams et al., 2018; 
Nahrendorf et al., 2016; Watanabe et al., 2019). Moreover, M2 phenotype has 
been found to have a spectral of transcriptional profiles (Janssen et al., 2011; 
Misharin et al., 2017; Reyfman et al., 2018; Guilliams et al., 2018; Nahrendorf et 
al., 2016; Watanabe et al., 2019). The current understanding is that these two 
profiles have overlapping features. There is no single gene that is sufficient to 
classify these phenotypes as M1 or M2. Instead, multiple gene signatures are 
required for such classification (Janssen et al., 2011; Misharin et al., 2017; 
Reyfman et al., 2018; Guilliams et al., 2018; Nahrendorf et al., 2016; Watanabe et 
al., 2019). 
Anatomical distribution of Lung Macrophages 
The lungs contain multiple types of macrophages, which differ in their origins, 
locations, numbers, and functions (Wynn et al., 2013; Watanabe et al., 2019; 
Mould et al., 2019; Xu-Vanpala et al., 2020; Gibbings et al., 2017; Hussel and Bell., 
2014; Evern et al., 2020). Regardless of their origins, distribution, or location, 
macrophages are capable of carrying out several functions, including; 
phagocytosis and killing of invading microbes, instigating an inflammatory 
response, secretion of cytokines and chemokines, antigen presentation to 
lymphocytes, efferocytosis of dying cells, repair of lung's anatomical structures and 
homeostasis (Wynn et al., 2013; Watanabe et al., 2019; Mould et al., 2019; Xu-
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Vanpala et al., 2020; Gibbings et al., 2017; Hussel and Bell., 2014; Evern et al., 
2020). In the lung airspaces, alveolar macrophages (AMs), which are the sentinels 
of the external alveolar space, establish homeostasis in the absence of injury and 
instigate and orchestrate the complex immune responses against invading 
microbes and prompt the repair and resolution of the lung once the microbial 
damage is under control and removed (Wynn et al., 2013; Watanabe et al., 2019; 
Mould et al., 2019; Xu-Vanpala et al., 2020; Gibbings et al., 2017; Hussel and Bell., 
2014; Evern et al., 2020). Interstitial macrophages (IM) exist in the lung interstitium, 
where they exist near vascular and neural structures in the lung patrolling for 
antigens (Gibbings et al., 2017; Chakarov et al., 2019). Several IM subsets display 
several distinct phenotypes depending on their distribution (Gibbings et al., 2017; 
Chakarov et al., 2019). IM subsets lack the ability to self-renew, and thereby they 
are replaced continuously by monocytes and carry out pro-inflammatory 
responses during injury, travel to neighboring lymph nodes (LN), where they carry 
out antigen presentation to lymphocytes (Evren et al., 2020; Gibbings et al., 2017; 
Chakarov et al., 2019). The third category of macrophages exists during 
inflammatory injury; recruited monocytes differentiate into inflammatory 
macrophages and help phagocytose and clear the microbial damage (Mould et al., 
2019; Watanabe., 2019). 
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Alveolar macrophages 
Discovery and Ontogeny 
Alveolar macrophages are long-lived cells that inhabit the lung alveoli and, to a 
lesser degree, the airways days after birth. Studies on stillborn fetuses have shown 
that lung airspaces are devoid of AMs at birth (Epelman et al., 2014; Watanabe et 
al., 2019). AMs have been long speculated to originate from monocytes from 
hematopoietic stem cells (HSC) (van Furth and Cohn, 1968; Volkman et al., 1983; 
Sawyer et al., 1982; Epelman et al., 2014). This speculation came from early 
studies by Van Furth and colleagues, where mouse bone marrows were depleted 
using whole-body gamma irradiation and replaced with new thymidine-labeled 
bone marrow (van Furth and Cohn, 1968; Volkman et al., 1983; Sawyer et al., 
1982; Epelman et al., 2014). In the studies mentioned above, AMs were observed 
to be replenished by thymidine-labeled monocytes and the AMs pool were 
incorrectly attributed to solely originate from adult HSC (van Furth and Cohn, 1968; 
Volkman et al., 1983; Sawyer et al., 1982; Epelman et al., 2014). However, with 
the advancement of lineage tracing mouse models to study immune cells, the use 
of chemicals to deplete AMs, and the use of chest shielding of mice during gamma 
irradiation, it is now recognized that lungs maintain a local niche to replace AMs 
independent from bone marrow derived-monocytes (Ginhoux et al., 2010; Schulz 
et al., 2012; Yona et al., 2013; Guilliams et al., 2013; Hashimoto et al., 2013; 
Epelman et al., 2014; Jakubzick et al., 2013). The reason for the initial incorrect 
speculation was due to local AM niche being depleted and damaged by gamma 
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irradiation and thereby hindering their ability to replenish depleted AMs (Ginhoux 
et al., 2010; Schulz et al., 2012; Yona et al., 2013; Hashimoto et al., 2013; Epelman 
et al., 2014; Guilliams et al., 2013; Jakubzick et al., 2013). It is now recognized 
that AMs can be replaced by local proliferation and by bone marrow derived-
monocytes, and the size and type of injury resulting in depletion of AMs is a major 
determinant of the replenishment source (Ginhoux et al., 2010; Schulz et al., 2012; 
Yona et al., 2013; Hashimoto et al., 2013; Epelman et al., 2014; Guilliams et al., 
2013; Jakubzick et al., 2013; Yao et al., 2018; Aegerter et al., 2020). Recent 
studies using lineage tracing mouse models have demonstrated that AMs originate 
from embryonic, fetal monocytes, and these AM can self-maintain during steady-
state in the absence of inflammation (Ginhoux et al., 2010; Schulz et al., 2012; 
Yona et al., 2013; Hashimoto et al., 2013; Epelman et al., 2014; Guilliams et al., 
2013; Jakubzick et al., 2013; Yao et al., 2018; Aegerter et al., 2020). A protein 
regulating the actin cytoskeleton called L-plastin helps fetal monocytes migrate 
into the alveolar airspaces (Deady et al., 2014; Todd et al., 2016). Once in the 
airspaces, a cytokine produced by type II alveolar epithelial cells called GM-CSF 
(Granulocyte-macrophage- colony-stimulating factor) induces a master 
transcriptional factor called PPAR (peroxisome proliferator-activated receptor-
gamma), which acts as a regulator of lipid metabolism (Guilliams et al., 2013; 
Schneider et al., 2014; Evren et al., 2019; Guilliams et al., 2020). TGF- is another 
cytokine that has been shown to act in an autocrine fashion and critical for AMs 
development and homeostasis (Yu et al., 2017; Schneider et al., 2014; Guilliams 
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et al., 2020). Inflation and oxygenation of the lung after birth have also been 
suggested to play an important role in AMs maturation (Schneider et al., 2014; 
Guilliams et al., 2020). Other cytokines like IL-36 have been shown to promote 
AM survival post influenza injury (Wein et al., 2018; Evren et al., 2019). AM's lower 
expression of MAF transcription factor has been suggested to be an important 
factor for their self-renewing capability (Aziz et al., 2009; Evren et al., 2019). AMs 
can be depleted during severe tissue injuries like ionizing radiation, bleomycin 
injury, and viral and bacterial infections (Ginhoux et al., 2010; Schulz et al., 2012; 
Yona et al., 2013; Hashimoto et al., 2013; Epelman et al., 2014; Guilliams et al., 
2013; Jakubzick et al., 2013; Yao et al., 2018; Aegerter et al., 2020).  Depending 
on the degree of injury, the pool of AMs may be restored either by local proliferation 
or, if the injury is more severe, by the marrow-derived AMs (Maus et al., 2006; 
Janssen et al., 2011; Evren et al., 2014; Ginhoux et al., 2010; Schulz et al., 2012; 
Yona et al., 2013; Hashimoto et al., 2013; Epelman et al., 2014; Guilliams et al., 
2013; Jakubzick et al., 2013; Yao et al., 2018; Aegerter et al., 2020). Several 
fibrotic model studies have demonstrated that monocytes-derived AMs inhabit the 
lung airspaces post-bleomycin-induced AMs depletion and persist for the long term 
(Misharin et al., 2017; McCubbery et al., 2017). In these studies, marrow-derived 
AMs promote fibrosis in the injured lung (Misharin et al., 2017; McCubbery et al., 
2017).  
AMs are essential for lung physiological functions. Lack of AM development and 
maturation due to loss of GM-CSF or PPAR results in a disease called pulmonary 
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alveolar proteinosis, an inflammatory lung syndrome that results from the 
accumulation of surfactant, which AMs usually catabolize to maintain homeostasis 
(Trapnell et al., 2019; Evren et al., 2019). Depletion of AMs post viral infections 
makes the lung vulnerable to bacterial infections and pneumonia (Ghoneim et al., 
2013; Evren et al., 2019). The lung microenvironment is an additional important 
determinant of the AM transcriptional and epigenetic profile (Gautier et al., 2012; 
Gosselin et al., 2014; Guth et al., 2009; Watanabe et al., 2019).  In a recent study, 
fetal monocytes, yolk-sac macrophages, and marrow-derived AMs were all shown 
to have the capacity to reconstitute an empty alveolar niche and thereby prevent 
diseases like PAP (Van de Laar et al., 2016; Watanabe et al., 2019). The 
proliferative capacity of fetal monocyte is likely a determinant of their inhabiting of 
the airspaces (Van de Laar et al., 2016; Watanabe et al., 2019). 
Isolation and Identification 
AMs retrievability through Broncho-alveolar lavage (BAL) collection has increased 
their likelihood to be studied. However, it is becoming more apparent that AMs 
collected through BAL fail to contain sessile AMs, firmly attached to lung alveolar 
epithelium (Westphalen et al., 2014). With the advancement of multi-color flow 
cytometry, the AMs phenotype has been more robustly characterized. AMs can be 
identified in whole lung single-cell suspensions and the BAL fluid by their high 
expression of CD11c, SiglecF, and CD64, along with low CD11b (Misharin et al., 
2013). SiglecF is a sialic acid-binding lectin-containing glycan exclusively 
expressed on AMs and eosinophils (Zhang et al., 2004; Feng et al., 2012; Misharin 
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et al., 2013). SiglecF is suggested to have negative feedback on eosinophils, 
where they induce cell death (Zhang et al., 2004; Feng et al., 2012; Misharin et al., 
2013). It is unclear what SiglecF's function is on AMs; however, inhibitory motifs 
on the cytosolic end suggest inhibitory effects (Zhang et al., 2004; Feng et al., 
2012; Misharin et al., 2013). CD11c is a transmembrane protein that combines 
with CD18 to form an adhesion molecule and complement receptor 4 (Lukacsi et 
al., 2017; Sandor et al., 2016; Erdej et al., 2019). CD11c is commonly expressed 
on DCs and AMs (Misharin et al., 2013). It functions to help cells in their trafficking 
as well as in opsonophagocytosis. CD64 is a transmembrane glycoprotein 
expressed on tissue macrophages (Misharin et al., 2013). CD64 is also known as 
FcRI because it functions as an Fc receptor to enhance opsonophagocytosis by 
binding the Fc domain of monomeric immunoglobulin G (Akinrinmade et al., 2017). 
Alveolar macrophages recognition of pathogens 
Alveolar macrophages utilize various pattern recognition receptors (PRR) to 
recognize the invading pathogens (Allard et al., 2018). These PRR act to recognize 
conserved molecular patterns conserved on the invading microbes (Allard et al., 
2018). During pneumococcal infection, AMs can identify pneumococcus by a 
variety of opsonic receptors and PRR, including Fc receptors, which recognize the 
Fc tail of immunoglobulin bound to bacteria; complement receptors CR1, CR3, and 
CR4, which recognize C3b protein on the bacterial surface; scavenger receptors; 
and Toll-like receptors (Gordon et al., 2000). 
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Once these PRR receptors are engaged, they send internal signals which 
converge on signaling hubs like nuclear factor κB (NF-κB) (Mizgerd, 2008; Quinton 
et a., 2018). NF-κB downstream elements then translocate into the nucleus, where 
they act as transcription factors that activate the production of cytokines, 
chemokines, and other pro-inflammatory mediators (Mizgerd, 2008; Quinton et al., 
2018). Alveolar macrophages first act to produce important cytokines like IL-1 and 
TNFα, which alarm other resident cells by ligating to receptors on their surfaces, 
thereby triggering a positive loop to amplify and coordinate the immune response 
(Mizgerd, 2008, Eisele and Anderson, 2011, Prince, 2013). Additionally, activation 
of NF-κB signals leads to the production of chemokines like CXCL1 and CXCL2, 
which act to recruit neutrophils to the infected lung (DidierLaurent et al., 2008; Cai 
et al., 2010; Yao et al., 2018). Impairment in these cytokines' production has been 
shown to reduce neutrophil recruitment and worsen the bacterial burden (Pittet et 
al., 2011). 
Alveolar macrophages' production of chemokines like CXCL1 and CXCL2 is an 
essential determining factor for the inflammatory response and infection outcome 
(DidierLaurent et al., 2008; Cai et al., 2010; Yao et al., 2018). After influenza 
infection, alveolar macrophages undergo a prolonged period of immune-paralysis 
where they exhibit a reduction in the induction of both CXCL1 and CXCL2 against 
secondary bacterial challenges (Didierlaurent A et al., 2008). In contrast, Yao et al 
demonstrated that post-recovery from respiratory infection with an adenoviral 
vaccine vector expressing a mycobacterial protein, AMs responses to subsequent 
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bacterial challenges become hyper-inflammatory. They exhibit increased induction 
of the chemokines CXCL1 and CXCL2 and neutrophil recruitment (Yao et al., 
2018). The disparities in the induction of these two chemokines post recovery from 
microbial challenges highlight the importance of AM remodeling on recruiting an 
inflammatory response and outcome of the disease (DidierLaurent et al., 2008; Cai 
et al., 2010; Yao et al., 2018). Once in the lung, bacteria utilize several virulence 
factors to evade recognition, proliferate, establish infection and avoid cell death 
(Casadevall and Pirofski, 2001). Pneumococcus use several virulence factors to 
establish an infection (Kadioglu et al., 2008, van der Poll and Opal, 2009). Some 
pneumococcus serotypes exhibit a thick capsule, preventing AMs and other 
phagocytic cells from engulfing the bacteria and phagocytosis. Another virulence 
factor utilized by pneumococcus to evade immune response is pneumolysin, a 
cholesterol-dependent, pore-forming exotoxin (Tuomanen, 2004). Pneumolysin 
cytotoxicity and pore-formation in leukocyte membranes lead to a significant 
impairment in immune cells' bactericidal functions (Prince, 2013, Kadioglu et al., 
2008; Hirst et al., 2004, Dockrell et al., 2012). In the last decade, another evasion 
strategy has been demonstrated, virulent pneumococcus escape activation of NF-
κB and instead target macrophages to a cell death pathway called necroptosis 
(Coleman et al., 2018). 
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Plasticity of tissue macrophages 
Tissue macrophages, including AMs, are incredibly plastic and undergo epigenetic 
reprogramming in a tissue-dependent manner. Microenvironment signals are 
integrated by tissue macrophages, allowing them to be shaped by tissue-specific 
needs (Wynn et al., 2013; Lavin et al., 2014). Additionally, AMs engage directly in 
numerous cross-talks with epithelium and other resident cells and recruited cells 
and the extracellular matrix (Hussel and Bell, 2014; Westphalen et al., 2014; 
Quinton et al., 2018). This plasticity and these numerous interactions with the 
environment and neighboring cells prepare AMs to play diverse roles during 
homeostasis, tissue injury, and resolution and repair (Hussel and Bell, 2014; 
Westphalen et al., 2014; Quinton et al., 2018). In contrast to dendritic cells and 
other resident immune cells, tissue macrophages display vast differences on the 
epigenetic level, suggesting that the tissue microenvironment shapes them. 
Recent transcriptomic profiling by ImmGen consortium of tissue macrophages 
from various tissues (Microglial cells, Kupffer cells, splenic red pulp macrophages, 
and peritoneal macrophages) demonstrated that different subsets of tissue 
macrophages are uniquely defined by microenvironment derived factors and 
exhibit more distinctions than similarities on the transcriptional programming level 
(Gautier et al., 2012; Gosselin et al., 2014; Guth et al., 2009; Watanabe et al., 
2019).  Further studies profiling tissue macrophages on the transcriptional and 
epigenomic level revealed that they can be distinguished by histone modification 
in both the promoter and enhancer regions (Gautier et al., 2012; Gosselin et al., 
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2014; Guth et al., 2009; Watanabe et al., 2019).  Macrophages typically share a 
common specific enhancer-binding domain for the transcription factor PU.1. 
However, each tissue exhibits distinct enrichment for other transcription factor 
binding domains; for example, AMs have enrichment for PPAR binding domain 
(Shibata et al., 2001; Baker et al., 2010; Gautier et al., 2012). Interestingly, both 
embryonically derived macrophages, as well as adult marrow-derived 
macrophages, share similar enhancer landscapes, emphasizing the plasticity as 
well as the importance of microenvironmental signals in shaping macrophages 
identity (Gautier et al., 2012; Gosselin et al., 2014; Guth et al., 2009; Watanabe et 
al., 2019). These epigenetic changes are reversible, where the adoptive transfer 
of macrophages from one tissue to another leads to macrophages undertaking the 
phenotype of recipient tissue (Gautier et al., 2012; Gosselin et al., 2014; Guth et 
al., 2009; Watanabe et al., 2019). 
Macrophages display additional plasticity by undergoing an M1 pro-inflammatory 
phenotype or an M2 anti-inflammatory phenotype (Mills et al., 2000; Mills et al., 
2012; Xue et al., 2014; Watanabe et al.,2019). A microenvironment rich in signals 
like lipopolysaccharide or IFN skews macrophage phenotype, thus inducing the 
production of pro-inflammatory cytokines like TNF and IL-6 (Mills et al., 2000; 
Mills et al., 2012; Xue et al., 2014; Watanabe et al.,2019). On the other hand, a 
microenvironment rich in IL-4 and IL-13 induces macrophage skewing towards an 
anti-inflammatory phenotype, producing cytokines like IL-10 and TGF (Mills et al., 
2000; Mills et al., 2012; Xue et al., 2014; Watanabe et al.,2019). While 
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macrophages can undergo skewing in their phenotype one way or the other due 
to the microenvironment, at any given condition, macrophages can partake both a 
pro-and anti-inflammatory phenotype (Janssen et al., 2011; Misharin et al., 2017; 
Reyfman et al., 2018; Guilliams et al., 2018; Nahrendorf et al., 2016; Watanabe et 
al., 2019). During acute injury, additional recruited macrophages exist in the injured 
tissues, which undertake a pro-inflammatory phenotype compared to tissue-
resident macrophages, which launch a more homeostatic anti-inflammatory 
phenotype (Janssen et al., 2011; Misharin et al., 2017; Reyfman et al., 2018; 
Guilliams et al., 2018; Nahrendorf et al., 2016; Watanabe et al., 2019). Studies that 
fail to examine macrophages on the single cells level are therefore likely to exhibit 
results that fail to correctly define M1 or M2 phenotype classification (Janssen et 
al., 2011; Misharin et al., 2017; Reyfman et al., 2018; Guilliams et al., 2018; 
Nahrendorf et al., 2016; Watanabe et al., 2019). 
Marrow Derived-Alveolar Macrophages 
During acute tissue injuries of the lung, AMs are subjected to numerous factors 
that modulate their functions and affect their cell survival. Engulfment of pathogens 
and infected cells, as well as efferocytosis of cells dying from necroptosis or 
pyroptosis 
release damage- or pathogen-associated molecular patterns (DAMPs or PAMPs); 
these factors activate an inflammatory signaling pathway in macrophages, which 
lead to the recruitment of neutrophils, monocytes, and other inflammatory cells to 
the injured lung (Cai et al., 2010; Greenberger et al., 1996; Herbold et al., 2010; 
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Jones et al., 2006; Xiong et al., 2015; Watanabe et al., 2019). Monocytes utilize 
several chemokines and chemokine receptors to traffic out from the bone marrow 
and into the lung during injury (Xiong et al., 2015; Maus et al., 2002). Most 
importantly, monocyte trafficking into the lung is dependent on the chemokine 
receptor (CCR2) (Xiong et al., 2015; Maus et al., 2002). Mice that are deficient in 
CCR2 exhibit impairment in monocyte recruitment and in the clearance of invading 
pathogens (Xiong et al., 2015; Maus et al., 2002). Upon entry into the lung, newly 
recruited monocytes differentiate into macrophages and assist in the pathogen's 
clearance. Once the injury is under control, both embryonic and newly recruited 
macrophages cooperate to suppress inflammation and initiate wound repair and 
resolution by producing growth factors (Watanabe et al., 2018; Vannella et al., 
2017). Once lung injury is resolved, recruited macrophages undergo two potential 
fates; they can either undergo apoptosis, allowing the embryonic niche to restore 
resident AMs that are lost during the inflammatory injury (Watanabe et al., 2019; 
Mould et al., 2019) or the continuous exposure to signals from tissue 
microenvironment, they acquire a phenotype resembling resident embryonic AMs 
and persist in the lung (Watanabe et al., 2019; Misharin et al., 2017; McCubbery 
et al., 2017; Mould et al., 2019). The type, the severity, and the duration of the 
inflammatory injury are likely to determine the fate of recruited macrophages 
(Watanabe et al., 2019; Mould et al., 2019). Recent transcriptional studies on a 
single-cell level have demonstrated at least five distinct AMs phenotypes during 
steady-state, inflammation, and injury resolution (Mould et al., 2019). While both 
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ontogenies of AMs generally undergo similar changes in gene expression in 
response to the same stimuli, marrow-derived AMs tend to display more robust 
responses (Jakubzick et al., 2013). Two recent studies examining the difference 
between AMs ontogenies in responses to lung fibrosis have demonstrated that 
targeted deletion of marrow-derived AMs or the use of CCR2-/- to prevent 
monocyte recruitment ameliorates lung fibrosis (Misharin et al., 2017; McCubbery 
et al., 2017). In contrast, targeted deletion of embryonic AMs had less favorable 
lung fibrosis outcomes (Misharin et al., 2017; McCubbery et al., 2017). Altogether 
these results highlight AM ontogeny's importance during acute injury and highlight 
the importance of a better understanding of how different models impact the 
recruitment and maintenance of marrow-derived AMs and how having these 
various ontogenic AMs impacts homeostatic functions and responses to injury. 
Remodeling of the pool of AMs 
Several recent papers have highlighted the impact of different injurious histories 
and length of time after injuring AMs remodeling and responses (Misharin et al., 
2017; McCubbery et al., 2017; Yao et al., 2018; Aegerter et al., 2020; Roquilly et 
al., 2020). The result on the impact of various injuries can be categorized into two 
themes; trained immunity or persistence of marrow-derived AMs in the lung 
(Misharin et al., 2017; McCubbery et al., 2017; Yao et al., 2018; Aegerter et al., 
2020; Roquilly et al., 2020). In one study, Yao et al demonstrated that recovery 
from a respiratory viral infection induces a long-lasting memory-like phenotype in 
AMs, where AMs exhibited a higher expression of MHC-II on their surfaces, a gene 
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signature that is defense ready, increased glycolytic metabolism as well as 
increased chemokine production upon memory recall (Yao et al., 2018). In their 
study, Yao et al demonstrated that effector CD8+ T cells prime AMs to undergo 
remodeling via IFN, independent of monocyte recruitment (Yao et al., 2018). In 
contrast to the study mentioned above, Aegerter et al demonstrated that recovery 
from influenza infection resulted in the recruitment of marrow-derived AMs, which 
persisted after recovering from flu injury (Aegerter et al., 2020). They further 
demonstrated that while recruited-AMs have a similar surface phenotype to 
embryonic AMs, recruited-AMs exhibited a uniquely distinct transcriptional, 
functional, and epigenetic profile compared to embryonic AMs (Aegerter et al., 
2020). Aegerter et al further demonstrated that embryonic AMs from influenza-
experienced mice remained very similar to naïve AMs (Aegerter et al., 2020). Both 
studies mentioned above highlighted a remodeled experienced AMs pool, which 
exhibited a superior anti-bacterial defense upon memory recall (Yao et al., 2018; 
Aegerter et al., 2020). While in the Yao et al study, experienced AMs exhibited 
their anti-bacterial defenses by increasing neutrophilic chemokines production, 
experienced AMs from Aegereter et al, the study demonstrated their anti-bacteria 
defenses via increased production of IL-6 cytokine from epigenetically more 
accessible chromatin (Yao et al., 2018; Aegerter et al., 2020). 
While both studies above highlighted experienced AMs with superior anti-bacterial 
defense mechanisms, other studies have highlighted AMs long-term immune-
paralysis post recovery from bacterial pneumonia (Roquilly et al., 2020). Roquilly 
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et al demonstrated that AMs underwent long-lasting epigenetic tolerogenic trained 
programming at different time-periods post recovery from E.coli or S.aureus 
pneumonia (Roquilly et al., 2020). This tolerogenic training was induced by 
secondary immunosuppressive signals like SIRPα from the lung 
microenvironment, not by the pathogen's encounter (Roquilly et al., 2020). They 
further demonstrated in this study that experienced AMs exhibited a lower 
phagocytic capacity, making the mice more vulnerable to secondary pneumonia 
(Roquilly et al., 2020). Other studies have also highlighted AMs immune paralysis 
during recovery from the influenza virus. Sun et al demonstrated that IFN  
produced during influenza infection reduced AMs phagocytic capacity and 
decreased the scavenger receptor MARCO expression on day 7, leading to the 
impaired binding and internalization of S. pneumoniae (Sun and Metzger, 2008). 
Thus, making the mice more vulnerable to secondary bacterial pneumonia. 
Similarly, Didierlaurent et al demonstrated that TLRs are long-term desensitized to 
their ligands after influenza infection, thus impairing AMs chemokine production 
(Diderlaurent et al., 2008). These studies collectively highlight the impact of 
different injury models on the remodeling of the pool of AMs phenotype and 
function (Yao et al., 2018; Aegerter et al., 2020; Roquilly et al., 2020). They also 
emphasize the importance of careful interpretation of data on AMs reprogramming. 
Lineage Tracing Alveolar macrophages origin 
Lineage tracing was developed as a powerful tool to trace a cell's origin and track 
its progeny during development, homeostasis, and disease (Kretzschmar and 
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Watt, 2012). Charles Whitman initially pioneered lineage tracing in the 19th century 
(Conklin et al., 1905; Kretzschmar and Watt., 2012). There are several methods 
for lineage tracing, one of which is genetic recombination to label mark cells. 
Lineage tracing using genetic recombination has become a consistent method for 
tracking cells (Kretzschmar and Watt, 2012). A recombinase enzyme is expressed 
under a cell- or tissue-specific promoter in one mouse line; the mouse line is then 
crossed with a mouse line in which a loxP-STOP-loxP sequence prevents 
expression of the reporter. The resulting progeny now has a recombinase enzyme 
that acts on the loxP sites resulting in genetic recombination leading to the 
reporter's activation by excising the stop sequence (Kretzschmar and Watt, 2012). 
Nowadays, multi-color reporters are being used more and more in tracking the 
contributions of different cells to the maintenance and resolution of a cell or tissue 
(Rinkevich et al., 2011; Kretzschmar and Watt, 2012). FlkSwitch mice are a dual-
color mouse reporter generated by crossing Cre recombinase enzyme under the 
control of FLK2 promoter to mice containing a dual-color fluorescent reporter 
driven by Rosa26 locus, a promoter that drives ubiquitous expression of the 
reporter (Benz et al., 2008; Muzumdar et al., 2007; Boyer et al., 2011). Cells from 
FlkSwitch progeny, which lack FLK2 Cre, express the red-fluorescing protein 
tdTomato (Boyer et al., 2011). In contrast, FlkSwitch mice cells that express FLK2 
Cre excise the loxP sites floxed tdTomato-STOP and instead express GFP 
resulting in an irreversible genetic episode progeny continuously express GFP 
(Boyer et al., 2011). AMs are initially embryonically derived from fetal monocytes 
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maintained under homeostatic conditions with minimal contributions from adult 
marrow-derived cells (Murphy et al., 2008; Guilliams et al., 2013; Hashimoto et al., 
2013). However, AMs are lost during injury and are replaced by both embryonic-
derived AMs and marrow-derived AMs during injury (Misharin et al., 2017; Maus 
et al., 2006). Embryonic derived AMs lack the expression of FLK2 Cre and thereby 
expressed tdTomato driven by Rosa26 locus. In contrast, AMs derived from adult 
HSC express FLK2 Cre and thereby excise tdTomato expression and instead 
express GFP, inherited by their progeny (Hashimoto et al., 2013). 
Resident Memory T cells 
Recruitment of adaptive cells and antigen presentation 
When AMs and other resident cells fail to control and the pathogen, they begin to 
recruit cells in multiple waves. Within the first few days of the infections, resident 
cells recruit a first wave in the form of innate immune cells like neutrophils and 
monocytes, which employ non-specific arsenals to assist in clearing the pathogen 
(Watanabe et al., 2019). Meanwhile, professional antigen-presenting cells 
(Dendritic cells and macrophages) travel to the adjacent mediastinal lymph nodes 
(Kugathasan et al., 2008; Jakubzick et al., 2013; Kirby et al., 2013). At local lymph 
nodes, APC activates adaptive cells called lymphocytes by presenting microbial 
antigens and providing secondary activating signals (Kugathasan et al., 2008; 
Jakubzick et al., 2013; Kirby et al., 2013). Activated lymphocytes will then undergo 
clonal expansion and differentiate into effector cells that migrate into the lung and 
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utilize antigen-specific arsenal to control and clear the pathogen (Rivera et al., 
2006). Once the pathogen has been removed, effector lymphocytes undergo one 
of two fates, they either undergo apoptosis or small subsets differentiate into 
memory cells that are capable of building a more robust and faster immune 
response upon memory recall (Farber et al., 2014).  
Establishment of residency 
Early studies on memory T lymphocytes identified two subsets, a central memory 
(TCM)  and an effector memory (TEM) cells, which differed in their anatomical 
locations, functions, and surface expressions (Farber et al., 2014). While TCM 
expressed CCR7 and CD62L are highly proliferative, they are predominantly found 
in secondary lymphoid organs; effector memory T cells, on the other hand, do not 
express these cell surface markers, are less proliferative, yield numerous 
modulatory effector cytokines such as IL-17 and IFN and exhibit varied migratory 
capacity (Mueller et al., 2013). In the last decade, a third non-circulating resident 
memory T cell (TRM) subset remained in the peripheral tissue after recovery from 
infections and inflammation (Mueller et al., 2013). TRM formation was first 
identified to form in the lungs post recovery from influenza infection (Hogan et al., 
2001). Shortly after, they were shown to reside in several non-lymphoid organs 
such as the liver, intestines, and lung after viral and bacterial challenges (Masopust 
et al., 2001). While early studies focused on generating CD8 TRM, resident 
memory CD4 TRM was also shown to form in non-lymphoid organs post recovery 
from infection (Reinhardt et al., 2001). Several studies have highlighted the 
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formation of CD4 TRM in several normal human and mice tissues, including the 
lungs, the skin, and the intestines (Purwar et al., 2011; Sathaliyawala et al., 2013; 
Teijaro et al., 2011; Turner et al., 2014). Resident memory T cells have been 
shown to express several receptors that act to retain and home these cells to 
specific tissues, including CD69, CD11a, and CD103 (Turner et al., 2014). In 
contrast to spleen memory T cells, which migrate to several tissues, adoptive 
transfer of resident memory T cells from the lung results in their homing and 
migration toward the recipient lungs (Teijaro et al., 2011). 
Having new lymphocytes reside in the tissues has an essential impact on the tissue 
microenvironment. Several papers have highlighted the roles of lymphocytes in 
priming trained immune resident cells and modulating the immune response upon 
memory recall (Smith et al.,2017; Yao et al., 2018; Shenoy et al., 2019). In their 
study, Smith et al show when CD4+ TRM cells are stimulated ex vivo, they produce 
significant amounts of effectors cytokines, including IFN, GM-CSF, and IL-17 
(Smith et al., 2017). They also show that experienced lungs that retain CD4 TRM 
have accelerated neutrophil recruitment and a multi-log reduction in bacterial 
burden upon memory recall. The depletion of CD4 TRM results in impairment of 
experienced lung protection (Smith et al., 2017). In a follow-up study, Shenoy et al 
show that the accelerated neutrophil recruitment Smith et al observed is due to the 
remodeling of lung epithelial cells by resident memory CD4 TRM (Smith et al., 
Shenoy et al., 2019). In their study, Shenoy et al demonstrate that CD4 TRM 
formed in the lung post recovery from pneumococcal challenges produce 
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significant IL-17, which induces CXCL5 production by epithelial cells by stabilizing 
epithelial cells mRNA (Shenoy et al.,2019). Yao et al showed in their study that 
effector CD8 lymphocytes produce increasing amounts of IFN, which primes AMs 
with an experienced like phenotype with increased MHC-II expression, a gene 
signature that is defense ready, increased glycolytic metabolism as well as 
induction of CXCL1 and CXCL2 upon memory recall (Yao et al., 2018). 
Interferon Gamma Biology 
Interferon-gamma (IFN) is a pleiotropic cytokine that plays a diverse role during 
development, health, and disease. IFN was originally named macrophage-
activating factor due to its importance in macrophage activation. Interferons are 
named as such due to interference with viral replication (Isaacs et al., 1957). IFN 
is the only member of type II interferons that differ from type I interferons with their 
sequence homology, structure, and receptor specificity (Schroder et al., 2004). 
Several cell types have been shown to produce IFN. Early studies attributed IFN 
production exclusively to NK cells, CD4 T helper cells (Th1 CD4 cells), and 
Cytotoxic CD8 T cells (Young et al., 1996; Bach et al., 1997). However, several 
other cells were later shown to produce IFN at different settings and time-points 
including, neutrophils, subsets of B cells, NKT cells, innate lymphocytes, and 
professional antigen-presenting cells like dendritic cells and macrophages 
(Gessani et al., 1998; Frucht et al., 2001; Fuchs et al., 2013; Yamada et al., 2011; 
Gomez et al., 2015).  
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IFN signaling 
IFN binds exclusively to the IFN receptor (IFNGR), consisting of two ligand-
binding chains (IFNGR1 and IFNGR2). While IFNGR1 is ubiquitously expressed 
on most cells, IFNGR2 chain expression levels are tightly regulated (Bach et al., 
1997, Bernabie et al., 2001). IFNGR chains lack enzymatic activity on their 
intracellular sides, and therefore they retain binding motifs for Janus tyrosine 
kinases (Jak) and signal transducer and activator of transcription 1 (Stat1) (Farrar 
et., 1991; Farrar et al.,1993). When IFN ligand binds to its receptors, Jak2 rapidly 
docks on its binding motif on the IFNGR2 chain and autophosphorylates itself as 
well as transphosphorylates Jak1 leading to a transformational change that creates 
docking sites for a pair of cytosolic Stat1 (Greenlund et al., 1994; Igarashi et al., 
1994; Greenlund et al., 1995; Heim et al., 1995). Within a minute, Stat1 homodimer 
gets phosphorylated by Jak kinases on Y701 within their C-terminal regions and 
are released, allowing them to translocate into the nucleus where they act as 
transcription factors (Greenlund et al., 1994; Briscoe et al., 1996; Igarashi et al., 
1994). Once in the nucleus, the Stat1 homodimers bind DNA at a conserved 
sequence called GAS elements triggering activation of waves of IFN 
transcriptions induction (Decker et al., 1997). Within 30 minutes of the binding, 
several transcription factors called Interferon regulatory factors (IRF) are induced, 
which help initiate the second wave of IFN induced genes that act on the cell to 
promote its cellular function (Kerr et al., 1991). IFN signaling also leads to the 
induction of the third wave of genes that negatively regulate and shut down IFN 
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signaling within an hour of the initial IFN ligand binding to its receptor (Stark et al., 
1998; Darnell Jr et al., 1997). IFN induces the production of a specific feedback 
inhibitor called SOCS-1 (Suppressor of cytokine signaling) as well as some 
phosphatases which associate with Jak kinases and Stat1 homodimers, 
dephosphorylate them and interfere with their kinase activity, thereby shutting 
down their downstream signaling (Endo et al., 1997; Starr et al., 1997; Sakamoto 
et al., 1998; Yasukawa et al., 1999; You et al., 1999). 
IFN signaling is additionally regulated on several other stages. Several cytokines, 
including IL-12 and IL-18, promote IFN productions (Salazar-Mather et al., 2000; 
Pien et al.,2000), while other cytokines including IL-4, IL-10, and TGF inhibit IFN 
production (Sen et al., 2001; Fukao et al., 2001; Schindler et al., 2001). Once the 
IFN ligand binds to its receptor, the ligand-receptor complex is internalized. It 
enters an endosome pathway where the complex dissociates, the ligand is 
degraded, and the receptors are recycled back to the surface in their uncoupled, 
dephosphorylated forms (Anderson et al.,1983; Celada et al., 1987; Farrar et., 
1993; Schreiber et al., 1993). 
IFN immune functions and macrophage activation 
IFN signaling plays essential diverse roles in both innate and adaptive immunity 
responses. While mice with knockouts of IFN or IFNGR1 proteins exhibit no 
discernable developmental defects, these mice exhibit insufficiencies in their 
natural resistance to both viruses and bacteria (Huang et al., 1993). IFN signaling 
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stimulates macrophages activation, which enhances their microbicidal effector 
functions on multiple levels. Activated macrophages exhibit increased pinocytosis 
and receptor-mediated phagocytosis. Additionally, activated macrophages exhibit 
enhanced microbial killing by induction of NADPH-dependent oxidase activity, 
which leads to an increase in the production of NO, tryptophan depletion, and up-
regulation of lysosomal enzymes (Boehm et al., 1997). Ultimately, induction of 
NADPH-dependent oxidase, as well as iNOS by IFN signaling, culminates in an 
increase in the making of reactive oxygen species (ROS) and reactive nitrogen 
intermediates (RNI) (MacMicking et al., 1997; Roos et al.,1992; Nathan et al., 
1992). Both ROS and RNI then penetrate microbial cell walls leading to the 
destruction of bacteria, viruses, and other pathogens (MacMicking et al., 1997; 
Roos et al.,1992; Nathan et al., 1992). IFN signaling enhances microbial killing by 
inducing complement-mediated phagocytosis through increased complement 
secretion and an increased surface expression of complement receptors, as well 
as antibody-dependent, cell-mediated cytotoxicity through upregulation of 
CD64/FcRI on macrophages (Strunk et al., 1985; Erbe et al., 1990). 
IFN signaling also plays essential roles in orchestration the trafficking of recruited 
immune cells to the site of infection by upregulating the expression of several 
chemokines (CCL2, CCL5, CXCL9, and CXCl10) and adhesion molecules (ICAM-
1 and VCAM-1) (Boehm et al., 1997). Moreover, IFN enhances cell recruitment 
by causing vasodilation of local blood vessels (Schroder et al., 2004). 
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IFN signaling can additionally impact macrophage's survival, proliferation, and cell 
death. IFN protects against microbe-induced cell death and inhibits macrophages 
cell growth driven by colony-stimulating factor-1 (Xaus et al., 1999). However, GM-
CSF has been shown to counter IFN growth inhibition on macrophages (Karupiah 
et al.,1993). IFN arrests cell growth at the G1/S checkpoint by induction of P21 
and P27 cyclin-dependent kinase inhibitors, which inhibit cyclin-dependent 
kinases' activity (Mandal et al., 1998; Chin et al., 1996; Takami et al., 2002). 
Additionally, IFN plays contradicting role in promoting cell survival or cell death 
(Schroder et al., 2004). While macrophages undergo apoptosis to protect the 
tissue from colonization by intracellular bacteria, many microbes have evolved 
virulent factors to induce macrophage cell death by production of toxin which cause 
DNA and cell membrane damage (Tanaka et al., 1994; Tanigushi et al., 1997; 
Tamura et al., 1997; Coleman et al., 2017; Gonzalez-Juarbe et al., 2015; Kitur et 
al., 2015). The level of expression of IRF-1 and IFNGR can explain these 
contradicting roles on the cell (Bernabie et al., 2001; Novelli et al., 1996; Bernabie 
et al., 2001). Increasing expression of IFNGR on cells that otherwise would have 
low expression of IFNGR induces these cells to undergo apoptosis in response to 
IFN stimulation rather than their natural anti-apoptotic/ proliferative response 
(Bernabie et al., 2001). Similarly, CD4 Th1 cells express low levels of IFNGR2, 
and thereby they are not subject to IFN induced proliferation inhibition and 
continue to proliferate during IFN stimulation (Pernis et al., 1995; Bach et al., 
1995). On the other hand, CD4 TH2 cells express high levels of IFNGR2 and are 
 
37 
 
thereby undergoing growth arrest and apoptosis upon IFN stimulation, enhancing 
the T cell population switch to Th1 phenotype (Bach et al., 1995). 
IFN signaling can drive additional functions on lymphocytes like promoting B cell 
isotype switching to IgG2a (Huang et al., 1994; Collins et al., 1993; Snapper et al., 
1987). IFN signaling can drive the transition from innate immune responses to 
adaptive immune responses by promoting antigen presentation. IFN stimulates 
an increase in expression of both MHC-I and MHC-II, as well as the co-stimulatory 
proteins essential for the antigen presentation process (Boehm et al., 1997; Mach 
et al., 1996). Additionally, IFN plays a vital role in processing and loading the 
peptide on MHC molecules by replacing proteasome subunits and inducing Tap 
transporter and DM regulator, respectively (Groettrup et al., 2001; York et al., 
1996; Lah et al., 1995). 
Major Histocompatibility Complex 
Antigen presentation represents a critical step for the transition from innate to 
adaptive immunity (Vyas et al.,2008; Kurts et al., 2010; Neefjes et al., 2011).  
Molecules called major histocompatibility complex (MHC) are surface proteins that 
carry out antigen presentation, acting to activate T lymphocytes (Vyas et al., 2008; 
Neefjes et al., 2011). Thus far, two MHC molecules have been identified, which 
share some similarities but exhibit significant differences in structure, distribution, 
and sources of peptides and the type of cells they present (Vyas et al., 2008; 
Neefjes et al., 2011). While MHC-I is ubiquitously expressed on almost all cells, 
MHC-II is more confined to cells that are professional antigen presenters (APC) 
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like macrophages, DCs, and B lymphocytes (Vyas et al., 2008; Neefjes et al., 2011; 
Misharin et al., 2013; Evren et al., 2019). MHC-II has also been shown to be 
induced on other cells, including fibroblasts, endothelial and epithelial cells under 
certain inflammatory conditions (Geppert et al., 1985; Bland et al., 1988; Koretz et 
al., 1987). While MHC-I typically presents intracellular peptides to CD8 T cells, 
MHC-II presents extracellular peptides to CD4 T cells (Vyas et al., 2008; Neefjes 
et al., 2011). Structurally, MHC-II is a dimer consisting of a larger alpha chain and 
a smaller beta chain connected by non-covalent bonds (Vyas et al., 2008; Neefjes 
et al., 2011). Each chain consists of three domains: a glycoprotein containing an 
intracellular tail, a transmembrane segment, and an extracellular domain (Vyas et 
al., 2008; Neefjes et al., 2011). The most proximal domains come together to form 
a groove called antigen-binding cleft (Vyas et al., 2008; Neefjes et al., 2011). MHC-
II components are synthesized in the endoplasmic reticulum before being 
transported through the Golgi apparatus into endosomal compartments (Vyas et 
al., 2008; Neefjes et al., 2011). To prevent endogenous peptides from binding the 
antigen-binding cleft, an invariant chain blocks the groove created by alpha and 
beta chains coming together (Vyas et al., 2008; Neefjes et al., 2011). Once in an 
acidic endosome, the invariant chain is removed, and MHC-II antigen-binding cleft 
is free to host peptides (Vyas et al., 2008; Neefjes et al., 2011).  When 
macrophages and other APCs uptake a pathogen via phagocytosis, the generated 
phagosome fuses with lysosomes, which slices the pathogen proteins into smaller 
peptides by their acidic environment (Vyas et al., 2008; Neefjes et al., 2011). Once 
 
39 
 
MHC-II is loaded with peptides, they are transported to APCs' cell surface for 
antigen presentation (Vyas et al., 2008; Neefjes et al., 2011). When cognate T cell 
receptor on CD4 T cells recognize the peptides on MHC-II, T cell activation ensues 
(Vyas et al., 2008; Neefjes et al., 2011). To prevent unwanted T cell activation 
against endogenous peptides, a secondary signal has evolved to ensure proper 
activation (Vyas et al., 2008; Neefjes et al., 2011). If secondary signals are absent, 
activated T cells undergo tolerance (Vyas et al., 2008; Neefjes et al., 2011). MHC-
II further regulates T cells by having secondary signals, which can come in the 
form of co-stimulatory or co-inhibitory signals that lead to either T cell activation 
and proliferation or T cell inhibition, tolerance, and apoptosis, respectively (Vyas 
et al., 2008; Neefjes et al., 2011). 
While AMs express MHC-II and co-stimulatory proteins on their surface, they only 
express them to a lesser degree than other APCs in the lung-like DCs and IM 
(Kugathasan et al., 2008; Misharin et al., 2013). Although AMs have been shown 
to stimulate subsets of T cells like gamma delta T cells, AMs are generally 
accepted to be weak stimulators of naïve T cells and some instances to have 
immunosuppressive signals on T cells (Thepen et al., 1989; Holt et al., 1993; 
Thepen et al., 1992; Balaji et al., 1995; Kugathasan et al., 2008). AMs' capacity to 
act as functional APCs has been supported by some studies that underscored 
AMs' ability to migrate to adjacent lymph nodes (Bellingan et al., 1996, Kirby et al., 
2009). In contrast to naïve T cells activation, some studies have highlighted AMs' 
role in activating antigen-experienced as well effector and memory T cells within 
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the lung (Constant et al., 2002; Kugathasan et al., 2008). The recent study by Yao 
et al has highlighted the importance AMs' MHC-II expression (Yao et al., 2018). 
Their research showed that mice previously challenged with a viral vector exhibit 
an increase in effector CD8 T cells, which primed AMs via IFN, thereby increasing 
AMs MHC-II expression (Yao et al., 2018). Experienced AMs also exhibited an 
enhanced ability to produce several chemokines, including CXCL1 and CXCL2, 
upon memory recall (Yao et al., 2018). However, it remains unclear whether there 
is a correlation between having higher MHC-II on AMs and having better antigen 
presentation and immune responses upon memory recall. 
Pneumonia prevention and macrophage reprogramming 
Vaccines have emerged over the last century as one of the best strategies for 
disease prevention and eradication. Several vaccine development strategies, 
including whole- pathogen vaccines, subunit vaccines, and nucleic acid vaccines, 
have been innovated (Niaid.NIH.gov, 2019). Before discovering and using 
antibiotics to treat bacterial pneumonia, both whole-pathogen and subunit (purified 
capsular polysaccharide) vaccines showed promising results against 
pneumococcal pneumonia. However, with the widespread emergence of antibiotic 
resistance, interests in the development of prevention strategies against 
pneumococcal pneumonia reemerged (Bridy-Pappas et al., 2005). In 1983, a 
pneumococcal polysaccharide vaccine (PPSV) composed of purified 
pneumococcal capsular polysaccharide was approved. The PPSV vaccine 
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contained antigens from 23 of the most commonly prevalent invasive serotypes 
(CDC, 2015). The PPSV vaccine showed early promising results where it 
successfully induced a long-lasting antibody response in healthy adults (Yildirim et 
al., 2015). However, PPSV failed to generate antibody responses in young children 
who are particularly susceptible to pneumococcal infection (CDC, 2015; Geno et 
al., 2015). Additionally, PPSV exhibited poor efficacy against nasal colonization 
and invasive infections in chronically ill older individuals (Geno et al., 2015; Yildirim 
et al., 2015). Finally, PPSV's lack of production T cell responses, immunological 
memory, and prompting booster responses prompted the development of a new 
pneumococcal vaccine (Geno et al., 2015; Yildirim et al., 2015). To tackle PPSV 
vaccine limitations, a new pneumococcal conjugated vaccine (PCV) was approved 
in the early 2000s (CDC, 2015). PCV vaccine initially consisted of the purified 
capsular polysaccharide from 7 of the most prevalent serotypes in young children 
in the US conjugated to a non-toxic protein from diphtheria toxin called CRM197 
(Pilishvili et al., 2010; van der Poll and Opal, 2009). Additional invasive serotypes 
were later added to the PCV vaccine to improve the coverage of prevalent 
childhood serotypes. Unlike the PPSV vaccine, the new conjugated vaccine-
induced T cell-dependent responses showed promising results in young children 
where it showed a 75-99% reduction in invasive disease prevalence (Whitney et 
al., 2003; Yildirim et al., 2015). It additionally leads to a reduction in 
nasopharyngeal colonization, which subsequently increased herd immunity 
(Whitney et al., 2003; Yildirim et al., 2015). Unfortunately, the PCV vaccine also 
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has its limitations, namely, induction in shifts in non-vaccine serotypes causing 
invasive disease, and they are expensive to produce (Jambo et al., 2010). 
Both vaccination strategies remain currently in use. The current recommendation 
is that young children take the PCV vaccine, whereas older adults and 
immunocompromised patients are recommended to take a combination of both 
PPSV and PCV (Nuorti and Whitney, 2010; CDC, 2015; Tomczyk et al., 2014). 
Alveolar macrophages are one of the earliest cell types to encounter invading 
pathogens. Growing evidence suggests that the AM's pool undergoes a spectrum 
of remodeling phenotypes post recovery from various pathogens (Yao et al., 2018; 
Aegerter et al., 2020; Roquilly et al., 2020). Similarly, AMs have been shown to 
undergo phenotypical remodeling after a variety of vaccines targeting various 
pathogens (Benoit et al., 2006; Kamei et al., 2016; He et al., 2017; Mukherjee et 
al., 2017; Koeken et al., 2020; Hunegnaw et al., 2020; Yang et al., 2020). Some 
studies have shown that AMs downregulate the expression of activation markers 
like CD11b and MHC-II post BCG vaccination (Koeken et al., 2020). Other BCG 
vaccination studies have shown that AMs undergo enhanced efferocytosis of 
apoptotic cells and subsequently enhanced protection against influenza infections 
(Mukherjee et al., 2017). Moreover, recombinant vaccines against tuberculosis 
have additionally been shown that macrophages undergo M1 polarization and 
exhibit enhanced protection against tuberculosis infection (Yang et al., 2020). 
Similarly, AMs have been shown to increase opsonic phagocytic receptors' 
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expression on their surfaces and enhance neutralizing antibody-mediated 
protection post both influenza and RSV vaccinations (Benoit et al., 2006; He et al., 
2017). Individuals who received the PPSV23 vaccine exhibit increased IgG levels 
in the serum and increased deposition of IgG and C3b on opsonized bacteria, 
thereby suggesting enhanced opsonophagocytosis (Gordon et al., 2000). 
Additionally, PCV vaccination increased mice survival post-secondary pneumonia 
(Mimura et al., 2020). Mice that received PCV vaccine decreased AMs loss, 
decreased neutrophils influx, and increased monocyte influx into the lungs (Mimura 
et al., 2020). Given AMs central location and their plasticity and ease of 
remodeling, further studies carefully examining AMs reprogramming and its 
efficacy and mechanisms of their protection after infections, vaccines, and 
treatment are increasingly needed. 
In this dissertation we hypothesized that recovery from pneumococcal pneumonia 
remodels the pool of resident alveolar macrophages which act in concordant with 
other immune cells to protect the lungs from future pneumococcal challenges. To 
test our hypothesis, we utilize mouse models to examine alveolar macrophages 
phenotype, transcriptomics and metabolomics. We additionally utilize transgenic 
mice and lineage tracing models to examine the mechanisms driving such 
remodeling. 
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CHAPTER II: Pneumonia recovery reprograms the alveolar macrophage 
pool 
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Abstract 
Community-acquired pneumonia is a widespread disease with significant morbidity 
and mortality.  Alveolar macrophages are tissue-resident lung cells that play a 
crucial role in innate immunity against bacteria that cause pneumonia.  We 
hypothesized that alveolar macrophages display adaptive characteristics after 
resolution of bacterial pneumonia.  We studied mice one to six months after self-
limiting lung infections with Streptococcus pneumoniae, the most common cause 
of bacterial pneumonia.  Alveolar macrophages, but not other myeloid cells 
recovered from the lung, showed long-term modifications of their surface marker 
phenotype.  The remodeling of alveolar macrophages was: (i) long-lasting (still 
observed 6 months post infection), (ii) regionally localized (only observed in the 
affected lobe after lobar pneumonia), and (iii) associated with macrophage-
dependent enhanced protection against another pneumococcal serotype. 
Metabolomic and transcriptomic profiling revealed that alveolar macrophages of 
mice that recovered from pneumonia had new baseline activities and altered 
responses to infection that better resembled those of adult humans.  The enhanced 
lung protection after mild and self-limiting bacterial respiratory infections includes 
a profound remodeling of alveolar macrophages that is long-lasting, 
compartmentalized, and manifest across surface receptors, metabolites, and both 
resting and stimulated transcriptomes. 
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Introduction 
While respiration is the main function of the lung, its role as an immune organ is 
essential to health and homeostasis.  The lung is under continual pressure from 
the omnipresent but dynamic microbiome of the respiratory tract (1).  Ineffective 
control of microbes in the lower airways leads to dysbiosis and pneumonia, 
particularly in younger and older individuals (2, 3).  Between these ends of the age 
spectrum, healthy young adults have a much lower incidence and severity of 
pneumonia.  Identifying mechanisms protecting healthy young adult lungs against 
pneumonia is a pressing research priority (4).  
Lung protection depends on an immunological tone that is established by microbial 
exposures (3).  This dictates outcome for subsequent infections and is as or more 
important than species or genome when using animal models to study human 
health and disease (5-7).  Lymphocytes become long-term residents in the lung 
after resolution of respiratory infection, including resident memory T (TRM) cells, 
BRM cells, and others, helping to improve pulmonary defense (3, 8-10).  How else 
lungs change after resolution of infection is less clear. 
Alveolar macrophages are constituent resident immune cells of the lung, present 
before infections occur.  While initially derived from embryonic precursors, a 
continuously expanding fraction is derived from monocytes instead of embryonic 
precursors, equilibrating around one-year of age in mice (11, 12).   This process is 
accelerated by infection, where alveolar macrophages often change in number 
acutely but return to starting values after resolution (13, 14).  The post-resolution 
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alveolar macrophage population can include a larger fraction of cells that are 
monocyte-derived (15, 16).  Whether alveolar macrophages of disparate origins 
differ functionally is uncertain.  In non-inflamed lungs, the embryo-derived and 
monocyte-derived alveolar macrophages appear largely similar to each other, 
including their transcriptomes and responses to microbes (15, 17), suggesting that 
environmental cues rather than cellular origins drive the alveolar macrophage 
phenotype.   
Infection-specific cues influence macrophage phenotypes through “trained 
immunity” (18).  The type, dose, and duration of microbial stimuli can guide 
monocytes and macrophages towards new anti-inflammatory, pro-inflammatory, 
or other more complex phenotypes (19).  Metabolic changes contribute to this 
training (20), with macrophage metabolism changes guided by diverse types of 
stimuli (such as different microbes and microbial products), tissue environments 
(such as different organs and their state of health or disease), and cell-types (such 
as monocytes or macrophages or subsets thereof).  There is scant information 
regarding trained immunity and lung infections.  After mice recover from influenza 
infection, their alveolar macrophages exhibit a prolonged tolerance-like phenotype 
with decreased induction of the chemokines CXCL1 and CXCL2 in response to 
bacterial flagellin (13).  After respiratory infection of mice with an adenoviral 
vaccine vector expressing a mycobacterial protein, alveolar macrophages show 
differences in surface marker expression, metabolites, and transcriptomes in the 
resting state, and their responses to subsequent bacterial stimulations are altered 
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to be hyper-inflammatory, including increased induction of the chemokines CXCL1 
and CXCL2 (21).  This pair of studies reveals a potential for extensive and profound 
changes in alveolar macrophage phenotypes due to prior experience with 
microbial stimuli, with opposing responses in the sole parameter similarly 
measured (chemokine induction) revealing that context may be critical.   
Pneumococcus is a paramount context for the respiratory tract.  All children 
experience multiple rounds of respiratory tract infection with pneumococcus during 
their first years of life, and such infections occur repeatedly throughout life (22).  
As a result, adult humans routinely possess multiple types of adaptive immune 
memory against pneumococcus (22).  Despite this, pneumococcus is the most 
common bacterial cause of pneumonia (23-25).  Although infections with 
pneumococcus are a hallmark human experience, and alveolar macrophage death 
is an important component of pneumococcal pneumonia (26-28), the effects of 
resolved respiratory infection by pneumococcus (or any bacterial pathogen) on 
alveolar macrophage phenotypes remain unexamined.  While recovery from 
infections alters the blood cells and lung lymphocytes of mice to be more similar 
to those of young adult humans (3, 6), alveolar macrophage remodeling after 
microbial exposures has yet to be connected to any human context.  Here, we 
begin addressing these knowledge gaps in lung immunology.  
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Results 
Murine model of resolving pneumonia 
We examined the time-course of infection, morbidity, and inflammation after lobar 
pneumonia caused by a pneumococcus serotype 19F isolate which causes a self-
limiting infection in mice (29).  Most mice eliminated living S. pneumoniae by 5 
days after infection, and all by 7 days (Figure 1a).  Body weight decreased over 
the first three days compared to control mice, but differences between groups 
disappeared in under a week (Figure 1b).  Gross morphology revealed that 
excised lungs had hepatization typical of lobar pneumonia at 1 and 3 days, which 
resolved before day 7 (Figure 1c). Pulmonary inflammation was measured by 
quantifying leukocytes in the bronchoalveolar lavage (BAL).  Concomitant with the 
weight loss and lung hepatization, we observed increases in neutrophils (by day 
1) and macrophages (by day 3) in the air spaces (Figure 1d).  BAL leukocytes 
returned to baseline by day 5 (Figure 1d).  Thus, this serotype 19F isolate causes 
a mild and self-limiting infection in mice.  A second infection is needed to establish 
heterotypic immunological memory effective against mismatched serotypes (9).  
We delivered this second infection on day 7, after mice had returned to baseline.  
More than 4 weeks from this second infection (day 37), mice remained free of 
infection (Figure 1a) and morbidity (Figure 1b).  The leukocytes in these lungs will 
be considered further below.  Mice that have recovered from the initial two rounds 
of infection and are studied after at least 4 weeks from the last infection will 
hereafter be referred to as “experienced,” to be compared with negative control 
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mice that received sterile saline instead of pneumococcus, hereafter referred to as 
“naïve.”   
Experienced lungs do not differ in numbers of myeloid cells 
The lungs of experienced mice have improved defense against an unrelated 
serotype of pneumococcus (Figure 2a).  These lungs contain new populations of 
cells, namely an increase in CD4+ TRM cells (9).  We considered whether there 
might also be increased populations of select myeloid cell subsets in such lungs.  
To differentiate and enumerate the myeloid cell populations in lung single cell 
suspensions from experienced and naïve mice, we used a systematic approach 
based on flow cytometry and sequential gating (Figure 2b) (30).  We excluded 
debris, doublets, and dead cells, and restricted analyses to CD45+ leukocytes.  
Alveolar macrophages were identified as CD11c+SiglecF+CD64+, which includes 
alveolar macrophages whether of embryonic or monocytic origin.  The  
CD11c+SiglecF-MHC-II+CD64+ cells were defined as interstitial macrophages 
(IMs), CD11c+SiglecF-MHC-II-Ly6C+ cells as plasmacytoid dendritic cells (pDCs), 
CD11c+SiglecF-MHC-II+Ly6C- cells as conventional dendritic cells (cDCs), CD11c-
Ly6Gbright cells as neutrophils, CD11c-SiglecF+ cells as eosinophils, and CD11c-
Ly6G-SiglecF-Ly6Cbright cells as monocytes.  Lymphocytes would not be 
discriminated using this gating strategy, and may account for undefined events in 
these panels such as the many CD45+SiglecF-CD11c-Ly6G-Ly6C- cells.  For all 
seven of the myeloid cell subsets, numbers per lung were similar in experienced 
and naïve mice (Figure 2c).  One month after recovery of mild and self-limiting 
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respiratory infections, experienced mice did not differ from naïve counterparts 
regarding the quantities of these populations of myeloid cells in the lung. 
Alveolar macrophages display a distinct phenotype in experienced lungs 
Our flow cytometry panel was designed to bin cells into pre-assigned categories 
so that numbers per lung could be calculated for each cell-type.  Unbiased 
approaches to simultaneously assessing multiple markers across all immune cells 
may reveal differences that were unappreciated from such manual analyses.  We 
applied nearest-neighbor-based PhenoGraph clustering (31) to identify all distinct 
populations based on 9 parameters 
(FSC/SSC/CD11c/CD45/CD64/Ly6C/Ly6G/MHC-II/SiglecF) in the lungs of naïve 
and experienced mice.  CD45+ cells were separated into 24 distinct clusters using 
this tool (Figure 3a).  Three of these clusters (2, 6, and 20) differed significantly 
between experienced and naïve lungs (Figure 3a).  To visualize the complete 
phenotypic space of these lung immune cells, the optimized t-distributed stochastic 
neighbor embedding (opt-SNE) algorithm (32) was used to present 
multidimensional single cell data on a single 2-dimensional plot for each of the 
PhenoGraph clusters (with the 20 most abundant shown in Figure 3b) or the 
manually gated populations (with the 7 cell assignments used in Figure 2 shown 
in Figure 3c).  Alveolar macrophages comprised 3 different clusters (2, 6, and 12), 
the larger two of which differed between groups (with cluster 2 increasing and 
cluster 6 diminishing in experienced lungs).  Neutrophils, monocytes, eosinophils, 
and pDCs each fell within their own distinct clusters (5, 11, 14, 17, respectively), 
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none of which changed due to experience.  IMs and cDCs together fell mostly 
within cluster 15, but this PhenoGraph-defined cluster was further sub-divided in 
opt-SNE maps; multiple distinct subsets of IMs were discernible, consistent with 
prior observations (33, 34), as well as multiple subsets of cDCs (35) that could be 
distinguished from those IMs.  None of these IM or cDC populations appreciably 
differed due to experience, although changes independent of the markers used 
here may remain undetected.  Non-identified cells using these surface markers 
likely included diverse lymphocytes from blood and lung tissue.   
The quantitative generation and statistical comparisons of clusters (Figure 3a) 
combined with the opt-SNE maps of those clusters (Figure 3b) and of manually 
gated cell-types of interest (Figure 3c) clearly revealed a major shift in alveolar 
macrophage phenotypes in the lungs of experienced mice, but not in other 
recognized myeloid subsets.  The majority of alveolar macrophages were in cluster 
6 in naïve mice, whereas most were in cluster 2 in experienced mice (Figures 3b-
c).  Most prominently, experienced alveolar macrophages (gated as in Figure 2b) 
expressed less SiglecF and more MHC-II than naïve cells, consistent across all 
mice examined (Figures 3d-e).  CD64 and CD11c also showed modest increases 
in surface expression due to experience with prior infections, despite overlap 
between groups (Figure 3d-e).  Ly6c (Figure 3d-e) did not demonstrate significant 
differences in surface expression due to prior experience.  Thus, the surface 
phenotype of alveolar macrophages significantly differed in mice with a prior 
history of resolved pneumococcal infections.  This could result from long-lived 
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alveolar macrophages that change their phenotype and/or from cell replacement 
by new alveolar macrophages with different phenotypes.  The remodeled 
phenotype of alveolar macrophages included decreased surface expression of 
SiglecF coupled with increased surface expression of MHC-II. 
The altered alveolar macrophage phenotype is long-lasting 
To address whether the bacteria-induced remodeling of alveolar macrophages 
persisted over longer time-frames, mice were maintained for extended periods 
after recovering from the initial mild and self-limiting respiratory infections.  Alveolar 
macrophage remodeling was still observed in experienced mice compared to naïve 
controls both 3 months (Figure 4a) and 6 months (Figure 4b) after prior infections.  
The decreased SiglecF and increased MHC-II surface expression levels were 
preserved in the lungs of experienced mice throughout the extended time-course 
of this experiment (Figure 4a-b).  In contrast, the modest difference between 
experienced and naïve mice in CD11c and CD64 surface expression at 1-month 
after infection (Figure 3d-e) waned at these later time-points (Figure 4a-b), 
suggesting that this aspect of the phenotype may persist for over a month but be 
less stable compared to the other surface marker changes.  
The alveolar macrophage phenotype spontaneously changes over time 
The experiments communicated in Figures 3 and 4a-b were designed to determine 
whether the alveolar macrophages of experienced mice that had recovered from 
pneumococcal pneumonia differed from those of naïve mice at multiple different 
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time-points after prior respiratory infection.  At each of the time-points examined, 
a significant effect of the prior infections was observed compared to age-matched 
mice who had previously received sterile saline vehicle instead of serotype 19F 
pneumococci.  However, even in the absence of experimental infections, mice are 
exposed to microbiota in the respiratory tract (36), leading us to consider whether 
the phenotypes triggered by resolution of pneumococcal pneumonia might emerge 
spontaneously over time.  To test this, we examined whether alveolar 
macrophages altered their surface marker phenotypes over time in naïve mice.  
We collected lungs from naïve mice of 3 different ages (2, 4, or 7 months), all of 
which had received saline instillations a 1 month of age, and we directly compared 
surface marker expression by alveolar macrophages across these age groups.  
Interestingly, alveolar macrophage surface markers changed over time, albeit to a 
lesser extent and not identically to what was observed in experienced mice.  There 
was a decrease in SiglecF and in CD11c and an increase in MHC-II (Figure 4c).  
In conjunction with the data from Figures 3, 4a, and 4b, the SiglecF decrease and 
MHC-II increase appear to be very consistent changes that are long-lasting when 
caused by pneumonia resolution and appearing spontaneously in mice housed in 
SPF conditions.  In contrast, the CD11c change is more labile, as this marker is 
increased only transiently after pneumonia recovery and decreases in expression 
over time as mice age in specific pathogen-free (SPF) housing.  Altogether, these 
data suggest that the SiglecF and MHC-II markers are characteristic of the alveolar 
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macrophage remodeling that results from pneumonia recovery, and perhaps 
similarly from routine alveolar macrophage interactions with lung microbiota. 
The remodeling of alveolar macrophages localizes regionally 
Pneumococcal pneumonia most often presents as a lobar infection, and the 
resident memory lymphocytes that result after recovery from such infections are 
restricted to the relevant lung lobe (9).  Whether and which other aspects of 
immune remodeling after lobar pneumonia are also restricted is unknown.  Only in 
the infected lobe can alveolar macrophages interact directly with pneumococcus, 
recruited leukocytes, and local immune signals.  However, systemic signals could 
affect macrophages in contralateral lobes, and macrophages are motile cells which 
can relocate over time.  To assess a potential regionalization of the alveolar 
macrophage remodeling, we generated mice selectively infected by serotype 19F 
pneumococci in the left lung through tracheostomy and left-bronchus instillation.  
Left lung infections were repeated a week later, after which mice rested for at least 
4 weeks in order to generate a cohort of left lobe-experienced mice (Figure 5a).  
Single cell suspensions were generated separately for the right lobes and left lobe 
from each mouse.  Compared to those in the right lobes, the alveolar macrophages 
from the left lobe showed decreased SiglecF, increased MHC-II, and increased 
CD64, but no change in CD11c (Figure 5a).  Thus, the majority of the remodeled 
alveolar macrophage phenotypes was seen to localize exclusively to cells from the 
tissue sites that were previously infected.   
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Both naïve and remodeled alveolar macrophages have essential roles in defense 
We tested whether the left lobe containing experienced alveolar macrophages had 
superior protection against diffusely distributed pneumococcus compared to the 
right lobes containing non-remodeled alveolar macrophages.  Mice were infected 
with a serotype 3 pneumococcus which is not recognized by the serotype-specific 
anti-capsular polysaccharide antibodies that may have been generated by the prior 
serotype 19F infections.  Diffuse infections of the entire respiratory tract were 
accomplished by delivering serotype 3 pneumococcus intranasally, both for left 
lobe-experienced mice and for naïve controls which had instead previously 
received left lobe instillations of saline (Figure 5b).  Numbers of living bacteria in 
each lobe were separately assessed and compared.  In naïve mice, the bacterial 
count was similar in the left and right lungs 24 hours after intranasal serotype 3 
infection (Figure 5b).  Experienced mice had lower bacterial burdens in both sides 
than did naïve mice (Figure 5b), reflecting improved defense against this 
respiratory tract-wide infection due to prior heterotypic infections.  In contrast to 
the naïve mice, bacterial CFU were diminished significantly in the left lung 
compared to the right in left lobe-experienced mice (Figure 5b), revealing that 
enhanced immune protection localizes in conjunction with alveolar macrophage 
remodeling.  Together, the above data indicate that the alveolar macrophage 
remodeling that is restricted to the previously infected lobe associates with 
improved antibacterial defense in that specific region during a diffuse respiratory 
tract infection.  
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To more specifically examine alveolar macrophage roles in the defense of naïve 
and experienced lungs, we examined the effects of alveolar macrophage depletion 
on bacterial infections in these different settings.  We sought to determine the 
contributions of alveolar macrophages to the defense of naïve and experienced 
lungs by depleting them prior to serotype 3 infection.  Alveolar macrophages were 
effectively depleted by liposomal clodronate, whether alveolar macrophage were 
enumerated based on morphological assessments of cells in BAL samples (Figure 
6a) or by surface markers on cells in single cell suspensions from digested lungs 
(Figure 6b).  Similar effects of clodronate on alveolar macrophage depletion were 
observed whether mice were naïve or experienced (Figure 6b).  We infected the 
liposome-pretreated mice with 0.75 x 106 CFU of serotype 3 pneumococcus.  In 
naïve mice, the bacteria isolated from lungs after 24 hours approximately equaled 
what was initially delivered, but depletion of alveolar macrophages significantly 
increased bacterial burdens (Figure 6c).  Thus, alveolar macrophages are 
essential to immunity in naïve mice.  Experienced mice had substantially better 
protection against pneumococcus than did naïve mice, eliminating nearly 99% of 
living bacteria in less than 24 hours (Figure 6c).  This highly effective protection in 
experienced lungs was unimpeded by alveolar macrophage depletion (Figure 6c).  
Thus, in contrast to naïve lungs, the ready elimination of pneumococcus in the 
setting of heterotypic immunity did not require alveolar macrophages, likely due to 
other elements of immune protection gained after prior experience such as lung 
CD4+ TRM cells accelerating neutrophil recruitment (9, 37).  To further challenge 
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the lung immune systems, we infected mice with higher doses of bacteria, 15 x 106 
CFU.  Under such conditions, the naïve mice were unable to control bacterial 
growth, and depletion of alveolar macrophages had no effect (Figure 6d).  Bacteria 
grew over 24 hours in the lungs of experienced mice as well, but this growth was 
significantly constrained as demonstrated by lower lung CFU in the experienced 
lungs compared to the naïve lungs (Figure 6d).  This immune control in 
experienced lungs was entirely dependent on alveolar macrophages, because 
alveolar macrophage depletion significantly increased bacterial burdens and 
rendered them akin to what was observed in naïve lungs (Figure 6d).  Thus, in the 
setting of severe infection, the remodeled alveolar macrophages are essential for 
the improved defense of lungs with naturally acquired heterotypic immunity.        
Alveolar macrophages in experienced lungs have altered metabolism 
Long-term alveolar macrophage adaptations due to prior interactions with 
microbial stimuli are suggestive of trained immunity, and trained immunity of 
monocytes and macrophages is girded by metabolic reprogramming (20).  
Therefore, we tested whether metabolomes of alveolar macrophages differed in 
experienced lungs compared to naïve lungs, using LC/MS-based metabolic 
profiling to assess metabolites.  We compared metabolomes of BAL cells from 
naïve mice to those from experienced mice that recovered from diffuse bilateral 
pneumonias.  From the LC/MS spectra, 73 metabolites were identified and 
compared between the experimental groups using an unsupervised multivariate 
analysis based on Principal Component Analysis (PCA).  PCA differentiated 
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experienced from naïve alveolar macrophages based on their metabolomes 
(Figure 7a) with the first principal component alone accounting for 32% of the 
variance.  Examination of the individual metabolites that changed between naïve 
and experienced mice revealed that phosphocreatine (fold change = 4.4, FDR-
adjusted P = 0.03) and creatine (fold change = 3.1, FDR-adjusted P = 0.01) differed 
prominently (Figure 7a).  Guanidinoacetate also showed statistically significant 
differences between alveolar macrophages from experienced and naïve lungs 
(Supplemental Figure S1).  Thus, 3 of the 5 metabolites that reached significance 
were immediately adjacent to each other within a distinct metabolic pathway 
(Supplemental Figure S2).   
Because the remodeling of alveolar macrophages localizes regionally, we 
leveraged lobar pneumonias to assess whether metabolic changes in alveolar 
macrophages differed throughout lung regions.  We compared whole-cell 
metabolomes of cells lavaged from right (uninvolved) and left (previously infected) 
lobes from mice that recovered from lobar rather than diffuse pneumonias.  PCA 
clearly discriminated the metabolomes of alveolar macrophages collected from 
lung lobes with different infection histories (Figure 7b) with the first principal 
component alone accounting for 58% of the variance.  As in studies of naïve vs 
experienced mice, increased phosphocreatine was the most dominant signal 
(Figure 7b), increased in cells lavaged from the left lung compared to the right 
(fold change = 2.8, FDR-adjusted P = 0.01).  Creatine showed a shift in that 
direction that did not reach significance (fold change = 1.3, FDR-adjusted P = 
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0.07).  However, the fact that right and left metabolomes differed and that 
phosphocreatine was a discriminating factor supports the idea that changes to 
creatine metabolism may localize to alveolar macrophages in the region that 
previously experienced pneumococcal infection. 
To further determine the metabolites that drive the differences between the groups, 
we used supervised multivariate analysis based on Partial Least Squares-
Discriminant Analysis (PLS-DA) to compare metabolomes of alveolar 
macrophages from naïve and experienced mice.  We observed a correct clustering 
by classification (data not shown) with accuracy, R2, and Q2 equal to 0.81, 0.89, 
and 0.54.  On the basis of the PLS-DA model, metabolites that contributed 
significantly to the classification were highlighted and ranked by the variable 
importance in projection (VIP) values that estimate the importance of each variable 
in the projection (Figure 7c).  Phosphocreatine was the most discriminant result 
(VIP>2.5), with creatine and guanidinoacetate prominent as well.  Altogether, 
these data reveal that alveolar macrophages of experienced lungs have altered 
metabolic activities, with elevated phosphocreatine and its precursors being 
cardinal features.  
Transcriptomes of remodeled mouse alveolar macrophages differ at baseline and 
in response to pneumococcus, better resembling human alveolar macrophage 
responses 
To define the transcriptomes of alveolar macrophages sorted from lung digests of 
naïve or experienced mice, we used genome-wide expression profiling.  We used 
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FACS to isolate alveolar macrophages from both groups of mice at baseline, to 
determine whether these cells were transcriptionally altered at rest.  
Pneumococcal infection dramatically and rapidly changes gene expression in lung 
cells (38, 39), so we also collected cells after 4 hours of serotype 3 pneumococcal 
pneumonia in order to determine whether alveolar macrophages in the better 
protected experienced lungs responded differently to pneumococcus.  A total of 
4158 transcripts significantly (FDR q < 0.05) differed in alveolar macrophages due 
to pneumococcal lung infection, reflecting changes to more than a tenth of the 
transcriptome.  On top of this, a substantial set of genes was significantly altered 
by prior history of resolved infections; a total of 443 genes differed with FDR q < 
0.05 due to prior history of resolved infections (Figure 8a), more than a tenth the 
size of the total effect of acute infection.  These data reveal that resolution of 
pneumonia results in substantial modifications to the transcriptomes of alveolar 
macrophages.  
Macrophages have been ascribed phenotypes of “classical” or M1 activation vs. 
“alternative” or M2 activation, based on in vitro experiments skewing cells in those 
directions (40).  However, the alveolar macrophages from pneumococcus-infected 
or -experienced lungs did not display such skewing (Figure 8b).  While experience 
with prior pneumococcal infections altered expression of some of these genes 
(including decreases in Ccl22, Retnla, Nfkbiz, Marco, and Tnf), the effects of 
experience did not push alveolar macrophages towards either of these two 
previously defined polarized directions (Figure 8b).  Using Gene Set Enrichment 
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Analyses (GSEA) to connect these transcriptome changes to biological pathways 
in a more open-ended fashion, we found that the manner in which alveolar 
macrophages in experienced lungs differed from alveolar macrophages in naïve 
lungs depended dramatically on whether or not there was an ongoing infection.  In 
the lungs at baseline (without an ongoing infection), no pathways were significantly 
(FDR q < 0.05) increased but multiple pathways were diminished in experienced 
compared to naïve alveolar macrophages (Figure 8c and Table 1).  The 
significantly altered pathways all aligned with decreased cell cycle activity or 
decreased processing of mRNA transcripts.  This suggests that the alveolar 
macrophages from experienced lungs tend to be more quiescent under resting, 
homeostatic conditions.  In contrast, during an acute infection, no pathways were 
significantly decreased but multiple pathways were increased in experienced 
compared to naïve alveolar macrophages (Figure 8d and Table 1).  These 
pathways aligned with increases in immune signaling, glycoprotein production, and 
energy metabolism.   
The transcripts that increased due to prior experience and differed most 
significantly (lowest FDR q values) compared to naïve lung macrophages included 
immune mediators as well as diverse other factors relating to metabolism and other 
cellular acivities (Figure 9a).  The changes in immune signaling differed from those 
observed after viral exposures (13, 21).  While relative expression of CXCL1 and 
CXCL2 is the dominant signal altered in alveolar macrophages from lungs 
previously infected with a virus (13, 21), neither of those chemokines were 
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changed in alveolar macrophages due to prior infection with pneumococcus 
(Figure 9b).  Both CXCL1 and CXCL2, as well other chemokines, were increased 
due to acute pneumonia but unaffected by prior experience.  However, several 
chemokines were affected by resolution of pneumococcal pneumonia, including 
an increase in Ccxl9 mRNA as well as decreases in Ccxl14, Ccl22, and Cx3cl1 
mRNAs (Figure 9b).  This suggests that how the alveolar macrophages remodel 
after infection depends on the type of infection (e.g., microbe, severity, location, 
and/or duration).  Phagocytosis receptors were also altered by prior experience, 
including increased expression of Msr1 (encoding Scavenger Receptor A) and 
Clec12a (encoding Dectin-1), along with decreases in Cd36 and Marco (Figure 
9c).  Probing the signature genes that differentiate monocyte-derived alveolar 
macrophages after clodronate challenge (17) revealed a strong but not universal 
enrichment of this signature in the alveolar macrophages of experienced lungs 
(Figure 9d), supporting the interpretation that monocyte recruitment and 
differentiation to alveolar macrophages occurred in these lungs.  However, the 
pronounced differences observed in the pneumococcus-experienced lungs far 
exceeded the few differences ascribed to alveolar macrophages of monocytic 
origin (17).  For example, Figure 9a shows many genes recognizably elevated in 
resting alveolar macrophages due to prior pneumococcal experience, only one of 
which (Apbb2) changes in alveolar macrophages of monocytic origin after 
clodronate (17).  In addition, one signature gene (Retnla) significant in both cases 
trends in opposite directions in the clodronate and pneumococcus studies (Figure 
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9d).  These observations reveal that pneumococcus influenced alveolar 
macrophages beyond effects on cell turnover.  Recovery from pneumococcal 
pneumonia reprograms alveolar macrophages in ways that are distinct from 
recovery after influenza, adenovirus, or clodronate challenges.  
To determine whether alterations implicated by transcriptome profiling influence 
immune functionality, we examined protein expression levels for some of the 
known immunomodulatory genes altered by prior infection history.  Examination of 
3 of the most significantly altered surface marker transcripts (Figure 9a) revealed 
that their protein products (CCR5, CD93, and Scavenger Receptor-A) were all 
significantly changed in the same direction as their mRNAs (Figure 9e).  However, 
there were discrepancies as well between transcript and protein changes, as 
should be expected.  For example, the transcript for CD36 was significantly 
decreased (Figure 9c), but CD36 baseline protein expression was unaffected by 
prior experience (Figure 9e).  Of the 4 surface markers measured at the protein 
level in Figures 3-5, the transcript for SiglecF decreased significantly (FDR q = 
0.008) whereas transcripts for CD11c, CD64, and MHC-II did not change 
significantly. Among soluble immune mediators altered by prior experience in the 
macrophage transcriptomes (Figures 9a-b), Cxcl9 was of interest for being the 
only chemokine increased by experience, and Osm for encoding Oncostatin M 
which enhances lung neutrophil recruitment by stimulating CXCL5 from epithelial 
cells (37, 41).  Both of these cytokines were measured by ELISA in lung 
homogenates at early time points of pneumonia in naïve and experienced mice, 
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and both were increased at the protein level by 7 hours of infection (Figure 9f).  
These results support the concept that transcriptomic changes observed in 
alveolar macrophages may influence the abundance of proteins with known 
immunomodulatory activity in the lung.  
Connecting to the metabolic changes observed in experienced alveolar 
macrophages (Figures 7 and S1), the transcriptomic analyses revealed that 
mediators of creatine metabolism (42) were altered in alveolar macrophages from 
experienced lungs (Figure S2).  Among the 4 creatine kinase genes, alveolar 
macrophages expressed Ckb, while Ckm, Ckmt1, and Ckmt2 were at most 
minimally expressed.  There were no significant differences in Ckb mRNA 
expression due to infection history (FDR q = 0.98), suggesting kinase expression 
is not responsible for altered phosphocreatine content.  However, other genes in 
the creatine metabolism pathway were significantly altered (Supplemental Figure 
S2).  The Gatm gene encoding the commitment step of the creatine biosynthesis 
pathway was significantly higher due to infection history.  The Slc6a8 gene 
encoding the plasma membrane importer of creatine was one of the most 
significantly altered transcripts due to infection history (Figure 9a and 
Supplemental Figure S2).  These studies implicate both the generation and 
import of creatine in alveolar macrophages as potential contributors to the altered 
metabolism of alveolar macrophages after infection resolution. 
To examine whether the mouse alveolar macrophage responses to 
pneumococcus observed here were relevant to humans, and if the prior lung 
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infection history of mice influenced their relationships to human alveolar 
macrophages, we compared our transcriptome datasets to relevant data collected 
from human samples (38).  The human studies relied on alveolar macrophages 
collected by BAL and then cultured with or without in vitro serotype 14 
pneumococcal infection for 4 hours.  The mouse data relied on alveolar 
macrophages sorted from single cell suspensions from lungs with or without in vivo 
serotype 3 pneumococcal infection for 4 hours.  The number of human transcripts 
that changed with FDR q<0.05 due to pneumococcus in vitro was larger than that 
observed in mouse cells in vivo from naïve or experienced lungs (Figure 10a).  
Only a fraction of the transcripts that changed were identical across species and 
studies, about 22% of the human transcriptome responses or 38% of the mouse 
transcriptome responses (Figure 10a), highlighting differences between the in 
vitro human experiments and the in vivo mouse experiments.  However, when the 
pathways that were associated with these transcriptome changes were compared, 
there was a marked convergence (Figure 10b). Thus, similar biological responses 
were stimulated in both the in vitro human experiments and the in vivo mouse 
experiments.  We used GSEA to specifically determine whether the experienced 
mouse alveolar macrophage responses were more similar or less similar to the 
human responses than were those of naïve mouse alveolar macrophages.  Both 
the naïve and the experienced alveolar macrophage responses in mice were 
significantly concordant with those of the human alveolar macrophages (Figures 
10c-d).  However, the similarities to human alveolar macrophage responses were 
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larger (NES shift to 1.5 from 1.3) and more precise (FDR q shift to 0.008 from 
0.035) for the alveolar macrophages from experienced compared to naïve mouse 
lungs (Figures 10c-d).  These data suggest that mouse alveolar macrophages 
respond to pneumococcus similarly to human alveolar macrophages, and a history 
of respiratory infections makes mouse alveolar macrophage responses even more 
human-like.  
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Discussion 
Our results demonstrate that the pool of alveolar macrophages is persistently 
altered after resolution of prior bacterial pneumonias.  While the numbers of 
alveolar macrophages in naïve and experienced lungs are similar, they differ in 
surface receptors, metabolomes, transcriptomes, and responses to subsequent 
pulmonary infections.  While prior studies of immune remodeling after infection 
highlight cells newly accumulating in experienced lungs (3, 6, 8-10), our study 
complements another (21) in emphasizing that the phenotype of cells whose 
numbers are similar between naïve and experienced lungs may be importantly 
modified by prior infection history.  These studies demonstrate that alveolar 
macrophage remodeling is a component of the immunological tone of lungs that 
experienced common respiratory infections (3).  The alveolar macrophage 
phenotype changes in conjunction with improved lung defense, and these alveolar 
macrophages are essential when lungs with heterotypic immunity are challenged 
by high doses of bacteria.  We postulate that such alveolar macrophage changes 
after repeated childhood infections may be integral parts of the many 
improvements in lung defense that render older children and young adults more 
resistant to pneumonia (3).   
Other myeloid cells in the lung do not show differences in either number or surface 
marker phenotype, but further investigations would be necessary before 
concluding that such cells are unaffected by infection history.  IMs or DCs (or IM 
or DC subsets) may change in experienced lungs in ways that could not be 
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discerned using the limited panel of surface markers employed here.  Studies 
should also address non-myeloid constituent cells of the lung to see if they may 
phenotypically remodel after resolution of past infections.   
Among the surface receptors we measured, SiglecF and MHC-II are the most 
consistent markers of the altered phenotype.  Surface SiglecF is consistently 
decreased due to experience, across all time-points in an extended time-course, 
in affected compared to contralateral lobes after localized infections, and due to 
spontaneous experiences that come with age in mice that did not receive 
experimental infections.  Some studies consider decreased SiglecF to characterize 
alveolar macrophages that developed from monocytes recruited to the inflamed 
lung (15, 17).   For the alveolar macrophages that remodel after adenoviral vector 
experience, SiglecF surface expression does not change (21), demonstrating a 
clear difference from the remodeling we observe after recovery from 
pneumococcal infection.  This importantly highlights that different types of 
infectious history cause different types of alveolar macrophage remodeling.  In the 
adenoviral vector studies, the remodeled alveolar macrophages are embryonic in 
origin, without contributions from bone marrow precursors (21); this is consistent 
with the concept that decreased SiglecF associates with cellular ontogeny.  This 
implies that bone marrow-derived alveolar macrophages may be a component of 
the remodeling of lungs recovered from pneumococcal infection, as has been 
previously observed (28) and as supported by transcriptome analyses in the 
present study.  During an inflammatory response, the autochthonous alveolar 
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macrophages and the monocyte-derived macrophages recruited by that 
inflammation have very different transcriptomes and behaviors (15, 43).  However, 
in the resting non-inflamed lung, alveolar macrophages with these different cellular 
ontogenies are largely similar in their resting transcriptomes and responses to 
bacteria (17).  The present studies reveal that the remodeled alveolar 
macrophages after pneumococcal infection have markedly different 
transcriptomes and metabolomes in the resting lung and distinct responses to 
bacterial infections.  Thus, whether or not SiglecF is an indicator of varied ontogeny 
in lungs with resolved infections, cellular origin is insufficient to explain the 
remodeled alveolar macrophage phenotype after the resolution of pneumococcal 
pneumonia.   
The other surface marker phenotype that was especially pronounced and 
consistent in these studies, MHC-II, was a defining feature of the alveolar 
macrophages that remodeled after adenoviral vector exposures (21).  While 
SiglecF changes differently in these two settings (decreased after pneumococcus, 
but not after adenoviral vector), MHC-II changes in a similar way (increased after 
either infection).  Thus, increased MHC-II surface expression may be a particularly 
robust marker of alveolar macrophages that have remodeled in response to 
infection history.  The physiological significance of increased MHC-II on remodeled 
alveolar macrophages is unknown.  It will be of interest for future studies to 
determine whether and how the MHC-II-expressing alveolar macrophages in 
experienced lungs present antigen to CD4+ T cells.    
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Metabolism is key for virtually all macrophage antimicrobial defenses (44).  
Creatine metabolism was a particularly prominent difference in experienced 
compared to naïve alveolar macrophages across multiple experimental designs 
and analyses (Figure S2).  Phosphocreatine is a store of readily accessible high-
energy phosphates, and elevated phosphocreatine facilitates ATP regeneration to 
improve responses for fluctuating energy demands.  In macrophages, 
phosphocreatine can serve as an energy source (45), and creatine kinase activities 
which generate phosphocreatine are necessary for optimal phagocytosis (46).  
Thus, elevated phosphocreatine could accelerate antimicrobial defense, typical of 
lungs with heterotypic immunity (9), by providing an increased source of energy 
for immune defenses including phagocytosis.  Upstream of phosphocreatine, 
creatine is an antioxidant that can help protect cells and tissues against oxidative 
damage (42).  Intriguingly, creatine and the Slc6a8 creatine transporter that was 
strongly increased by prior pneumococcal exposures can directly influence 
polarized macrophage cytokine expression, favoring the “alternative” activation 
phenotype in bone marrow-derived macrophages, perhaps by modifying chromatin 
accessibility (47).  The alveolar macrophages that remodeled after pneumococcal 
pneumonia displayed elevated creatine without a skewing towards “alternative” 
activation, but it is possible that creatine may influence chromatin accessibility and 
transcriptome changes in this setting as well.  Increased Slc6a8 expression and 
elevated intracellular creatine also contribute to the efficacy of tumor-infiltrating 
CD8+ T cells, likely via energy metabolism (48).  Together with our data, these 
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observations suggest that enhancing creatine uptake may emerge as a broadly 
applicable means for immune cells to orient and augment their activities.  Our 
metabolic and transcriptomic analyses highlighted creatine generation and import 
in alveolar macrophages remodeled after infection resolution, suggesting 
mechanisms by which creatine and phosphocreatine may be bolstered to empower 
hardier and healthier responses to subsequent infectious challenges. 
The transcriptomic analyses reveal that alveolar macrophages with different 
infection histories not only have a new baseline but also respond distinctly to 
subsequent infection.  At rest, experienced alveolar macrophages exhibit 
decreased cell cycle and mRNA processing activities, with no pathways reflecting 
a converse increase in activity.  However, when lungs are acutely infected by a 
highly virulent pneumococcus, the alveolar macrophages that had recovered from 
prior infections again differ from naïve counterparts, but in this case a distinct 
spectrum of activities is implicated and change in the opposite direction.  The 
experienced lungs contain alveolar macrophages with no pathways identified to be 
decreased in activity, but multiple pathways are increased in activity including 
immune signaling, glycoprotein processing, and energy metabolism.  Alveolar 
macrophages in the experienced lung appear therefore to be more dynamic in their 
activity states, with quieter resting periods and more exuberant responses to an 
acute infectious challenge.   
Alveolar macrophage transcriptome analyses showed that the mouse responses 
to pneumococcus are significantly concordant with human responses, and 
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resolution of prior infections renders mouse alveolar macrophages even more 
adult human-like in their responses.  The effect of prior experience with infections 
on similarities between species was small, but in the right direction.  The 
similarities are especially notable since incongruous experimental designs 
between the studies introduce many differences beyond the species difference of 
interest.  The human studies involved alveolar macrophages cultured under highly 
controlled in vitro settings, while the mouse experiments involved alveolar 
macrophages in the more dynamic and much more physiologically complex setting 
of a living lung.  The human studies involved alveolar macrophages from subjects 
with diverse and unknown variations throughout their genomes, throughout their 
infection histories (including the numbers, causes, and severities of prior 
infections), and throughout the rest of their environmental histories (including 
innumerable variables such as age, diet, exercise, co-morbidities, toxins, drugs, 
psychological stresses, sleep cycles, microbiota, etc.).  In contrast, the mouse 
experiments involved alveolar macrophages from an inbred strain so study 
subjects had nearly identical genomes, and environmental histories were designed 
to be as fully uniform as possible (other than differences introduced for the purpose 
of the experiment).  Furthermore, the serotype 14 isolate of pneumococcus used 
as a stimulus in the human studies differed from the serotype 3 isolate used in the 
mouse studies.  Despite these many experimental design differences, the 
bioinformatics analyses suggest that mouse and human alveolar macrophages 
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respond quite similarly to pneumococcus, and a prior history of respiratory 
infections makes the mouse alveolar macrophage responses more human-like.   
The infections under study here were self-limited pneumococcal infections.  They 
were not severe enough to require antibiotics or any other treatment, which 
represents a much milder and more limited infectious history than the typical 
human experiences.  This setup is expected to simulate at best a small fraction of 
the immunological remodeling that occurs in humans, and the evidence supports 
that conclusion.  Exposure of laboratory mice to mice purchased in pet stores is a 
much more intense infectious challenge (with laboratory mice seroconverting 
against many diverse pathogens including bacteria, viruses, and parasites, and 
more than a fifth of those mice dying) and leads to more profound immunological 
remodeling (6).  More controlled and lifelong exposures of laboratory mice to 
microbiota from wild mice extensively remodels leukocytes in the blood and spleen 
but not leukocytes in the vagina or skin (7), suggesting that infections of relevant 
tissues may be key.  Practical ways to provide animals with relevant infection 
histories will help drive next waves of immunological breakthroughs.  Localized 
effects observed here (with alveolar macrophages in the infected but not the 
contralateral lobes remodeling after lobar pneumonia), which similarly apply to 
CD4+ TRM cells (9), indicate that the site of infection can be paramount.  In addition, 
microbial factors like species and virulence properties are important.  As an 
example, alveolar macrophages have now been observed to remodel after 
resolution of influenza infections (13), adenoviral vector exposures (21), or 
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pneumococcal infections (here), but how they remodel differs in each case.  
Surface SiglecF was decreased after pneumococcus but not adenovirus (21).  
Induction of CXCL1 and CXCL2 by bacterial stimuli was increased after adenovirus 
(21), decreased after influenza (13), and unaltered after pneumococcus.  The 
types, numbers, and severities of infections in an animal’s history must now be 
considered critical elements of experimental design and interpretation.   
Alveolar macrophages remodel after resolution of pneumococcal pneumonia.  The 
remodeled alveolar macrophages are quieter at rest, more active and effective 
when challenged, and more human-like in their responses.  Infection history is an 
important experimental design component that can and should be factored into 
animal studies and their interpretations in order to elucidate the biological 
processes that determine how human lungs respond to pathogens.  An improved 
understanding of how resolution of infection impacts systemic and localized lung 
immunity will help translate findings between animal studies and human medicine, 
further guiding the development of immunomodulatory strategies designed to 
prevent or cure pneumonia and other infectious diseases.   
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Methods 
Mice. Female and male C57BL/6J mice were used, from Jackson Laboratories 
(Bar Harbor, ME).  Experiments were initiated when mice were 5 weeks of age.  
Mice were maintained in specific pathogen-free conditions.  
Lung infections. Bacteria were grown on blood agar plates at 37°C with 5% CO2 
and suspended in sterile saline prior to infecting mice, including Streptococcus 
pneumoniae serotype 19F (EF3030) and serotype 3 (catalog number 6303; ATCC, 
Manassas, VA). Mice were infected by either intranasal (i.n.) or intratracheal (i.t.) 
routes, after anesthesia with a ketamine (50 mg/kg) and xylazine (5 mg/kg) mixture 
delivered intraperitoneally (i.p.).  The i.n. deliveries were performed by 
administering 50 µL of liquid suspension to the nares until the inoculation was 
inhaled completely.  The i.t. deliveries were performed by placing an angiocatheter 
into the left bronchus through a tracheostomy, and administering 50 µL of liquid.  
To generate self-limiting lung infections, mice were infected with 1–3 x106 CFU of 
serotype 19F.  To generate heterotypic immunity, mice received 2 serotype 19F 
infections with a 1-week interval between them, and then rested at least 4 weeks 
to allow elimination of infection, resolution of inflammation, and contraction of 
adaptive immunity (9).  These experienced mice were compared to naïve mice 
who received sterile saline by the same route instead of serotype 19F infections.  
To generate severe lung infections in order to test the efficacy of heterotypic 
immunity, mice were infected with serotype 3 pneumococcus at doses ranging 
from 0.75 x106 to 15 x106 CFU, as indicated.  To assess bacterial burden, mice 
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were euthanized by isoflurane overdose, and CFU were enumerated in the lungs 
homogenized with a Bullet blender (Next Advance, Averill Park, NY) in water 
containing a protease inhibitor cocktail (Roche, Risch-Rotkreuz, Switzerland).  
Bronchoalveolar lavage (BAL). The trachea was cannulated with an 18-gauge 
angiocatheter and the lungs were lavaged 4 times with 0.5 ml of ice-cold PBS.  
Cells were enumerated using LUNA-FL™ Dual Fluorescence Cell Counter (Logos 
Biosystems) and differentiated using cytocentrifuge preparations stained with Diff-
Quick (VWR). 
Alveolar macrophage depletion.  For alveolar macrophage depletion 
experiments, mice received i.n. delivery of 100 µL of liposomes (Liposoma, 
Amsterdam, Netherlands) containing either clodronate (5 mg of clodronate per mL 
of solution) or PBS vehicle, and were studied or infected 72 hours after liposome 
delivery.  
Lung cell suspensions.  Lungs were perfused through the right ventricle with 5 
mL of PBS for exsanguination.  Excised lung lobes were digested in a solution 
containing type 2 collagenase (1 mg/ml), DNase I (150 mg/ml), and CaCl2 (2.5mM) 
in phosphate-buffered saline while shaking at 37°C for 1 hour before being passed 
through a 70-mm cell strainer (Fisher, Grand Island, NY).  Erythrocytes were 
removed using red blood cell lysis buffer (Sigma, St Louis, MO). Cells were 
enumerated using the LUNA-FL™ Dual Fluorescence Cell Counter (Logos 
Biosystems). 
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Flow cytometry and cell sorting.  After Fc receptor blockade (FcBlock, 
eBioscience), cells were incubated with combinations of monoclonal antibodies for 
30 minutes on ice in the dark, and then washed with PBS containing FBS and 
EDTA.  Fluorochrome-conjugated monoclonal antibodies used include the 
following: CD4-APC (clone RM4-5, eBioscience), CD3-APC (clone 17A2, 
eBioscience), CD11c-PE/Cy7 (clone HL3, BD Bioscience), CD19-APC (clone 1A3, 
eBioscience), CD45-FITC (clone 30-F11, eBioscience), CD64-PE (clone X54-
5/7.1, BioLegend), Ly6C-eFluor 450 (clone HK1.4, eBioscience), Ly6G-APC 
(clone 1A8, BD Bioscience), Ly6c-APC/Cy7 (clone 1A8, BD Bioscience), MHCII-
PerCP-Cy5.5 (clone M5/114.15.2, BD Bioscience), and SiglecF-APC/Cy7 (clone 
E50-2440, BD Bioscience).  Cells were stained with viability dye eFluor 506 
(eBioscience) or 7-AAD Viability Staining Solution (BioLegend).  Unstained, single-
stained using OneComp eBeads (eBioscience), and fluorescence-minus-one 
(FMO) controls were used for each analysis.  Data were acquired on a BD LSR II 
flow cytometer (BD Biosciences) using BD FACSDiva software. For cell sorting, a 
BD FACSARIA II SORP cell sorter was used (BD Biosciences). 
Cytometry data analysis.  Expert-guided/manual data analyses and data pre-
processing for algorithmic analyses were performed using FlowJo 10 software 
(FlowJo, Inc).  Equal numbers of single, live, CD45+ immune cells (3.5 x 104 per 
animal) were concatenated and the resulting dataset was clustered with 
PhenoGraph algorithm (31) and mapped into 2D opt-SNE space using Omiq.ai 
cloud computing platform.  Embedding parameters were automatically defined by 
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the opt-SNE algorithm (32).  Statistical comparison of phenograph clusters was 
performed in the R environment (versions 3.3-3.6) using Wilcoxon rank-sum test 
with Benjamini-Hochberg correction for multiple comparisons and DepecheR 
package (49) for results visualization.  Corrected P < 0.05 was considered 
significant for group differences.  Heatmaps, phenograph cluster overlays in opt-
SNE space, and manually gated population overlays in opt-SNE space were 
created with Omiq.ai.  
Measurement of metabolites.  LC/MS was used to profile and quantify the polar 
metabolite contents of alveolar macrophages.  Because FACS has a significant 
impact on the cellular metabolome (50, 51), we collected alveolar macrophages 
for metabolite analyses by BAL without sorting.  LC/MS analyses were conducted 
on a QExactive benchtop orbitrap mass spectrometer equipped with an Ion Max 
source and a HESI II probe, which was coupled to a Dionex UltiMate 3000 UPLC 
system (Thermo Fisher Scientific, San Jose, CA).  External mass calibration was 
performed using the standard calibration mixture every 7 days. The metabolite 
extraction mix was composed of 80% methanol in water, supplemented with a 
mixture of 17 isotope-labeled amino acids at 90.9 nM each, used as internal 
standards (Cambridge Isotope Laboratories, MSK-A2-1.2).  After extraction, the 
protein level of each extracted sample was quantified using a BCA assay for 
biological normalization.  The pre-determined quality control cutoffs for each 
metabolite were CV<0.25 for the peak area ratio across the triplicate injections, 
and R > 0.975 for the raw peak area across the dilution series (including the 
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average of the triplicate injections).  Samples were run in a randomized order to 
minimize effect of technical variation. 
Metabolome analyses.  Values of metabolites levels were normalized to the sum 
of all metabolites levels, log-transformed, and auto-scaled (mean-centered and 
divided by the standard deviation of each variable).  Results were analyzed as 
paired-data for comparing left and right lungs and as unpaired data for comparing 
naïve and experienced mice.  The univariate analysis was based on volcano plots 
and the non-parametric Wilcoxon test, and results were expressed as FDR-
adjusted P values.  For multivariate analysis, the classification method was based 
on unsupervised Principal Component Analysis (PCA) to evaluate distribution of 
samples.  Supervised analysis based on Partial Least-Squares Discriminant 
Analysis (PLS-DA) was performed to highlight the most discriminant variables.  
Permutation tests were not performed due to the small sample size. Values of 
Variable Influence on Projection (VIP) represent the importance of the compound 
(metabolite) for the PLS-DA models.  Data were analyzed using MetaboAnalyst 
4.0 software (52).  
Gene expression analyses.  Alveolar macrophages were isolated by FACS from 
collagenase-digested lungs of naïve and experienced mice with 0 or 4 hours of 
serotype 3 infection.  Four mice per group from two independent experiments were 
analyzed.  RNA was extracted from the samples using RNeasy Micro Kit (Qiagen) 
and profiled using GeneChip mouse Gene 2.0 ST arrays (Affymetrix).  Mouse 2.0 
ST CEL files were normalized to produce gene-level expression values using the 
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Robust Multiarray Average (RMA) (53) from the affy package (version 1.36.1) (54) 
in the Bioconductor software suite (version 2.11) (55) and an Entrez Gene-specific 
probeset mapped (17.0.0) from the Molecular and Behavioral Neuroscience 
Institute (Brainarray) at the University of Michigan (56).  Array quality was 
assessed using Relative Log Expression (RLE) and Normalized Unscaled 
Standard Error (NUSE) in the affyPLM package (version 1.34.0).  Differential 
expression was assessed using the moderated (empirical Bayesian) t-test 
implemented in version 3.14.4 of the limma package (i.e., creating simple linear 
models with lmFit, followed by empirical Bayesian adjustment with eBayes). The 
Benjamini-Hochberg procedure was applied to generate a false discovery rate 
(FDR) and correct for multiple comparisons.  Differences were considered 
significant if FDR q < 0.05.  All microarray analyses were performed using the R 
environment for statistical computing (version 2.15.1).  Complete datasets were 
deposited with NCBI GEO (Series ID GSE133975). 
Gene Set Enrichment Analysis (GSEA). GSEA version 2.2.1 (57) was used to 
identify biological terms, pathways and processes that are coordinately up- or 
down-regulated within each pairwise comparison. The Entrez Gene identifiers of 
the human homologs of the genes interrogated by the array were ranked according 
to the t statistic computed for each main effect (SP19 history and SP3 infection), 
for each pairwise comparison, and the history:infection interaction effect. Mouse 
genes with multiple human homologs (or vice versa) were removed prior to 
ranking, so that the ranked list represents only those human genes that match 
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exactly one mouse gene. This ranked list was then used to perform pre-ranked 
GSEA analyses (default parameters with random seed 1234) using the Entrez 
Gene versions of the Hallmark, Biocarta, KEGG, Reactome, Gene Ontology (GO), 
and transcription factor and microRNA motif gene sets obtained from the Molecular 
Signatures Database (MSigDB), version 6.0 (58).  Restricting results to the 
Reactome pathways provided a dataset size amenable to manual inspection and 
arrangement; Reactome pathways reaching significance (FDR q<0.05) were 
assembled into groups defined by the authors (Table 1). 
Comparisons to human datasets.  Results from our studies were compared to a 
prior study that examined human alveolar macrophage transcriptomes with and 
without a 4 hour pneumococcal stimulation (38).  Only expression data from 
healthy human subjects were included in analyses.  Both mouse and human 
datasets were restricted to include only genes with homologs across species.  
Three differential expression analyses for infection vs. control were used to 
compare effects of infection in alveolar macrophages from healthy humans, 
experienced mice, and naïve mice.  In addition to genes differentially expressed, 
pathways were detected using GSEA.  The t statistics from the differential 
expression results were used to perform a GSEA employing the fgsea 
Bioconductor package with the MsigDB gene set database version 6.2, looking 
into only the c2.cp (canonical pathways), c5.all (GO gene sets) and c7.all 
(immunological signatures) enrichment.  Degrees of similarity between the human 
and naïve or experienced mouse responses were calculated using the approach 
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previously applied to compare responses of humans to those in laboratory mice or 
laboratory mice that had been co-housed with pet store mice (6).  GSEA statistics 
for gene sets corresponding to the top 400 infection-induced genes in the 
differentially expressed gene sets from experienced and naïve mice were 
computed against the human differentially expressed t statistic dataset as a table 
and leading edge plots, and the resulting plots were used in figure panels (6).  All 
code needed to reproduce the results comparing these data to the human data are 
available at 
https://bitbucket.org/bubfnexus/murine alveolar transcriptional response. 
Statistics. Statistical analyses used for each dataset including measures of central 
tendency and variation were specified in the Figure Legends.  Unpaired data other 
than CFU were analyzed using parametric tests, with two groups compared using 
the Student’s t-test and more-than-two groups compared using a one-way or two-
way ANOVA followed by post hoc Sidak’s tests for multiple comparisons.  CFU 
data were analyzed using non-parametric tests for comparing two groups (Mann 
Whitney U test) or more-than-two groups varying across only one independent 
variable (Kruskal-Wallis test followed by post hoc Dunn’s tests for multiple 
comparisons).  For CFU analyses varying across 2 independent variables, data 
were log-transformed prior to two-way ANOVA followed by post hoc Sidak’s tests 
for multiple comparisons.  Sets of paired data were analyzed using the non-
parametric Sign test.  Differences were considered significant if P < 0.05. Statistics 
used for bioinformatics analyses of cytometry, metabolome, or transcriptome 
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datasets were presented individually in the description of methods for those 
approaches.   
Study approval. Animal protocols were approved by the Boston University 
Institutional Animal Care and Use Committee.   
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Figure 1. Murine model of self-limiting pneumonia. To determine effects of acute 
pneumonia, mice were infected with  106 CFU of serotype 19F instilled into the left 
lung lobe on day 0. To establish heterotypic immune protection, mice receive a 
second infection with 106 CFU of serotype 19F instilled into the left lung lobe on 
day 7, and then were rested at 30 more days before lungs were examined. Sterile 
saline was used as control. Infected mice and controls were compared for (a) 
bacterial burden, (b) body weight, (c) gross morphology of lungs, and (d) leukocyte 
count in BAL, enumerated using a LUNA automated cell counter followed by a 
differential determined morphologically from cytocentrifuge preparations of BAL 
cells. In (a), every individual symbol represents a single mouse with horizontal lines 
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showing median values for the group, and asterisks (*) indicate statistically 
significant (P < 0.05) differences from day 1 values using the Kruskal-Wallis test 
and Dunn’s post hoc multiple comparisons test. In (b), box and whisker plots show 
mean, quartiles, and range, with asterisks (*) indicating significance (P < 0.05) of 
difference between saline and pneumococcus groups as determined using two 
way ANOVA and Sidak’s post hoc multiple comparisons tests. In (d), summary 
data show mean and SEM, with significance (P < 0.05) of difference from day 0 
determined using two way ANOVA and Sidak’s post hoc multiple comparisons test 
and communicated with letters representing cell-type (T=total, N=neutrophils, 
M=macrophages).  For (b) and (d), pooled data represent a total N of 5-12 mice 
per group.  For all, two independent experiments were performed.  LOD = limit of 
detection.   
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Figure 2. Immunophenotyping of lung myeloid cells one month after recovery from 
mild pneumonia. (a) Defense against a serotype 3 pneumococcal pneumonia in 
naïve mice and experienced (“Exp’d”) mice with a history of serotype 19F 
pneumococcal infections as described in Figure 1. Naïve or experienced mice 
were infected i.n. with 0.5-1 x106 CFU, and lung bacterial burdens were 
determined after 24 hours of infection. Asterisk (*) indicates statistically significant 
(P < 0.05) difference between groups using Mann-Whitney U test. For panels (b-
c), mice received i.t. left lobe serotype 19F infections (Exp’d) or saline instillations 
(Naïve) on days 0 and 7, before left lung lobes were collected at day 37 with no 
further infections. (b) Gating strategy for myeloid cells in lung single cell 
suspensions. Cells were isolated from enzymatically digested mouse lungs, and 
after the exclusion of doublets, debris, and dead cells, immune cells were identified 
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by CD45 staining. Sequential gating strategy was used to identify myeloid-cell 
subsets. Representative sample from the naïve group is shown. (c) Absolute cell 
counts of identified myeloid cell subsets were obtained and compared. Numbers 
per mouse were plotted for each cell-type, with data collected over 2 independent 
experiments and each datapoint representing an individual animal. Groups were 
compared using Student’s t-test, and naïve and experience mice did not 
significantly differ for any cell-type. Abbreviations: AM, alveolar macrophages; 
cDC, conventional dendritic cells; eos, eosinophils; IM, interstitial macrophages; 
monos, monocytes; neutro, neutrophils; pDC, plasmacytoid dendritic cells.  
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Figure 3. Myeloid cell subsets differentiating experienced mice from naïve mice. 
For panels a-c, a flow cytometry dataset containing equal numbers of live single 
cell CD45+ events from left lung lobes of N=6 mice in each of the 2 groups (naïve 
or experienced) was phenotyped for relative surface expression of myeloid cell 
markers CD11c, CD64, Ly6C, Ly6G, MHC-II, and SiglecF. (a) Leukocyte subsets 
in the lungs of naïve and experienced mice. Unsupervised clustering of 24 cell 
subsets (numbered according to cell quantity) was generated using the 
PhenoGraph algorithm, with heatmap color intensity representing median surface 
expression for each marker across the entire dataset including all cells from all 
mice. The Wilcoxon rank sum-test with Benjamini & Hochberg multiple comparison 
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adjustments was used to compare relative numbers of events (cells) within each 
cluster between naïve and experienced mice, with the FDR-adjusted P value 
shown for each cluster. (b) Distributions of leukocyte phenotypes in the lungs of 
naïve and experienced mice. The 20 most abundant PhenoGraph clusters based 
on multidimensional single cell data (panel a) were color-coded and plotted on a 
2-dimensional graph using the opt-SNE algorithm for naïve (left) and experienced 
(right) mice. X,Y axes show opt-SNE 2D coordinates. (c) Distributions of manually 
gated myeloid cells on the opt-SNE map. Myeloid cell-types were binned as in 
Figure 2 based on expression levels of the surface markers of interest. (d) 
Expression of surface markers across alveolar macrophages from the lungs of 
Naïve or Experienced mice, depicted as a representative histogram from a single 
naïve (red) or experienced (blue) mouse. (e) Comparisons of individual surface 
markers on alveolar macrophages between Naïve and Experienced (“Exp’d”) 
mice. Median fluorescence intensity (MFI) values per mouse were plotted for each 
surface marker, with data collected over 2-3 independent experiments and each 
datapoint representing an individual animal and horizontal lines representing group 
means. Asterisks (*) indicate comparisons reaching statistical significance (P < 
0.05) using unpaired Student’s t-tests.   
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Figure 4. Effects of time on the remodeling of alveolar macrophage surface 
markers. Alveolar macrophages from lung single cell suspensions of naïve and 
experienced mice were gated as described on Figure 2, and MFI of surface 
markers was shown for lungs collected (a) 3 months or (b) 6 months after 
intratracheal instillations of serotype 19F pneumococcus (for the experienced 
mice) or sterile saline (for naïve).  Data in (a) and in (b) were each collected across 
two independent experiments, and asterisks (*) represent comparisons reaching 
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statistical significance (P < 0.05) using unpaired Student’s t-tests. (c) To determine 
effects of age in the absence of experimental infection, alveolar macrophages from 
lung single cell suspensions were collected from naïve mice of varying ages, as 
indicated. Data from (c) were from a single experiment, and asterisks (*) represent 
statistically significant (P < 0.05) effects of age using one-way ANOVA. For all 
panels, each individual dot represents a single mouse, with horizontal lines 
representing group means.  
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Figure 5. Regional localization of alveolar macrophage remodeling. (a) Mice were 
infected with 2 doses of 1–3 106 CFU of serotype 19F pneumococcus with 1 week 
intervals between infections and then rested at least one month. To generate the 
initial selective left lung infections, an angiocatheter was placed into left bronchus 
through a tracheostomy to administer bacteria or sterile saline. Right and left lung 
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were harvested separately to generate single-cell suspensions. Surface marker 
MFI on alveolar macrophages (gated as in Figure 2) from right lobes (RL) and left 
lobe (LL) were compared within each mouse. Each pair of connected dots 
represents a single mouse. (b) A month after serotype 19F pneumococcus 
infections of the left lung lobe, mice were challenged i.n. with 7.5 x 105 CFU 
serotype 3 pneumococcus. Bacterial burden was assessed after 24 hours in the 
RL vs. LL. Each pair of connected dots represents a single mouse. Data were from 
two (a) or three (b) independent experiments. Asterisks (*) indicate comparisons 
that reached statistical significance (P < 0.05) using the non-parametric two-tailed 
Sign test. 
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Figure 6. Alveolar macrophage roles in defending naïve and experienced lungs. 
(a-b) Liposomal clodronate effectively depleted mouse lungs of alveolar 
macrophages. Mice received i.n. liposomes that contained either PBS or 
clodronate (“Clod”).  (a) Alveolar macrophage numbers were assessed using 
microscopy and cellular morphology with bronchoalveolar lavage (BAL) samples 
from naïve mice. Every individual symbol represents a single mouse with 
horizontal lines showing mean for the group. Asterisk (*) represents a significant 
(P < 0.05) difference using unpaired Student’s t-test. Results include data pooled 
from two independent experiments. (b) Alveolar macrophage numbers were 
assessed using flow cytometry and surface marker characteristics with lung single 
cell suspensions from naïve or experienced (“Exp’d”) mice. Every individual 
symbol represents a single mouse with horizontal lines showing mean for the 
group. Asterisks (*) represent significant (P < 0.05) differences from naïve PBS 
group using one-way ANOVA and Sidak’s post hoc multiple comparisons tests. 
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Results include data from two independent experiments. (c-d) Naïve or 
experienced mice received i.n. liposomes that contained either PBS or clodronate 
(“Clod”) 72 hours prior to i.n. infections with either (c) a medium dose (0.75 x106 
CFU) or (d) a high dose (15 x106 CFU) of serotype 3 pneumococcus. Infecting 
dose was depicted on graphs with a dotted line. Lung bacterial burdens were 
determined 24 hours after infection. Every individual symbol represents a single 
mouse with horizontal lines showing mean for the group. Asterisks (*) indicate 
significant (P < 0.05) effects of clodronate using two way ANOVA on log-
transformed data and Sidak’s post hoc multiple comparisons tests (ns = not 
significant). Results include data from three independent experiments for each 
bacterial dose.   
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Figure 7. Altered metabolomes of alveolar macrophages after resolution of 
pneumococcal infections. (a) Score plot of Principal Component Analysis (PCA) 
performed on the LC/MS data of alveolar macrophages collected from whole lungs 
of naïve (circle) and experienced (square, “Exp’d”) mice. The explained variances 
are shown in brackets. (b) Score plot of PCA performed on the LC/MS data of 
alveolar macrophages collected selectively from the right (circle) or left (square) 
lung lobes of left-experienced mice that recovered from prior lobar pneumonias in 
the left lobe. The explained variances are shown in brackets. For (a) and (b), 
features selected by volcano plot that reached the threshold of 2x fold-change and 
P < 0.1 by t-tests were represented in box plots, log-transformed and normalized 
to constant sum. (c) Metabolites identified by Partial Least Squares - Discriminant 
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Analysis (PLS-DA) and Variable Importance in Projection (VIP) scores 
(comparison of metabolomes of alveolar macrophages from naïve and 
experienced mice). Significant contribution was considered for VIP > 1. Colored 
boxes on the right indicate relative concentrations of the corresponding metabolite 
(elevated in condition with darker box). Two independent experiments with 4 mice 
per group were performed (N=8) for both designs.   
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Figure 8. Transcriptome remodeling of experienced alveolar macrophages, at rest 
and during infection. (a) Hierarchical clustering and heatmap of 443 transcripts 
differentially expressed with FDR q < 0.05 in alveolar macrophages of experienced 
(“Exp’d”) and naïve mice. Each column represents a mouse, and each row a gene. 
Color coding indicates directionality (with blue, white, and red showing below, at, 
or above average expression, respectively). (b) Relative expression of genes 
associated with “Alternative / M2” or “Classical / M1” activation states in mouse 
macrophages (40). Each bar and error represents the mean and SEM from N=4 
mice per group in genome-wide transcriptome analyses. (c-d) Plots of Reactome 
pathways resulting from GSEA analyses of the transcriptome profiles of alveolar 
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macrophages from experienced compared to naïve lungs, at rest (c) or 4 hours 
after infections with serotype 3 pneumococcus (d).  All pathways that crossed the 
FDR q < 0.05 threshold were examined (listed in Table 1), colored differently from 
black in the figures, and grouped by manual inspection (as detailed in Table 1) into 
overarching pathways that were communicated in the figures via inset boxes.  
Normalized enrichment scores (NES) below zero indicate pathways decreased in 
the experienced lungs, while positive NES scores indicate pathways increased in 
experienced lungs.  
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Figure 9. Transcripts and proteins altered by prior pneumonia experience. 
Transcripts were culled from the full datasets of alveolar macrophages from naïve 
or experienced (“Exp’d”) mice with or without acute (4 hour) infections by serotype 
3 pneumococcus and presented in panels (a) through (d). (a) The 25 transcripts 
that increased most significantly due to past history of infections. These had the 
lowest FDR q values for effect of pneumonia history and were increased rather 
than decreased in alveolar macrophages of experienced lungs. (b) The chemokine 
transcripts detected in alveolar macrophages. Arrows indicate FDR q < 0.05 effect 
of pneumonia history. (c) The phagocytosis receptor transcripts detected in 
alveolar macrophages. Arrows indicate FDR q < 0.05 effect of pneumonia history. 
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(d) Transcripts differentiating recruited vs. autochthonous alveolar macrophages 
in prior studies of replacement after clodronate depletion (17). Asterisks (*) indicate 
FDR q < 0.05 effect of pneumonia history with changes in the direction consistent 
with monocyte-derived alveolar macrophages in the Experienced group, and 
hashtag (#) indicates FDR q < 0.05 effect of pneumonia history with changes in the 
opposite direction. (e) Surface protein levels of surface markers implicated in 
transcriptome studies as differing between naïve and experienced mice at the 
mRNA level. Median fluorescence intensity (MFI) values on alveolar macrophages 
were plotted for each surface marker, with data collected over 2-3 independent 
experiments and each datapoint representing an individual animal and horizontal 
lines representing group means. Asterisks (*) indicate comparisons reaching 
statistical significance (P < 0.05) using unpaired Student’s t-tests. (f) Protein levels 
of soluble cytokines implicated in transcriptome studies as differing between naïve 
and experienced mice at the mRNA level. Concentrations were quantified by 
ELISA in left lung homogenates (LLH) from naïve or experienced mice infected 4 
or 7 hours with serotype 3 pneumococcus. Data were collected over 2-3 
independent experiments, with each datapoint representing an individual animal 
and bars representing group means. Asterisks (*) indicate comparisons reaching 
statistical significance (P < 0.05) using 2-way ANOVA.  
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Figure 10. Comparison of mouse and human alveolar macrophage responses to 
pneumococcal infection. (a-b) Euler diagrams representing relative sizes and 
overlap of (a) gene sets or (b) biological pathways that were significantly altered 
by pneumococcal stimulation of mouse alveolar macrophages that were naïve or 
experienced (datasets collected here) or of human alveolar macrophages from 
Bewley et al (38). (c-d) GSEA comparisons of human alveolar macrophage 
responses to pneumococcus [from Bewley et al (38)] to mouse alveolar 
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CYTOPLASM, D INTERFERON GAMMA SIGNALING, E INTERFERON ALPHA 
BETA SIGNALING, F CYTOKINE SIGNALING IN IMMUNE SYSTEM, G ANTIGEN 
PRESENTATION FOLDING ASSEMBLY AND PEPTIDE LOADING OF CLASS I 
MHC, H NEGATIVE REGULATORS OF RIG I MDA5 SIGNALING, I ASPARAGINE 
N LINKED GLYCOSYLATION, J BIOSYNTHESIS OF THE N GLYCAN 
PRECURSOR DOLICHOL LIPID LINKED OLIGOSACCHARIDE LLO AND 
TRANSFER TO A NASCENT PROTEIN, K RESPIRATORY ELECTRON 
TRANSPORT, L RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS 
BY CHEMIOSMOTIC COUPLING AND HEAT PRODUCTION BY UNCOUPLING 
PROTEINS.  
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Supplemental Figure S1. Metabolome analyses of alveolar macrophages after 
resolution of pneumococcal infections. Volcano plot of the LC/MS data of alveolar 
macrophages collected from whole lungs of naïve and experienced mice. The 5 
metabolites that reached significance (FDR-adjusted p<0.05, indicated with dotted 
line) in comparisons between naïve and experienced mice were identified by name 
and color coding. The other metabolites measured were listed alongside, none of 
which differed by FDR-adjusted p<0.05 for comparisons between naïve and 
experienced mice. 
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Supplemental Figure S2. Interconnections between alveolar macrophage 
metabolome changes and transcriptome changes due to prior pneumonia 
experience. Metabolic pathways for creatine, urea cycle, and methionine cycle 
were depicted, including relationships to each other. Gene names for the proteins 
involved in these metabolic pathways were indicated in italics. The Gatm transcript 
encoding arginine:glycine amidinotransferase was significantly increased in 
experienced alveolar macrophages. The Slc6a8 gene encoding sodium- and 
chloride-dependent creatine importer was significantly increased in experienced 
alveolar macrophages. None of the other genes in these pathways were 
significantly changed due to experience. The metabolites guanidinoacetate, 
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creatine, and phosphocreatine were significantly increased due to experience, but 
no other of the depicted metabolites. Biological effects of increased creatine and 
phosphocreatine were depicted in green.  
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Abstract 
Recovery from pneumococcal pneumonia remodels the pool of alveolar 
macrophages so that they exhibit new surface marker profiles, transcriptomes, 
metabolomes, and responses to infection. New alveolar macrophage phenotypes 
can result from CCR2-mediated monocyte recruitment and cell turnover, or from T 
cell-derived IFN-driven reprogramming of resident cells without replacement, but 
mechanisms mediating alveolar macrophage phenotypes after pneumococcal 
pneumonia were unknown. In mice infected or recovering from pneumococcus, 
monocytes were recruited to the lungs and the monocyte-derived macrophages 
developed characteristics of alveolar macrophages, but CCR2 was not essential 
to development of the remodeled alveolar macrophage phenotype. IFN was 
produced by many and changing cell sources and CD4+ cell depletion did not 
prevent alveolar macrophage remodeling, but IFN and its receptor on alveolar 
macrophages were essential for some aspects of the remodeled alveolar 
macrophage phenotype. Lineage tracing of the pool of AMs from naïve and 
experienced lungs demonstrated that recovery from pneumococcal pneumonias 
flipped the pool of alveolar macrophages from being primarily of embryonic origin 
to being primarily of adult hematopoietic stem cell origin, but alveolar macrophages 
of either origin demonstrated similar remodeled phenotypes, suggesting that 
ontogeny did not dictate phenotype. Altogether, our data reveal alveolar 
macrophage turnover but similar programming for both the initially resident and the 
newly recruited cells, partially dependent on IFN. The remodeled alveolar 
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macrophage phenotype characteristic of lungs recovered from pneumococcal 
pneumonia results from a combination of new recruitment plus training of both the 
original cells and the new recruits.  
 
 
 
Introduction 
Lung infections are a leading cause of morbidity and mortality (Mandell et al., 2007; 
Mizgerd et al., 2012). Microbes that enter the air spaces of the lung encounter 
alveolar macrophages (AMs), which function as sentinels and immune modulators. 
These cells protect the lung by clearing microbial and non-microbial agents, 
initiating pulmonary inflammation, and contributing to resolution and repair (Hussel 
et al., 2014; Morales-Nebreda et al., 2015).  
AMs can arise from either of two disparate origins. Initially, they derive from 
embryonic sources, including yolk sac precursors and fetal liver hematopoiesis 
(Guilliams et al., 2013; Murphy et al., 2008; Gomez Perdiguero et al., 2015). 
Postnatally, AMs appear that derive from bone marrow hematopoiesis (Maus et 
al., 2006; Gomez Perdiguero et al., 2015, with this fraction continuously expanding 
and encompassing ~40% of the AMs pool at 1 year of age in C57BL/6 mice in 
specific pathogen-free environments (Gomez Perdiguero et al., 2015). Factors that 
kill AMs can more rapidly convert the AMs pool to becoming dominated by 
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monocyte-derived cells from adult hematopoiesis (Maus et al., 2006; Taut et al., 
2008; Aegerter et al., 2020). Several pneumonia-causing microbes target 
macrophages for programmed cell death (Coleman et al., 2017; Gonzalez-Juarbe 
et al., 2015; Kitur et al., 2015) and accelerate turnover of the AMs pool (Taut et al., 
2008; Guillon et al., 2020). The AMs of fetal origin and of adult hematopoietic origin 
are largely similar but not identical to each other, across multiple characteristics 
including surface markers, gene expression, and functional activities (Gibbings et 
al., 2015; Watanabe et al., 2019; Mcquattie-Pimentel., 2018). 
After recovery from respiratory infections, the AMs pool can exhibit remodeled 
phenotypes (Yao et al., 2018, Aegerter et al., 2020). Recovery from adenoviral 
pneumonia results in AMs with increased surface MHC-II and improved responses 
to subsequent bacterial infections including elevated induction of neutrophil 
chemokines (Yao et al., 2018); this remodeling occurs entirely within the initial AMs 
pool of embryonic origin, with no replacement by monocyte-derived AM. The 
adenovirus-induced remodeling is dependent on IFN derived from CD8+ T cells 
recruited to the lung during the initial adenovirus infection (Yao et al., 2018). In 
contrast, recovery from influenza pneumonia can result in AMs with increased 
surface MHC-II, decreased surface SiglecF, and improved responses to 
subsequent bacterial infections including elevated induction of IL-6 (Aegerter et 
al., 2020); this remodeling requires CCR2-mediated recruitment of monocytes 
which differentiate and replace the AMs of embryonic origin and is only confined 
to the recruited AM (Aegerter et al., 2020). These are two alternative paradigms 
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for how AMs remodel after pneumonia recovery, new phenotypes developing in 
the initial cells vs. replacement of initial cells by new AMs having different 
phenotypes. 
Recovery from pneumococcal pneumonia results in profoundly improved 
protection against heterotypic infection, due to a combination of resident memory 
lymphocytes as well the remodeling of AMs (Smith et al., 2018; Shenoy et al., 
2020; Guillon et al., 2020). The remodeled AMs in this setting have increased 
surface MHC-II, decreased surface SiglecF, reprogrammed creatine metabolism, 
and profoundly altered transcriptomes both at rest and in response to infection, 
better matching the immune responses of human AMs (Guillon et al., 2020). 
Mechanisms by which AMs remodel in pneumococcus-recovered lungs are 
unclear. Pneumococci can kill AMs (Coleman et al., 2017), and the transcriptomes 
of remodeled AMs in pneumococcus-recovered lungs include transcript changes 
consistent with AMs derived from adult monocytes (Guillon et al., 2020), which 
suggests remodeling by replacement as observed after influenza pneumonia 
(Aegerter et al., 2020). Pneumococcal pneumonia elicits IFN from neutrophils 
(Yamada et al., 2011; Gomez et al., 2015) and results in IFN-producing CD4+ T 
cells (6, 22-28), which may contribute to AMs remodeling like the IFN from CD8+ 
T cells during adenoviral pneumonia (Yao et al., 2018). The phenotypes of AMs 
recovered from pneumococcal pneumonia (Guillon et al., 2020) differ from those 
that have recovered from adenoviral (Yao et al., 2018) or influenza (Aegerter et 
al., 2020) pneumonia, suggesting the possibility that neither paradigm may apply. 
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.  
 
Results 
Dynamics of lung macrophages while progressing to a protected lung 
Naturally acquired immune defense against pneumococcal pneumonia can be 
achieved in mice by administering two self-limiting respiratory infections with 
Streptococcus pneumoniae serotype 19F (Sp19F) spaced one week apart 
followed by a month for recovery, after which they demonstrate a long-lasting 
heterotypic protection that involves remodeled AMs of unknown sources (Smith et 
al., 2018; Shenoy et al., 2020).To determine whether and how AMs numbers 
change during the infection history that establishes heterotypic protection against 
pneumococcal pneumonia (Smith et al., 2018; Shenoy et al., 2020), naïve mice 
were ushered through serial infections and at designated time-points lungs were 
collected and digested to single cell suspensions for flow cytometry. After gating 
on singlet cells, live cells, and CD45+ cells, AMs were identified as Ly6G-Ly6C-
CD11c+SiglecF+CD64+ cells (Figure 11A). AMs numbers were significantly 
reduced by two-thirds 1 day after Sp19F challenge, but they returned to baseline 
between day 3 and day 7 (Figure 11B). AMs numbers followed a similar trend after 
the second pneumococcal challenge, dropping by two-thirds at one day but 
becoming restored soon after (Figure 11B). AMs numbers continued to increase 
and were elevated at days 14 and 24 before returning towards the original baseline 
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by day 35 (Figure 11B). These results are consistent with rapid AMs losses due to 
pneumococcus-induced programmed cell death (Coleman et al., 2017), followed 
by restoration from recruitment and/or proliferation. 
Because AMs can derive from differentiation of recruited monocytes, we quantified 
extravascular inflammatory monocyte-macrophages (Mo-Macs) throughout the 
time-course. Mo-Macs were identified as CD45+Ly6G-Ly6C+CD64+ cells and 
were readily distinguished from the intravascular (stained by an anti-CD45 
antibody delivered i.v.) and extravascular Ly6C+ cells that were CD64- (Figure 
11A). At baseline, there were many more AMs than Mo-Macs in the lung (Figure 
11B). Within 1 day after each infection, a substantial increase in Mo-Macs led to 
them becoming more abundant than AMs in the lungs (Figure 11B). By one week 
after either infection, Mo-Macs were declining in numbers in the lungs (Figure 
11B). By day 35, Mo-Mac numbers returned to their initial low baseline values 
(Figure 11B). Thus, AMs and Mo-Macs were both dynamic, with complementary 
kinetics. Mo-Macs increased whenever AMs declined and declined when AMs 
increased, until both returned to near baseline values by day 35.   
Cardinal features of the remodeled AMs in experienced lungs are surface marker 
changes, particularly decreased SiglecF and increased MHC-II (Gibbings et al., 
2015; Misharin et al., 2017; Yao et al., 2018; Aegerter et al., 2020). We examined 
these surface markers on AMs and Mo-Mac over the course of infections and 
recovery. SiglecF diminished in intensity on AMs within one day of the first infection 
and never fully recovered, hovering around half the baseline levels throughout the 
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time-course and at the experienced lung time-point of 35 days (Figure 11C). MHC-
II was slower to change and then far more dynamic. MHC-II first increased on AMs 
at day 3, reached peak intensity at day 10, and then established a new stable 
elevated set-point by day 14 which was maintained through the experienced lung 
time-point of 35 days (Figure 11D). The lung Mo-Macs demonstrated similar 
changes. SiglecF was low on Mo-Macs compared to AM, but this dim signal 
diminished due to infection (Figure 11D). MHC-II was present at similar intensities 
on Mo-Macs and AMs and showed similar changes throughout the time-course 
(Figure 11D). Thus, SiglecF and MHC-II display different kinetics, with the former 
accomplishing most of its change within a day (suggesting innate immune 
signaling) while the latter develops over a longer time-frame, peaking at day 10 
before dropping to a new baseline (more consistent with adaptive immunity 
signaling). Both AMs and Mo-Mac respond analogously during the infection and 
recovery periods. 
Effect of CD4+ cells on the experienced phenotype of AM 
The AMs remodeling induced by adenoviral infections, including increased MHC-
II, depends on T cell-derived IFN (Yao et al., 2018). Pneumococcal-experienced 
lungs exhibit a transient recruitment of effector CD4+ T cells that become a 
population of resident memory CD4+ T cells, and these CD4+ cells express IFN, 
IL-17, and other cytokines (Smith et al., 2018; Shenoy et al., 2020; Shenoy et al., 
2021). To test whether CD4+ T cells are essential for the remodeled phenotype of 
AMs in pneumococcus-experienced lungs, mice received doses of GK1.5 to 
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deplete CD4+ cells (or non-specific IgG as control) throughout the initial infections, 
and then lungs were characterized at day 35. This GK1.5 regimens completely 
eliminated CD4+ TRM cell accumulation (Figure 12A), demonstrating that this 
hallmark of experienced lungs requires CD4+ T cells during the initial infections. 
We examined whether CD4+ cell depletion had an impact on AMs numbers and 
phenotype in experienced lungs (Figure 12B-D). Experienced mice which had 
CD4+ cell depletion during initial rounds of infection exhibited significantly less 
AMs numbers compared to control experienced mice (Figure 12B).  SiglecF 
intensity on AMs was significantly decreased on experienced mice, regardless of 
whether the mice had received the GK1.5 depletion regimen or non-specific IgG, 
suggesting that the diminished SiglecF intensity on AMs associated with 
pneumococcal experience was not dependent on adaptive immune signaling 
(Figure 12C). Analogously, MHC-II intensity was increased in both experienced 
mice which received GK1.5 depletion antibody as well as in the experienced mice 
which received non-specific IgG in comparison to naïve mice, with comparable 
MHC-II intensity between the 2 groups of experienced mice (Figure 12D). Thus, 
CD4+ T cells during initial infection and CD4+ TRM cell formation are not essential 
for the remodeled AMs phenotype in pneumococcus-experienced lungs.   
IFN dynamics and sources while progressing to a protected lung. 
During pneumococcal infections, neutrophils have been shown to produce 
significant amounts of IFN within one day of infection (Yamada et al., 2011; 
Gomez et al., 2015). Similarly, CD8 effector T cells have been previously been 
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implicated in priming MHC-II upregulation on AMs via IFN after recovery from 
adenovirus infections (Yao et al., 2018). Because CD4+ T cells were dispensable, 
we considered whether other cells might be sources of IFN during the initial 
infection stages. To determine kinetics, we measured IFN in bronchoalveolar 
lavage fluids collected during infections. IFN concentrations were elevated one 
day after infection, declined, and then rose to even higher levels on day 8, one day 
after the second infection (Figure 13A). To determine the sources of IFN at these 
time-points, single cell suspensions were generated and IFN+ cells were 
discriminated using intracellular cytokine staining. After the first pneumococcal 
infection, many cells could express IFN, but neutrophils were by far the most 
abundant sources in the lungs (Figure 13B). After the second infection that elicited 
higher amounts of IFN, sources were even more diverse and heterogeneous, with 
neutrophils accounting for a smaller fraction and more prominent roles emerging 
for leukocyte subsets that were CD45+ and positive for either but not both of 
CD11b or Ly6c (Figure 3B). An additional subset of cells emerging as an IFN 
source at day 8 failed to stain for any of the markers examined other than CD45 
(Figure 13B). The total numbers of IFN+ cells per lung peaked on day 1 for 
neutrophils but at day 8 for the other cell-types (Figure 13C-F). In separate 
analyses, CD4 and CD8 were examined, and the number of CD4+ cells and CD8+ 
cells producing IFN were significantly higher on day 8, immediately after the 
second pneumococcal infection (Figure 13G-H). These T cells would be 
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components of the Ly6G-CD64-CD11c-CD11b-Ly6C+ sources of IFN, with the 
remainder perhaps being NK cells and other innate lymphocytes. Together, these 
data highlight that there are many and diverse sources of IFN during 
pneumococcal pneumonia. If IFN is a driving factor for AMs remodeling, then 
multiple different cells work together to provide this signal. 
IFN requirements for remodeled and protected macrophages 
Since transcriptomes of AMs in experienced lungs exhibit a signature of IFN 
signaling (Guillon et al., 2020), and since IFN is necessary to remodel AMs after 
adenoviral infection (Yao et al., 2018), we investigated whether IFN was sufficient 
to influence AMs interactions with pneumococcus and the resulting remodeled 
phenotype. The immediate drop in AMs numbers after infection (Figure 11B) is 
consistent with macrophage necroptosis induced by pneumococci (Coleman et al., 
2017), leading us to test whether IFN could affect macrophage survival. We used 
the RAW264.7 macrophage-like cell line, which accurately reports pneumococcus-
induced necroptosis (Coleman et al., 2017), to investigate this concept. When 
stimulated with IFN, these cells became more resilient and better able to survive 
pneumococcal infection (Figure 14A-C). Thus, macrophage numbers may be 
influenced by this cytokine. To test whether IFN was sufficient to influence the 
surface marker phenotype of AMs, uninfected mice received intratracheal 
instillations of either IFN or vehicle twice with a one-week interval (to mimic the 
timing of infections that establish immune protection) and the AMs were immuno-
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phenotyped four weeks later (to model the wait period in experienced lung studies). 
Mice which received prior IFN stimulation exhibited slightly but significantly fewer 
AMs per lung compared to those stimulated with vehicle (Figure 14D), suggesting 
that IFN has complex and context-specific effects on macrophage survival. 
Examining their surface marker phenotypes, mice stimulated with IFN had AMs 
with significantly less SiglecF and significantly more MHC-II on their surface, 
compared to control mice stimulated with vehicle (Figure 14B-C). Although less 
pronounced, these results mirror the remodeling of AMs observed in lungs with 
pneumococcal pneumonia experience (Figure 11 and (Guillon et al., 2020)). Thus, 
IFN is sufficient to push AMs phenotypes towards the surface marker changes 
observed in pneumococcus-experienced mice.  
Role of IFN in pneumonia-induced MHC-II remodeling of AM 
To complement IFN gain of function, we tested whether IFN loss of function 
would prevent AMs from gaining some or all of the experienced phenotype. Wild 
type (WT) and IFN-/- mice were ushered through the pneumococcal experience 
model and immunophenotyped 4 week after the last infection. Numbers of AMs 
per lung did not differ in IFN-/- mice compared to wild type (Figure 15A). The 
decrease in SiglecF expression was observed in AMs of experienced IFN-/- mice, 
with no significant difference from WT mice (Figure 15B). Thus, this aspect of 
immune remodeling did not require IFN. In contrast, the MHC-II changes on AMs 
did. The surface MHC-II of AMs from experienced IFN-/- mice was significantly 
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less than in WT counterparts, and not different from naïve mice without a 
pneumococcal infection history (Figure 15C). Since CD4+ TRM cells are another 
critical component of immunity in lungs with pneumococcal experience (Smith et 
al., 2018; Shenoy et al., 2020; Shenoy et al., 2021), we investigated whether loss 
of IFN would impact numbers of these cells. Like AMs SiglecF but contrasting with 
AMs MHC-II, the CD4+ TRM cell numbers were unaffected by deficiency of IFN 
(Figure 15D). Thus, IFN has essential but select roles in remodeling lung immunity 
after recovery from pneumococcal pneumonia, in particular being responsible for 
the increased MHC-II on AM.  
Roles of IFN receptor on AMs in development of the experienced phenotype 
To test whether the essential role for IFN in remodeling AMs after pneumococcal 
pneumonia required IFN signaling to AM, we crossed Ifngr1-floxed mice (Lee et 
al., 2013) with Itgax-driven cre transgenic mice (Canton et al., 2007) to deplete 
IFN receptors from CD11c+ cells. As designed, the IFN receptor was effectively 
targeted, with diminished expression of the receptor on AMs from Cre+ mice 
compared to their Cre- littermates (Figure 16A). The instillation of IFN to the lungs 
was sufficient to increase MHC-II on AM, but this was abrogated in the Cre+ mice 
without IFN receptors on these cells (Figure 16B). Littermates that were Cre+ and 
Cre- were ushered through the pneumococcal experience model and 
immunophenotyped 4 week after the last Sp19F challenge. AMs were present in 
similar numbers in the experienced Cre- and Cre+ mice (Figure 16C), and they 
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retained their differences in IFN receptor expression (Figure 16D). Exactly 
analogous to the results with IFN-/- mice, the experienced Cre+ mice exhibited 
no changes compared to Cre- controls in SiglecF levels (Figure 16E) but 
significantly less MHC-II (Figure 16F), suggesting that this element of immune 
remodeling depends on IFN signaling to AMs directly. Other aspects of remodeled 
immunity, including CD4+ TRM cells in the lung (Figure 16G) and immune defense 
against pneumococcus (Figure 16H) were unaffected by AMs deficiency of the 
IFN receptor. These data reveal that many aspects of lung immune remodeling 
are independent of IFN and AMs receptors for this cytokine, but distinct aspects 
of this remodeling including a stable and prolonged increase in surface MHC-II are 
entirely dependent on IFN signaling directly to AM. 
CCR2 independence of AMs numbers and phenotype 
IFN is essential for remodeling AMs after adenoviral infections in which there is 
no replacement of AMs by recruited monocytes (Yao et al., 2018), and the above 
data suggest IFN contributes to select aspects of AMs remodeling after 
pneumococcal pneumonia. In contrast to adenovirus, lungs recovered from 
influenza infection include replacement of the initial AMs by recruited monocyte-
derived AMs (Aegerter et al., 2020). After recovery from pneumococcus, 
transcriptomes of the remodeled AMs pool also suggest the possibility of AMs of 
monocyte origin (Guillon et al., 2018), but this has not been established. Monocyte 
recruitment into the inflamed lungs is typically dependent upon the chemokine 
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receptor CCR2 (Lechner et al., 2017; Maus et al., 2002; Xiong et al., 2015), which 
we observed to be the case when elicited by acute pneumococcal infection (Figure 
17A). To determine whether CCR2-mediated monocyte recruitment influenced 
AMs remodeling, we measured AMs numbers and phenotype in WT and CCR2-/- 
mice that recovered from prior pneumococcal pneumonias. The CCR2-/- mice 
demonstrated no differences from WT mice related to AMs numbers (Figure 17B) 
or surface levels of SiglecF (Figure 17C) or MHC-II (Figure 17D). Although the loss 
of CCR2 impairs CD8+ TRM cell accumulation in influenza models (Dunbar et al., 
2020), CD4+ TRM cell accumulation after pneumococcal pneumonia did not 
depend on this chemokine receptor (Figure 17D). These data reveal that CCR2-
mediated monocyte recruitment is not essential for any of the immunological 
remodeling here measured in lungs recovered from pneumococcal pneumonia. 
Remodeling of AMs from distinct origins in experienced lungs 
To determine whether AMs remodeling in lungs with prior pneumococcal 
experience involves monocyte recruitment, we used lineage tracing to differentiate 
AMs from embryonic vs. adult hematopoietic stem cell (HSC) origin (Boyer et al., 
2011; Boyer et al., 2012; Muzumdar et al., 2007; Hashimoto et al., 2013). With this 
mouse model, the embryonic-origin macrophages express the red fluorescent 
tdTomato protein whereas the adult monocyte-derived macrophages express 
green fluorescent protein (GFP) instead (Boyer et al., 2011; Boyer et al., 2012; 
Muzumdar et al., 2007; Hashimoto et al., 2013). In naïve mice, most but not all 
AMs were tdTomato+, indicating that they were predominantly from embryonic 
 
141 
 
origin (Figure 18A-B). In contrast, for mice with prior experience with 
pneumococcal pneumonias, most but not all AMs were GFP+, indicating the 
majority were from adult HSC origin (Figure 18A-B). These data confirm what had 
been inferred but uncertain from transcriptome analyses, that AMs in the 
remodeled pool of pneumococcus-experienced lungs include more AMs that are 
differentiated from recruited monocytes (Guillon et al., 2020). To determine 
whether one or the other or both lineages remodeled their surface phenotypes after 
resolution from pneumonia, we compared SiglecF and MHC-II on each subset of 
cells. Both AMs subsets exhibited a significant decrease in SiglecF in experienced 
lungs compared to their naïve counterparts (Figure 18C). Both AMs subsets 
exhibited a significant increase in MHC-II in experienced lungs compared to their 
naïve counterparts (Figure 18D). Altogether, these data suggest that phenotypic 
remodeling after pneumococcal experience is not confined to either the original 
AMs or the AMs products from new cells recruited into the lung; rather, both AMs 
subsets are similarly subject to remodeling. Monocyte-derived AMs are a major 
component of the remodeled AMs pool after recovery from pneumococcal 
pneumonia, but the AMs of embryonic origin and of monocyte origin display 
matching phenotypic characteristics, suggesting that the tissue microenvironment 
exerts a dominant influence on AM phenotype regardless of their cell origins. 
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Functional differences of AMs from distinct origins 
In addition to new resting phenotypes that include lesser SiglecF and greater MHC-
II, remodeled AMs have different responses to challenge, which include increases 
in CXCL9 after pneumococcus-induced remodeling, in CXCL2 after adenovirus-
induced remodeling, or in IL-6 after influenza-induced remodeling (Guillon et al., 
2020; Yao et al., 2018; Aegerter et al., 2020). We tested whether there were 
distinctions between expression of these cytokines in trained AMs of embryonic 
origin vs. new recruits. Consistent with prior remodeling after pneumococcal 
pneumonia, the AMs from experienced lung had increased Cxcl9 induction during 
infection compared to AMs from infected lungs of naïve mice (Figure 19A). Like 
the surface marker changes (Figure 18), there were no differences in Cxcl9 
expression between tdTomato+ embryonic origin AMs and GFP+ monocyte-derive 
AMs (Figure 19A), further confirming that the tissue microenvironment influences 
trained responses of these cells more than ontogeny does. Unlike after adenovirus 
or influenza infections (Yao et al., 2018; Aegerter et al., 2020), AMs from lungs 
that have recovered from pneumococcal pneumonia do not demonstrate elevated 
Cxcl2 or Il-6 expression (Figure 19B-C). Again, there were no differences between 
tdTomato+ embryonic origin AMs and GFP+ monocyte-derived AMs (Figure 19B-
C). Altogether, these data reveal that the training in lungs recovering from 
pneumococcal pneumonia differs from that reported for other infections and does 
not influence the originating AMs differently from the recently recruited AM. 
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The defining feature of AMs is their ability to phagocytize materials in the air spaces 
(Nagre et al., 2019), so we examined whether these different AMs subsets differed 
at ingesting pneumococcus in experienced lungs. Serotype-mismatch precluded 
opsonophagocytosis driven by antibodies against capsular polysaccharides. To 
test whether embryonic-derived and adult HSC-derived AMs had different 
phagocytic capacity, the lineage tracing mice were ushered through the 
pneumococcal experience protocol and challenged after 4 weeks with 
fluorescently labeled pneumococci in the air spaces. Within 40 minutes, 25-35% 
of the tdTomato+ AMs were positive for the labeled bacteria, but significantly 
smaller fractions of the GFP+ AMs from the same lungs were demonstrably 
phagocytic (Figure 19D). To compare relative bacterial loads per AMs among cells 
that were phagocytic, we examined MFI for AMs subsets that were positive for the 
labeled bacteria (Figure 19D). Again, the embryonic origin AMs were more 
phagocytic, with greater fluorescent bacteria MFI in the tdTomoto+ AMs compared 
their GFP+ counterparts from the same lungs (Figure 19E). These results reveal 
that, although they remodel similarly after recovery from pneumococcal 
pneumonia, the trained AMs of embryonic or adult HSC origin do manifest 
functional differences. 
  
 
144 
 
Discussion 
After recovery from pneumococcal pneumonia, AMs undergo adaptive 
characteristics where they become phenotypically, transcriptionally, and 
metabolically altered (Guillon et al., 2020). In this manuscript, we uncovered 
mechanisms driving these changes. Some but not all of the AMs get replaced after 
pneumococcal pneumonia. However, the newly recruited and embryonic-origin 
AMs are similar for the features of training that are characteristic results of 
recovering from pneumococcal pneumonia. IFN derived from diverse cells is an 
important driver of the AMs experienced phenotype, signaling directly to these cells 
via the IFN receptor. 
Our study highlights different dynamics of SiglecF and MHC-II kinetics, where 
changes in SiglecF expression occur within one day suggesting a role for innate 
immune signaling and MHC-II intensity undergoes slow changes that are amplified 
by a secondary challenge suggesting a role for adaptive immune signaling. 
Furthermore, our study highlights how depletion of CD4 effector cells affects AMs 
numbers but not their SiglecF or MHC-II experienced phenotypes. These finding 
contrast with previous findings showing that, after adenovirus infections, CD8+ T 
cells are essential to the increased MHC-II on AMs (Yao et al., 2018). Additionally, 
our study demonstrates a change in SiglecF intensity after pneumococcal injury 
that is not observed in the aforementioned adenovirus study (Figure 11, (Yao et 
al., 2018)). This raises the question of to what extent adaptive immune effector 
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cells impact AMs and other lung resident immune cells phenotypes under different 
infectious settings. 
Our results highlight the importance of IFN signaling in changing MHC-II intensity 
on AM, and how this MHC-II experienced phenotype is directly dependent on IFN 
ligand binding to their established receptor. These data support previous data 
highlighting the role of IFN in AMs developing an increase in MHC-II (Yao et al., 
2018). Additionally, our data complements previous data identifying neutrophils as 
an important source of IFN after infection with pneumococcus (Yamada et al., 
2011; Gomez et al., 2015). Our study revealed multiple additional sources for IFN, 
particularly, after a secondary challenge. Many diverse sources combined with 
required roles for this singular cytokine emphasize its contributions to skewing and 
shaping immune response in the lungs. However, our data also demonstrate that 
aspects of AMs remodeling, such as the decreased SiglecF, can be independent 
of IFN. Mechanisms responsible for the decreased SiglecF on AMs are yet to be 
determined, after recovery from pneumococcus or other pulmonary challenges. 
The kinetics of AMs loss and recovery after pneumococcal infection, combined 
with the surface marker changes over the time-course, suggested a degree of cell 
turnover and replacements by AMs of adult monocyte origin. The lineage tracing 
mouse confirmed this inference, shifting the pool of AMs from ~20% adult HSC 
origin to ~80% adult HSC origin. These results support previous data highlighting 
the contributions of recruited monocytes to recovering AMs numbers after 
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pneumococcal pneumonia (Taut et al., 2007). Recruited monocytes contribute to 
the remodeled AMs phenotypes after recovery from influenza infections (Aegerter 
et al., 2020), but not after adenovirus infection (Yao et al., 2018). And although 
AMs turnover occurred in both pneumococcal and influenza settings, CCR2 was 
essential for AMs remodeling defined by MHC-II and SiglecF after influenza 
(Aegerter et al., 2020) but not after pneumococcus infections. These data raise the 
question of which determinants drive these divergent paths to remodeling 
phenotypes.  
Our data demonstrate that both embryonic and recruited AMs subsets undergo 
similar remodeling after recovery from pneumococcal pneumonia. This 
substantiates the paradigm that in tissue microenvironment is key to imparting 
macrophage phenotype (19-22). Prior studies comparing AMs of adult HSC and 
embryonic origins suggested they were largely similar (Gibbings et al., 2015; 
McQuattie-Pimentel et al., 2018). Consistent with this, we found that MHC-II, 
SiglecF, and cytokine induction were similar between these AMs of disparate origin 
in lungs recovered from pneumococcus. However, within naïve mice, embryonic- 
AMs exhibited less phagocytosis compared to their monocyte-derived-AMs 
counterparts. Upon experience, this observation was changed, and embryonic- 
AMs exhibited better phagocytosis compared to their monocyte-derived-AMs 
counterparts from the same lungs. Altogether, these data highlight the need to 
better understand how AMs origin influences AMs function, and when and how the 
influences of ontogeny on behavior are modified by prior infectious history.   
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Alveolar macrophages are different after recovery from pneumococcal pneumonia, 
and these changes involve an element of cell replacement as well as trained 
immunity occurring in both the initial and newer cells. How AMs and other resident 
cells of the lug or other tissues are remodeled after recovery from challenges is 
only beginning to be appreciated and needs to be defined and differentiated across 
infection settings. AMs changes likely contribute to the improved defense against 
respiratory infection developing in childhood and preventing pneumonia in young 
adults, and further studies should determine how aging influences remodeled AMs 
phenotypes and may contribute to pneumonia in older subjects. Elucidating 
mechanisms underlying AMs phenotypes will empower measuring and 
manipulating AMs biology and development of future precision medicine 
approaches for countering pneumonia susceptibility.  
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Methods 
Mice  
C57BL/6J, CCR2-/- (44), and IFN-/- (45) mice used in pneumococcal experience 
model were purchased from Jackson laboratories (Bar Harbor, Maine). Mice with 
a conditional knockout of IFNGR1 on CD11c cells were created at our mouse 
facilities by crossing CD11c-Cre mice (30) with IFNGR1 floxed mice (29)  
purchased from Jackson laboratories. Flk-switch mice were kindly provided by 
Dr. Camilla Forsberg (UC Santa Cruz) and Dr. Thomas Boehm (Max-Planck 
Institute of Immunobiology and Epigenetics) (36-38). All mice were maintained at 
our pathogen free facilities. Age and sex-matched and littermate control mice 
were used as controls for mice created and maintained in-house. All experiments 
were carried out on mice between 6-12 weeks old mice. 
Bacterial Strains 
S. pneumoniae serotype 19F (Sp19F, EF3030) was kindly provided by Dr. Marc 
Lipsitch, Boston, MA. S. pneumoniae serotype 3 (Sp3) was purchased from 
ATCC (6303). Bacteria were grown for 13-14 hours at 37°C in a humidified 5% 
CO2 environment on inverted tryptic soy agar plates containing 5% sheep blood 
before being suspended in antibiotic-free media for cell culture experiments or 
sterile saline for in vivo experiments to the desired optical density as a means of 
estimating concentration. Bacterial inputs were confirmed using serial dilution 
CFU assays.  
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Pneumococcal Experience Model  
Experienced mice and saline controls were generated by intratracheally infecting 
mice with two doses of Sp19F (Strain EF3030) or saline at a one-week interval, 
respectively, in order to generate effective heterotypic immunity (21, 23-26). All 
mice were allowed four weeks of rest to allow resolution of previous pneumonia 
and to restore homeostasis. Mice ushered through experience were either 
phenotyped at baseline or challenged with virulent pneumococcal strain Sp3 
(Strain 6303) as described in figure legends. 
Intratracheal Instillation Model 
Mice were anesthetized by intraperitoneal injection of ketamine (50mg/kg) and 
xylazine (5mg/kg). Mouse tracheas were surgically exposed and cannulated with 
an angiocatheter directed to the left bronchus. Mice were challenged with either 
S. pneumoniae EF3030 (Sp19F) or serotype 6303 (Sp3). Naïve control mice 
received equal volumes of sterile saline. 
Whole Lung Homogenates  
Mice were euthanized at end-time points, and left lung lobes were harvested into 
5ml tubes containing and mechanically digested into 1x protease inhibitor (Roche 
#11849300) in sterile water. Homogenates were either serially diluted in sterile 
saline and plated on 5% sheep blood agar plates and incubated overnight at 
37°C for measurement of bacterial burden, or homogenates had cytokine lysis 
buffer added and were centrifuged at 15000g for 20 minutes for cytokines 
 
150 
 
measurements. Colonies were counted on the following day. Data were 
expressed as total CFU/lung. 
 
Broncho-Alveolar Lavage (BAL) 
At indicated time-points, mice were euthanized, exsanguinated, and had their 
right bronchus \ closed by ligature. A catheter was inserted via the trachea, 
through which 5 boluses of 400-µl PBS were instilled and retrieved. BAL fluids 
were centrifuged at 300g for 5 minutes and supernatant transferred and stored at 
-80C. 
IFN Protein Measurement 
IFN concentration during generation of pneumococcal experienced were 
measured in broncho-alveolar lavages using mouse IFN ELISA duo sets (R&D 
systems DY485). 
Single Cell Suspensions 
At indicated time-points, mice were euthanized, lungs perfused and left lungs 
collected into 3 ml RPMI-1640 containing 10% fetal bovine serum, lungs were 
minced with a razor blade while in a 1ml digestion solution containing 1mg/ml 
type II collagenase (Worthington Biochemicals, Lakewood, NJ), 150µg/mL 
DNase, and 2.5mM CaCl2. Volume was brought up to 5 ml of digestion solution 
and transferred into 50ml conical. Digested lungs were placed in a shaker at 250-
300 round per minute at 37C for an hour, before digestion solution was passed 
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through a 70µm cell strainer (Fisher, Grand Island, NY) and the remaining pieces 
were pushed through the strainer to create single cell suspensions (SCS). Cells 
were pelleted via centrifugation and resuspended in 1mL red blood cell lysis 
buffer (Sigma, St. Louis, MO) for 2 minute at room temperature. 10mL PBS was 
added to each sample to stop the lysis and cells were pelleted again by 
centrifugation. Single-cell suspensions were counted using a Luna cell counter 
(Logo biosystems). Experiments differenting intra- and extravascular CD45 cells, 
an intravascular CD45.2-BUV737 or FITC antibody (clone 104 BD Biosciences) 
was introduced for 3 minutes prior to eutahnisia. 
Flow Cytometry 
Single Cell Suspensions were resuspended in Fc receptor blocking solution 
containing FACS solution (PBS, 2mM Ethylenediaminetetraacetic acid and 0.5% 
FBS), FC block (αCD16/CD32, Thermo Fisher) and Brilliant Stain buffer (BD 
Biosciences, San Jose, CA). The following Fluorochrome-conjugated monoclonal 
antibodies were used to stain SCS: CD45-BV510, FITC, or PercpCy5.5 (clone 
30-F11, Thermo Fisher™), CD64-PE or APC (clone X54-5/7.1, BioLegend), 
Ly6C-eFluor 450 (clone HK1.4, Thermo Fisher™), Ly6G-FITC  (clone 1A8, BD 
Biosciences), MHCII- PerCP-Cy5.5, or BV421 (clone M5/114.15.2, BD 
Biosciences), SiglecF- APC/Cy7 (clone E50-2440, BD Biosciences), CD11b-
BUV395 (clone M1/70 BD Biosciences), CD11c-PE/Cy7 (clone HL3, BD 
Biosciences), CD119-Biotin (clone GR20, BD Biosciences), IFN-PE (clone 
XMG1.2 Biolegend), CD103 (clone M290, BD Biosciences), CD4-BV510 (clone 
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GK1.5. Biolegend), CD8-APC/Cy7(clone 53-6.7 Biolegend), CD3-FITC (clone 
17A2, Thermo Fisher™), CD19-BUV395 or FITC (6D5, Biolegend), CD44-
BV421(clone IM7 BD Biosciences), CD69-PE (clone H1.2F3 Biolegend), CD11a-
APC (clone M17/4 Thermo Fisher), CD62L-PE/Cy7 (clone MEL-14 Biolegend), 
CD45.2-BUV737 or FITC (clone 104 BD Biosciences), Streptavidin-PE (BD 
Biosciences).  Cells were stained with 7-AAD Viability Staining Solution 
(Biolegend). Unstained, single-stained and fluorescence-minus-one (FMO) 
controls were used for each analysis. All staining was performed on ice in the 
dark for 30 minutes. Stained cells were analyzed using a LSR-II (BD 
Biosciences, San Jose, CA) or Cytek Aurora and sorted using BD FACS Aria and 
the data were analyzed using FlowJo V10 software (BD Biosciences, San Jose, 
CA). 
Intracellular Flow Cytometry Staining 
SCS were plated in RPMI media containing Brefeldin A (Biolegend) and 
Monensin (Biolegend) 1000X solutions for 4 hours. After which cells were 
collected and stained with a fixable viability dye, Fc blocked and stained for 
extracellular receptors for 30 minutes. Cells were washed 2x with FACS buffer 
and fixed (IC Fixation & permeabilization buffer kit, Thermo Fisher) for 20 
minutes, washed with FACS buffer and resuspended overnight in FACS buffer. 
The following day SCS were permeabilzed (IC Fixation & permeabilization buffer 
kit, Thermo Fisher), stained with IFN-PE (clone XMG1.2 Biolegend) for 30 
minutes, washed and resuspended in FACS buffer. Unstained, single-stained 
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and fluorescence-minus-one (FMO) controls were used for each analysis. All 
staining was performed on ice in the dark for 30 minutes. Stained cells were 
analyzed using a LSR-II (BD Biosciences, San Jose, CA) or sorted using BD 
FACS Aria and the data were analyzed using FlowJo V10 software (BD 
Biosciences, San Jose CA). 
 
Phagocytosis Assays 
Strptococcus pneumoniae (Strain 6303) were labeled with CellVue Claret dye for 
3 minutes, inactivated with FBS, thoroughly washed. Mice were challenged 
intranasally with fluorescently labeled pneumococcus. At 40 minutes, mice were 
euthanized and Broncho-alveolar lavages were collected, cells were pelleted via 
centrifugation, washed, and counted using a Luna cell counter (Logo 
biosystems). Cells were blocked and labeled as described previously. Stained 
cells were analyzed using Cytek Aurora and the data were analyzed using 
FlowJo V10 software (BD Biosciences, San Jose CA). 
CD4+ Cell Depletion Studies 
Naïve mice being ushered through pneumococcal experience were subjected to 
multiple doses of anti-CD4 monoclonal (clone) GK1.5. or IgG2b isotype control 
(BioXcell, West Lebanon, NH) antibodies via intraperitoneal instillations 
(500µg/100µl), intranasal instillations (100µg/100µl) or both. Four weeks after the 
second pneumococcal challenge, mice were administered intravascular CD45.2-
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FITC (clone 104 BD Biosciences) and SCS and flow cytometry processing were 
obtained and carried out as described above.  
Cell Culture 
RAW264.7 cells were purchased from American Type Culture Collection (ATCC) 
and maintained in Dulbecco’s Modified Eagle’s Media (DMEM) Supplemented 
with 10% Fetal Bovine Serum and 1% Pen/Strep.  
Confocal Imaging 
RAW 264.7 cells were seeded at 5x105 cells/well in 35-mm glass bottom culture 
dishes (Mat Tek), 2 hours later DMEM media was replaced with DMEM media 
containing recombinant IL17A, IFN (R&D systems), or vehicle overnight. The 
following day, cells incubated with Sp3 in antibiotic-free DMEM media for 2 
hours. Cells were washed with PBS and replaced with phenol red free DMEM 
(supplemented with 10% FBS + L-glutamine & Sodium Pyruvate) containing 
Hoechst (Life Technologies #33342) and Cell Mask Green plasma membrane 
stain (Life Technologies #C37608) according to manufacturer recommendations 
and kept for 30 minutes at 37°C in a humidified atmosphere containing 5% CO2. 
Following, cells were washed once with PBS and placed in phenol red free 
DMEM (supplemented with 10% FBS + L-glutamine & Sodium Pyruvate), 1 drop/ 
ml of NucRed Dead 647 Ready Probes Reagent (Molecular Probes #R37113) 
was added to measure cell membrane permeability. Confocal images were 
captured with a Zeiss LSM 710-Live Duo scan microscope with 20x objective. 
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Images were blinded and processed using Image J software and Zen imaging 
software. 
 
Lactate Dehydrogenase Assay 
RAW 264.7 cells were seeded at 5x105 cells/well in 24 well-plate. 2 hours later 
DMEM media was replaced with DMEM media containing recombinant 
IFN (R&D systems), or vehicle overnight. The following day, cells incubated with 
Sp3 in antibiotic-free DMEM media for 2 hours. Media was replaced with 
complete DMEM media containing antibiotics for 4 hours. 50µl of supernatants 
were transferred into 96 well plates, and LDH assay (Promega) was carried out 
as described by the manufacturer. 
Measurement of mRNA 
Sorted alveolar macrophages were centrifuged at 300g for 5 minutes and 
resuspended in RLT lysis buffer. RNA was processed using Qiagen micro-kits 
(Qiagen Rneasy Micro kit) as described by the manufacturer. 
Statistics 
Statistical analyses were carried out using GraphPad Prism software (Version 
8.4.3). Specific statistical analysis used for each dataset are described in Figure 
Legends. Unpaired data were analyzed using parametric tests, with two groups 
compared using the Student’s t-test and more than- two groups compared using 
a one-way or two-way ANOVA followed by Tukey’s or Dunnet’s for multiple 
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comparisons.  Data that failed to pass normalcy tests, Kruska-Wallis followed by 
Dunn’s multiple comparison test was used to compare data with more than two 
groups. Paired data were analyzed using the paired t-test analysis. Differences 
were considered significant if p < 0.05.  
 
Study Approval 
All animal protocols were approved by the Boston University Institutional Animal 
Care and Use Committee. 
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Figures 
 
Figure 11: Alveolar macrophages and inflammatory macrophages exhibit similar 
dynamics. Single cell suspensions were created from left lungs and processed 
using flow cytometry at select time-points during generation of pneumococcal 
experience. A. AMs and inflammatory macrophages (Mo-Macs) were identified as 
CD45+Ly6g-CD64+SiglecF+CD11c+ and CD45+Ly6g-CD64+SiglecF+Ly6c+, 
respectively. Panels in figure were from a mouse with Sp19F pneumonia 7 days 
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after infection. B. Numbers of AMs and Mo-Macs were back calculated from the 
frequency of total measured by FlowJo software. Median Fluorescent Intensity 
(MFI) of C. SiglecF, D. MHC-II, E. CD11c, F. CD64, G. CD11b, H. Ly6c expression 
on AMs and Mo-Macs at select time-points post a single or dual Sp19F infection. 
One-way ANOVA Dunnett’s multiple comparisons test was used to examine 
significance. 
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Figure 12: CD4+ cells are not essential for the experienced AMs phenotype. A. 
C57Bl6 mice being ushered through pneumococcal experience received multiple 
doses of intraperitoneal and intranasal GK1.5. to deplete CD4 T cells or IgG as 
control at select time-points. B. Enumeration of extravascular 
CD4+CD69+CD11a+CD44+CD62L-, numbers were calculated from the frequency 
of total measured by FlowJo software. C. Enumeration of extravascular 
CD8+CD69+CD11a+CD44+CD62L-, numbers were calculated from the frequency 
of total measured by FlowJo software. B. Enumeration of alveolar macrophages 
(CD11c+SiglecF+CD64+), numbers were calculated from the frequency of total 
measured by FlowJo software E. Median Fluorescent Intensity (MFI) of SiglecF 
expression on AM. F. Median Fluorescent Intensity (MFI) of MHC-II expression on 
AMs G. Correlation of the number of resident memory CD8 T cells with MFI of 
MHC-II on AM. (N= 8-12 mice/group). B-F. One-way ANOVA Tukey’s multiple 
comparisons test was used to examine significance. 
  
 
160 
 
  
Figure 13: Multiple sources of IFN. A. ELISA Measurement of IFN concentration 
in broncho-alveolar lavages from left lungs at 0,1,3,7 days’ post first Sp19F 
infection and 1,3,7 days’ post second Sp19F infection. (Pg/ml) B. Pie chart 
representing average percentage of IFN+ cells for each cell type. (N=6-7 mice). 
Myeloid cells were identified as described (Guillon et al., 2020). C. Number of 
IFN+ neutrophils (Identified as CD11b+Ly6G+). (N=6-7 mice). D. Number of 
IFN+ CD45+Ly6G-CD64-CD11c-CD11b-Ly6C+ cells (N=6-7 mice). E. Number of 
IFN+ CD45+Ly6G-CD64-CD11c-CD11b-Ly6C- cells (N=6-7 mice). (N=6-7 mice). 
F. Number of IFN+ CD45+Ly6G-CD64-CD11c-CD11b+Ly6C- cells (N=6-7 mice). 
G. Number of IFN+ CD4+ cells (Identified as CD19-CD8-CD4+ cells). (N=6-7 
mice). H. Number of IFN+ CD8+ cells (Identified as CD19-CD4-CD8+ cells). (N=6-
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7 mice). One-way ANOVA Tukey’s multiple comparisons test was used to examine 
significance. 
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Figure 14: IFN is sufficient to remodel and protect macrophages. A-C. RAW264.7 
cells treated with recombinant mouse IFN or vehicle overnight, were infected with 
Sp3 for 2 hours. A. Infected cells stained with Hoechst (Nucleus, Blue), Cell Mask 
Green (Plasma Membrane, Green) and Nuclear Red Dye 647 (Permeable dye, 
Red). B. Quantification of blinded images identified as Nuclear red positive or 
negative. (N=2). C. Cell death as measured using LDH assay. (N=5). Values are 
expressed as mean ± SEM. Paired T test analysis was used to examine 
significance. D-F. 7-8 week old mice were intratracheally (i.t.) stimulated with IFN 
or 1%BSA in saline directed to the left lung twice at a one-week interval. Four 
weeks post last stimulation with IFN, single cell suspensions were created from 
left lungs and processed using flow cytometry. AMs were identified as 
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CD11c+SiglecF+CD64+. D. AMs Numbers were calculated from the frequency of 
total measured by FlowJo software. E. Median Fluorescent Intensity (MFI) of 
SiglecF and F. MHC-II expression on AM.   
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Figure 15: Pneumonia-induced MHC-II remodeling of AMs requires IFN, 7-8 week 
old C57Bl6 or IFN -/- mice were intratracheally (i.t.) challenged with Sp19F or 
saline directed to the left lung twice. Mice challenged with Sp19F and saline are 
henceforth referred to as experienced, and naïve controls, respectively. 4-6 weeks 
later (to allow resolution of inflammation), the mice were Immunophenotyped at 
baseline. Single cell suspensions were created from left lungs and processed 
using flow cytometry. AMs were identified as CD11c+SiglecF+CD64+. A. AMs 
Numbers were calculated from the frequency of total measured by FlowJo 
software. B. Median Fluorescent Intensity (MFI) of SiglecF. C. Median Fluorescent 
Intensity (MFI) of MHC-II expression on AM. D. Resident memory CD4 T cell were 
identified as extravascular CD4+CD69+CD11a+CD44+CD62L-, and numbers 
were calculated from the frequency of total measured by FlowJo software. One-
way ANOVA Tukey’s multiple comparisons test was used to examine significance. 
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Figure 16: Pneumonia-induced MHC-II remodeling requires receptor for IFN on 
AM. CD11c Cre and IFNGR1 floxed mice were purchased from Jaxon labs and 
crossed for several generations to produce IFNGR1 knockout from CD11c+ cells, 
hereafter referred to as 11cGR mice. A. Cre- and Cre+ 11cGR mice were instilled 
intra-naslly with 200ng/ml IFN or kept at baseline. Single cell suspensions were 
created from left lungs and processed using flow cytometry. AM were identified as 
CD11c+SiglecF+CD64+. A. MFI of IFNGR1 and B. MHC-II expression on AM in 
Cre- and Cre+ ± IFN. Values are expressed as mean ± SEM. (N= 4-9 mice/group). 
Ordinary Two way ANOVA followed by Tukey’s multiple comparsion test were 
used to calculate significane.. C. Enumeration of AM identified as 
CD11c+SiglecF+CD64+ in experienced Cre- and Cre+ 11cGR mice ushered 
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through pneumococcal pneumonia model at baseline (N= 14-24 mice/group). D. 
Median Fluorescent Intensity (MFI) of IFNGR1, E. SiglecF, and F. MHC-II 
expression on AM isolated from single cell suspensions from Cre- and Cre+ 11cGR 
mice. AM were identified as CD11c+SiglecF+CD64+. (N= 8-12 mice/group). G. 
Enumeration of extravascular CD4+CD69+CD11a+CD44+CD62L-, numbers were 
calculated from the frequency of total measured by FlowJo software in experienced 
lungs from Cre- and Cre+ 11cGR mice. (N= 8-12 mice/group). H. 7-8 weeks naïve 
Cre- and Cre+ 11cGR mice ushered through pneumococcal experience model 
were challenge with Sp3 for 24 hours 4 weeks post last Sp19F challenge and left 
lungs were mechanically digested and plated on blood agar for bacterial burden 
measurements. (N=6-8 mice/group). C-H. Values are expressed as mean ± SEM. 
Unpaired t-tests were used to examine significance.  
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Figure 17: CCR2 is not essential for experienced AMs number or phenotype. 6-7 
week old C57Bl6 or CCR2-/- mice were intratracheally (i.t.) challenged with Sp19F 
or saline directed to the left lung twice. Mice challenged with Sp19F and saline are 
henceforth referred to as experienced, and naïve controls, respectively. 4-6 weeks 
later (to allow resolution of inflammation), the mice were Immunophenotyped at 
baseline. A. Enumeration of extravascular CD11b+Ly6c+ (monocytes) in 
C57BL/6J or CCR2-/- mice challenged with Sp19F for two days from single cell 
suspensions using flow cytometry. Single cell suspensions were created from left 
lungs at baseline of experienced mice and processed using flow cytometry. AMs 
were identified as CD11c+SiglecF+CD64+. B. AMs Numbers were calculated from 
the frequency of total measured by FlowJo software. C. Median Fluorescent 
Intensity (MFI) of SiglecF, and MHC-II expression on AM. D. Resident memory 
CD4 T cell were identified as extravascular CD4+CD69+CD11a+CD44+CD62L-, 
and numbers were calculated from the frequency of total measured by FlowJo 
software. (N= 8-10 mice/group). Unpaired t-tests were used to examine 
significance.  
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Figure 18: Experienced lungs contain greater fraction of AMs from hematopoietic 
origin, but all AMs are similarly remodeled regardless of origin. Dual reporter mice 
expressing a Rosa driven floxed tdTomato Stop followed by GFP were crossed to 
FLK2 cre recombinase mice to generate a lineage tracing mouse model that allow 
the differentiation of AMs origin. Naïve and experienced mice were ushered 
through pneumococcal experience model. A. Panels in figures are representative 
figure for AMs subsets from naïve (Left) and experienced (Right) lungs. B. 
Percentage of AMs subsets in naïve and experienced lungs. C. Median 
Fluorescent Intensity (MFI) of SiglecF expression on AMs subsets in naïve and 
experienced lungs. D. Median Fluorescent Intensity (MFI) of MHC-II expression on 
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AMs’ subsets in naïve and experienced (N=7- mice/group). Two-way ANOVA 
Sidak’s multiple comparisons test were used to examine significance.  
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Figure 19: Although all AMs remodel in similar ways, recent recruits functionally 
differ from initially resident AMs in the experienced lung. Dual reporter mice 
expressing a Rosa driven floxed tdTomato Stop followed by GFP were crossed to 
FLK2 cre recombinase mice to generate a lineage tracing mouse model that allow 
the differentiation of AMs origin. Experienced mice were ushered through 
pneumococcal experience model. A. Fold induction of Cxcl9 transcripts within 
tdTomato+ and GFP+ AM, normalized to average induction in naïve mice. One-
way ANOVA Tukey’s multiple comparisons test. B. Fold induction of Cxcl2 within 
tdTomato+ and GFP+ AM, normalized to average induction in naïve mice. One-
way ANOVA Tukey’s multiple comparisons test. C. Fold induction of Il6 within 
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tdTomato+ and GFP+ AM, normalized to average induction in naïve mice. One-
way ANOVA Tukey’s multiple comparisons test. D.  Percentage tdTomato+ and 
GFP+ AMs subsets that are positive for Claret vue labeled pneumococcus in 
experienced lungs (N=6 mice). E. Median Fluorescent Intensity (MFI) of Claret vue 
labeled pneumococcus within AMs subsets in experienced lungs. (N=6 mice). F. 
Percentage tdTomato+ and GFP+ AMs subsets that are positive for Claret vue 
labeled pneumococcus in naive lungs (N=6 mice). G. Median Fluorescent Intensity 
(MFI) of Claret vue labeled pneumococcus within AMs subsets in naive lungs. (N=6 
mice). Paired t-test analysis was used to examine significance. 
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Chapter IV: DISCUSSION 
Summary of the main results 
Pneumococcal pneumonia is a leading cause of morbidity and mortality around the 
world. It disproportionally affects young children and older individuals compared to 
young adults. Over the last few years, several studies have highlighted the 
remodeling of non-lymphoid tissues like the lung after recovery from prior 
infections like pneumococcus (Smith et al., 2018; Shenoy et al., 2020). These 
studies have particularly highlighted the establishment of resident memory 
adaptive immune cells and the accelerated recruitment of innate cells like 
neutrophils upon injury in protecting the lung (Smith et al., 2018; Shenoy et al., 
2020). In this dissertation, we postulated that recovery from pneumococcal 
pneumonia remodels the pool of alveolar macrophages, which plays an integral 
role in conjunction with other remodeled immune cells to provide enhanced 
protection against future pneumococcal infections. Here, we demonstrate that the 
resolution from pneumococcal pneumonia results in an AM pool developing 
phenotypically, metabolically, and transcriptionally altered profiles. Moreover, we 
uncover some of the mechanisms driving these changes. Marrow-derived AMs 
replace many of the embryonic-derived AMs. Regardless of cell origin, the AMs 
undergo analogous remodeling due to changes in the microenvironment including 
IFN, which serves as an essential driver of the AMs' pneumococcal experienced 
phenotype, signaling directly through the IFN receptor. 
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On the phenotypic level, the pool of AMs exhibited numerous changes in surface 
protein expressions. Among these changes, two changes are particularly 
prominent, lowering of SiglecF intensity and increased MHC-II intensity. In our 
study, the lowering of SiglecF intensity could be seen almost immediately within 
one-day after the 1st challenge with pneumococcus, suggesting an important role 
for innate immune signaling. Additionally, this change in SiglecF intensity is long-
lasting and restricted to the infected lung lobes. Although the SiglecF phenotype 
is consistently apparent with pneumococcal challenges, it does not seem to be 
replicated in other models using various microbial injuries like adenoviral vector 
experience (Yao et al., 2018). In contrast to our study, the remodeling of AMs 
observed after recovery from adenovirus is observed only on embryonic AMs 
independent of any marrow recruited AMs (Yao et al., 2018). Thus, the 
phenotypical change of diminished SiglecF has been postulated to develop due to 
the increased recruitment of AMs from marrow origins. Pneumococcal 
experienced AM's transcriptome is enriched for genes consistent with a marrow 
origin for AMs. Thus, our data support previous data highlighting the correlation 
between lowered SiglecF intensity on AMs and their marrow origin (Gibbings et 
al., 2015).  
In contrast to SiglecF, MHC-II intensity was prominently increased on 
pneumococcal-experienced AMs. Changes in MHC-II are delayed and augmented 
after a 2nd pneumococcal challenge consistent with adaptive immune signaling 
changes. Our data show that this phenotype is directly dependent on the IFN 
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ligation of its cognate receptor IFNGR1.  Increased MHC-II after the resolution of 
pneumococcal pneumonia is consistent with the adenoviral study (Yao et al., 
2018). Both studies demonstrate an increase in MHC-II intensity on AMs long-term 
after recovery from the initial injuries. The adenovirus study showed that effector 
CD8 T-cells are essential for priming AMs MHC-II changes via IFN (Yao et al., 
2018). This contrasts with our study, demonstrating that effector CD4 T cells are 
not as critical for priming AM's MHC-II phenotype. Many cells produce IFN at its 
peak in the pneumococcal setting, likely compensating for the loss of CD4 T cells. 
Our study supports prior data highlighting the importance of neutrophils in IFN 
production, particularly after 1st challenge (Yamada et al., 2011; Gomez et al., 
2015). Moreover, our data describe additional cells to become particularly more 
dominant IFN producers after the 2nd pneumococcal challenge, including CD4 T-
cells but even more prominently by cells other than neutrophils or CD4+ cells. 
Recovery from pneumococcal pneumonia additionally produces changes in the 
AM metabolic profile. Pneumococcal experienced AMs exhibit high enrichment for 
high energy metabolites like creatine and phosphocreatine and enzymes required 
for their formation like creatine kinase (Murray et al., 2014; Jomcquel-Chevalier et 
al., 2015; Mould et al., 2017). These metabolites have previously been shown to 
limit oxidative damage and facilitate ATP regeneration via making available high-
energy phosphates (Murray et al., 2014; Jomcquel-Chevalier et al., 2015; Mould 
et al., 2017). AMs, like other macrophages, are highly plastic and continuously 
adapt their functions to fit the tissue's needs. Thus, having such high energy 
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sources could allow AMs to carry out their anti-microbial functions rapidly. While 
our data do not delineate a classical or alternatively activated AMs phenotype in 
experienced mice, such energy sources like creatine and phosphocreatine could 
ease the transition between such phenotypes upon various future injuries. 
Another feature of pneumococcal-experienced AMs is the change in their 
transcriptional profiles both at rest and after 4 hours of response to pneumonia. In 
the absence of infection, pneumococcal-experienced AMs exhibit a more restful 
transcriptomic profile where cell cycle genes and mRNA processing activities are 
diminished. In contrast, upon memory recall, experienced AMs exhibit a distinct 
spectrum of activities when responding to acute virulent pneumococcal injury 
including their immune signaling responses, glycoprotein processing, and energy 
metabolism. Changes in experienced AMs' transcriptional immune signaling 
response can also be observed on the protein level. For example, experienced 
AMs upregulate production of several cytokine and chemokines during acute 
infection, including CXCL9 and OSM. Even at rest, experienced AMs exhibit 
upregulation of several phagocytic and cell trafficking receptors, including CD64, 
MSR-1, CD11c, CD93, and CCR5. It remains unclear whether this upregulation on 
the protein levels translates into better or accelerated functional responses.  
Previous transcriptional studies have highlighted the differences in the 
transcriptional profiles of AMs isolated from children and adults (Beura et al., 2016; 
Bewley et al., 2017). Interestingly, recovery from pneumococcal injury remodels 
AMs' transcriptional responses to resemble those of adult human AMs. Although 
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sharing such similarities in responses is promising, the various differences in study 
design, history of subjects, and limitation of inbred mice genetic diversity should 
be kept in mind (Beura et al., 2016; Bewley et al., 2017). The literature on AM 
remodeling after recovery from microbial injuries is continuously expanding (Yao 
et al., 2018; Aegerter et al., 20120; Roquilly et al., 2020). This expanding literature 
continues to pinpoint the importance of the type, number, and severity of these 
injuries in determining the immunological remodeling of AMs (Yao et al., 2018; 
Aegerter et al., 2020; Roquilly et al., 2020). While our study highlights changes in 
SiglecF, MHC-II, CXCL9, metabolism, and changes in cell origin, various studies 
share some similarities but highlight distinct remodeling profiles (Yao et al., 2018; 
Aegerter et al., 2020; Roquilly et al., 2020). For example, the adenoviral AM 
remodeling study highlighted changes in MHC-II, CXCL1, CXCL2, and metabolism 
independent of SiglecF and cell origin changes (Yao et al., 2018). 
Similarly, AM remodeling after influenza highlighted differences in epigenetic 
accessibility, IL-6 production from recruited AMs independent of any changes in 
embryonic AMs (Aegerter et al., 2020). Finally, while both studies mentioned 
above highlight AMs improved ability to recruit neutrophils into the lung upon 
bacterial injuries, not all remodeling results in superior function (Yao et al., 2018; 
Aegerter et al., 2020). A recent study has demonstrated that AM remodeling after 
S. aureus and E.coli renders AMs long-term paralyzed due to epigenetic 
remodeling via microenvironment negative signals (Roquilly et al., 2020). 
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Consistent with our transcriptional data and using an established lineage tracing 
mouse model, our data demonstrate a massive increase in the contributions of 
marrow-derived AMs to the pool of AMs. These data are consistent with other data 
pinpointing the contributions of marrow-derived AMs after pneumococcal 
pneumonia (Mould et al., 2017). These data are additionally consistent with AMs' 
remodeling after influenza recovery (Aegerter et al., 2019). However, a significant 
difference among both studies is the role of CCR2 in driving such changes 
(Aegerter et al., 2020). While CCR2 was shown to be critical to the changes in the 
AMs pool after influenza, CCR2 is expandable after recovery from pneumococcal 
pneumonia (Aegerter et al., 2020). 
Regardless of AMs' origin, pneumococcal experience drives changes in SiglecF, 
MHC-II, and CXCL9, suggesting that the tissue microenvironment plays an 
essential role in driving the experienced phenotype. These data potentiate 
previous data highlighting the microenvironment in shaping resident macrophages' 
identities (Watanabe., 2019; Gautier et al.,2012; Gosselin et al., 2014; Guth et al., 
2009). Despite experienced AMs subsets undergoing similar remodeling, marrow-
derived AMs exhibit better phagocytosis in naïve mice and worse phagocytosis 
upon experience. These data contrast with previous data showing no functional 
differences in phagocytosis regardless of AMs' origin (Gibbings et al., 2015). 
In conclusion, pneumococcal pneumonia resolution results in remodeling of the 
pool of alveolar macrophages to acquire adaptive-like characteristics. These new 
characteristics include changes in surface phenotype, developing an altered 
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metabolic profile and a more quiescent transcriptome at rest, and changed 
transcriptome during acute infection. These features are driven by the recruitment 
of marrow-derived cells and tissue microenvironment changes, suggesting a role 
for trained immunity for the pool of AMs regardless of cell origin.  A better 
understanding of alveolar macrophage remodeling determinants is a critical next 
step in understanding these cells' biology in health and disease. Finally, a better 
understanding of AMs' subsets and their functional roles is essential for developing 
approaches for countering pneumonia in susceptible individuals. 
Limitations of the Study 
Our study highlights consistent changes in AM phenotype after recovery from 
pneumococcal pneumonia. Two of these notable changes are modifications in the 
intensity of SiglecF and MHC-II on AMs' surfaces. While IFN signaling is 
responsible for transforming MHC-II intensity, the mechanisms driving SiglecF 
remain unclear. Despite these changes being a prominent feature, the significance 
of such changes to AMs' function is yet to be determined. 
IFN signaling is an essential driver of AMs' experienced phenotype suggesting a 
role for trained immunity and tissue microenvironment changes. However, it is yet 
to be determined how other tissue microenvironment changes contribute to 
changes in AMs' profile upon experience. Similarly, a hallmark of pneumococcal 
experience is developing resident memory cells in the lung (Smith et al., 2018). 
Our data indicate that these cells are producers of several cytokines, including 
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IFN (Smith et al., 2018). However, our data fails to show a complete picture to the 
extent that how these new adaptive cells modulate AMs and other resident innate 
cells responses upon memory recall. 
Our repeated pneumococcal pneumonia model uses self-limiting pneumococcus 
under specific conditions and timely introduction to establish AM and lung 
remodeling. In addition, our model examines the effect of pneumococcal 
remodeling in the context of inbred mice. However, our data fails to consider the 
extensive and various histories that pneumonia patients encounter, the diversity of 
microbial infections encountered, and the care and treatments provided for 
pneumonia patients under hospitalization settings. 
In the last decade, several groups have shown AMs undergoing remodeling after 
recovering from various microbial agents (Yao et al., 2018; Aegerter et al., 2020; 
Roquilly et al., 2020). Although such literature shows similar remodeling in some 
contexts, each microbial response demonstrates distinct unique responses (Yao 
et al., 2018; Aegerter et al., 2020; Roquilly et al., 2020). These responses' diversity 
raises several questions about the determinants and mechanisms driving these 
divergent AM remodeling phenotypes. 
Our data indicate that marrow-derived AMs and IFN signaling are essential drivers 
of AM experience. Moreover, our data highlight similar remodeling features in 
experienced AM subsets despite changes in AM's subsets function upon 
experience. However, the full extent of phenotypic, metabolic, transcriptional, and 
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functional differences among AM subsets remains unclear. Altogether, our data 
emphasize the need to better understand AM biology during health and disease 
and youth and aging. 
Future Directions 
Our data focus on the remodeling of AM's MHC-II surface expression after 
recovery from pneumococcal injuries. Moreover, our data demonstrate an 
essential role for IFN signaling in driving MHC-II changes. However, our data do 
not show what role MHC-II has on AMs within the experienced lung. Additional 
studies examining the effect of conditional MHC-II knockout on AMs will be needed 
to verify MHC-II importance on AMs in the experienced lung. These data will need 
to be further supported by examining AM's expression of co-stimulatory and co-
inhibitory proteins as well as in vivo and ex vivo studies examining AM's abilities 
to activate or regulate CD4 T cells. Furthermore, sequencing experiments 
comparing experienced AMs from IFNGR1 knockout with their wild-type 
counterparts will be needed to verify the full extent of IFN impact on AMs 
remodeling. 
Our data also demonstrates that experienced AMs, regardless of cell origin, 
produce more CXCL9, a chemokine that regulates T cells' migration, particularly 
memory T cells. Conditional knockout studies examining the impact of the loss of 
CXCL9 from AMs on the migration and recruitment of effector memory T cells into 
the lung during acute pneumonia will be required. 
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Our data pinpoint the importance of marrow-derived AMs in driving AMs 
experience and highlight some phenotypic and functional similarities and 
differences among AM's subsets. Additional transcriptional sequencing and 
functional assay experiments are required to better understand the subtypes of 
AMs at rest, during acute pneumonia, and resolution of pneumonia. 
A more comprehensive understanding of AM contributions to healthy adult human 
lung protection from pneumonia is needed to understand better the aging AM's 
contributions to the immune responses to pneumonia in the elderly and how AM 
dysfunction may contribute to the elderly's vulnerability to pneumonia. Elucidating 
such mechanisms should open the door to developing precision medicine to tackle 
pneumonia in vulnerable groups. 
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